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1.2 Abstract 
Non-Hodgkin Lymphoma (NHL) is a diverse group of more than 80 
predominantly B cell cancers of the lymphatic system. Poor survival rates in 
aggressive subsets, the transformation of indolent subsets into aggressive 
forms, and the emergence of therapy-resistance warrants research into 
novel therapies. Oncolytic viruses (OV) preferentially replicate in and kill 
malignant cells. Here we investigate the efficacy of two OV, reovirus Type 3 
Dearing and Coxsackievirus Type A21 (CVA21), against NHL cell lines and 
primary patient samples, examine the role of the tumour microenvironment 
in virus susceptibility, characterise the cellular determinants of CVA21 
infection of malignant cells and test the ability of both viruses to potentiate 
an immune response against NHL, alone or in combination with monoclonal 
antibodies (mAbs). 
CD40L on T cells can signal through CD40 on NHL B cells, resulting in pro-
survival signals that induce resistance to standard chemotherapy. CD40L 
stimulation induced vincristine resistance in NHL cell lines but enhanced 
CVA21-induced cell death, implying a role for CVA21 in targeting drug-
resistant NHL cells. CD40L stimulation and had no effect on reovirus-
induced cell death. 
To investigate possible determinants of CVA21 susceptibility, the effects of 
the interferon (IFN) response and mTOR pathway on CVA21-induced cell 
death of NHL cells were investigated. Despite possessing an intact IFN 
response, NHL cell lines remained susceptible to CVA21 infection, 
suggesting that CVA21 may utilise mechanisms to subvert the antiviral IFN 
response. Moreover, mTOR inhibition by rapamycin reduced CVA21-
induced cell death in NHL cell lines, demonstrating the importance of mTOR 
signalling for CVA21-induced cell death. 
MAbs bind to their cognate antigen and mark cells for destruction by immune 
cells and have shown promising results in combination with OV in a variety 
of malignancies. Anti-CD20 antibodies, such as rituximab, target CD20 on 
NHL cells and are being investigated in combination with OV for 
haematological malignancies, such as Chronic Lymphocytic Leukaemia 
(CLL). CVA21, reovirus and our candidate anti-CD20 antibody, BHH2, 
induced NK cell recognition of NHL cell lines as single agents. This targeting 
was enhanced in some cell lines when either virus was used in combination 
with BHH2, outlining a potential role for an OV-mAb combination for the 
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treatment of NHL. Importantly, CD40L stimulation and the induction of a 
drug-resistant phenotype did not impair recognition of NHL cell lines by OV 
activated NK cells. 
The results reported here outline a promising role for CVA21, but not 
reovirus, as a potent lytic agent against NHL cells. This data also implicates 
both reovirus and CVA21 as potent immunogenic agents that can induce NK 
cell targeting of NHL cell lines alone and in combination with anti-CD20 
mAbs.  
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Chapter 2  
2.1 Haematopoiesis and B cell Development 
The human body consists of a diverse range of cell types, each with specific 
characteristics and functions. Cells can form solid tissues such as muscle, 
skin and organs, or can exist individually in suspension, such as 
haematological (blood) cells. Blood is composed of red blood cells for 
transporting oxygen throughout the body, and white blood cells that are 
primarily responsible for defending the body from infection through innate 
mechanisms that can occur immediately upon contact with the infection, or 
adaptive mechanisms that require pre-exposure to the infection to allow the 
priming of a specific, targeted response. The human body can generate a 
diverse arsenal of blood cells from a common progenitor (haematopoietic 
stem cell) that must undergo a complex process of differentiation and 
maturation to become a specific cell type, such as B cells and T cells. These 
cells can undergo further maturation and differentiation, upon contact with 
specific pathogens or foreign material, resulting in clones of cells that are 
reactive to specific infections. 
B cells are a vital member of the human immune system, that can 
differentiate into a multitude of cell clones that protect against specific 
pathogens through the recognition of pathogenic antigens. B cells exert their 
protective effect by producing huge quantities of proteins called antibodies or 
immunoglobulins (Igs), that bind to very specific regions on antigens. These 
antibodies can act in several ways to interfere with the activity of the 
pathogen, such as binding to and directly blocking target viruses, and 
binding to target pathogens and marking them for destruction by other 
immune cells. For B cells to achieve the heterogeneity that is required to 
target the diverse onslaught of pathogens that threaten the host body, they 
must be capable of undergoing a series of differentiation steps that introduce 
extreme variability into their Igs, thus expanding their targeting abilities. 
B cells begin in the bone marrow as progenitors to fully matured B cells. In 
the bone marrow, these B cell progenitors undergo genetic rearrangement of 
their Ig locus, resulting in the first stages of varying their Igs, and the 
production of a B cell receptor that is a surface-bound Ig. A selection 
process targets B cells that react with host antigens, prohibiting the 
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generation of an autoreactive clone. Upon completion of this phase, these 
immature B cells leave the bone marrow and travel to secondary lymphoid 
tissues, such as the spleen and lymph nodes, where the antigen to which 
they react is presented to them by antigen-presenting cells. This contact with 
their cognate antigen, as well as co-stimulatory signals from T cells, results 
in further variability of the Ig locus by a process known as somatic 
hypermutation, allowing clones with stronger and weaker reactivity to be 
generated. The weaker responders are selected out of the population by 
further clonal deletion, and the optimal B cell clone is allowed to proceed 
with its maturation into a mature plasma cell, that produces Ig, or a memory 
B cell, that monitors the body in preparation for re-exposure to their cognate 
antigen. A more detailed account of B cell differentiation is available from 
Hardy and Hayakawa (Hardy and Hayakawa, 2001). 
2.2 The Development of Cancer 
Cancer is characterised by the uncontrolled proliferation and immortality of a 
clone of cells that can outgrow other cell populations, spread throughout the 
body and destroy the patient’s immune system and organs. While the root 
cause of cancer can be due to a combination of hereditary and acquired 
factors, DNA plays a crucial role in facilitating the transformation of healthy 
cells into malignant. Genetic changes can include the loss of genes that slow 
cell cycle or facilitate cell death, or the over-expression of genes the promote 
cell division and survival. Most nucleated cells can develop into malignant 
cells, forming solid cancers, such as skin cancer, liver cancer and breast 
cancer, or haematological malignancies, such as leukaemia or lymphoma, 
where a clone of the patient’s white blood cells outgrows their non-
transformed counterparts and spreads throughout the body. While huge 
progress has been made in the last century for the treatment of cancer, 
increasing incidence of these diseases and the emergence of cases that 
resist current therapies elevates the need for research into novel areas of 
therapeutic intervention. 
One such process that is frequently manipulated in cancer is programmed 
cell death or apoptosis, whereby a cell, in response to infection, stress or 
irreparable damage, will undergo a form of highly-coordinated suicide 
(Elmore, 2007). Apoptosis prevents pathogens from exploiting living cells 
and spreading, and prevents damaged cells from growing and dividing, 
reducing the chances of transforming into cancerous cells. Cancer, however, 
can arise when mutations occur in pathways and proteins that control 
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apoptosis, such as the deletion of a pro-apoptotic genes, such as Bcl-2-like 
protein 11 (BIM) and p53 upregulated modulator of apoptosis (PUMA), which 
can be downregulated in Burkitt’s Lymphoma (Fitzsimmons et al., 2017), or 
the amplification of anti-apoptotic ones, such as members of the B-cell 
lymphoma 2 (BCL-2) family of proteins which as overexpressed in a variety 
of solid and haematological malignancies, such as leukaemias and 
lymphomas (Reed, J.C., 2017). This results in a cell clone that is more 
resistant to pro-apoptotic signals and more difficult to kill. Recent cancer 
therapy research has involved a focus on treatments that overcome the anti-
apoptotic state in cancer cells, such as BH3 mimetics like Obatoclax that 
blocks BCL-2 and renders the cancer cells more sensitive to apoptotic cell 
death (Baig et al., 2016).  
2.3 Non-Hodgkin’s Lymphoma 
2.3.1 Background 
Non-Hodgkin Lymphoma (NHL) is a diverse group of predominantly B cell 
cancers of the lymphatic system that affected over 13,000 people in the UK 
in 2015, accounting for 4% of the total number of cancer cases (CRUK, 
2018). NHLs range from indolent or “slow-growing”, such as follicular 
lymphoma (FL) and small lymphocytic lymphoma, to aggressive or “fast-
growing”, such as Burkitt’s lymphoma (BL), Diffuse Large B Cell Lymphoma-
Germinal Centre B cell (DLBCL-GCB) subset and Diffuse Large B Cell 
Lymphoma-Activated B cell (DLBCL-ABC) subset. However, this binary 
system of classification is not definitive as some individual cases of indolent 
NHL can be highly aggressive or can transform from an indolent to a more 
aggressive form (Correia et al., 2015). Likewise, some cases of otherwise 
aggressive subsets may present with a slower rate of progression and a 
more favourable survival (Menon et al., 2012), demonstrating the 
heterogeneity of this class of diseases. The factors associated with disease 
progression depend on the specific NHL subset and the tumour 
characteristics. These can include the presence of chromosomal 
aberrations, such as the t(14:18)(q32:q21) translocation in FL which conveys 
constitutive expression of the anti-apoptotic protein BCL-2, or the 3q27 
rearrangement in DLBCL which causes the over-expression of BCL-6 (Ong 
and Le Beau, 1998). BCL-6 is a transcriptional repressor that prevents 
premature activation and differentiation of germinal centre (GC) B cells 
during their development, and suppresses p53 expression, allowing the cells 
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to tolerate DNA breaks during chromosomal rearrangements (Basso and 
Dalla-Favera, 2012).  
Other factors, such as expression of the CD20 antigen (Bellesso et al., 
2011) bone marrow (BM) infiltration (Beider et al., 2013), and expression of 
the anti-apoptotic protein, Mantle Cell Lymphoma 1 (MCL-1), are commonly 
associated with poor prognosis in DLBCL-ABC (Wenzel et al., 2013). 
Mutations in the RAS–RAF–MEK–ERK–MAP kinase pathway, which are 
associated with enhancing the proliferation of cancer types such as 
pancreatic cancer, lung cancer and leukaemia (Bos, 1989), are also present 
in some cases of DLBCL (Lee, J.W. et al., 2003). 
NHLs are predominantly B cell in nature; however, some rare cases are 
composed of malignant T cells or Natural Killer (NK) cells such as anaplastic 
large cell lymphoma and blastic NK cell lymphoma. These forms of NHL are 
rare and together comprise only 10-15% of NHL cases in the Western world 
(American Cancer Society, 2017). To demonstrate the variety of subtypes of 
NHL, a pie chart showing the proportions of NHL subtypes is shown in 
Figure 2-1.  
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Figure 2-1: Prevalence of NHL subtypes. 
DLBCL and FL represent large groups of NHL cases (31% and 22%, 
respectively), and a variety of other subtypes are present at lower 
frequencies, such as MCL (6%) and Marginal Zone B cell lymphoma nodal 
type (1%). Although not all subsets are represented on this chart, it 
demonstrates the heterogeneity of this group of diseases (Armitage and 
Weisenburger, 1998). 
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NHL is typically classified at diagnosis as being at one of four stages, 
depending on the degree to which malignant cells have spread throughout 
the body. This staging system is termed the Cotswold system (formerly the 
Ann Arbor Staging System) and is described in Table 2-1. 
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Stage Characteristics 
I Lymphomas that are restricted to one lymph node (LN) 
II Lymphomas that have spread to other LN on the same side 
(above or below) the diaphragm 
III Lymphomas that have spread to other LN on both sides of the 
diaphragm 
IV Lymphomas that have spread outside of the lymphatic system to 
an organ that is not immediately associated with a malignant LN 
 
Table 2-1 Description of NHL staging criteria.  
The stage denoted to a patient with NHL typically reflects the location(s) in 
the body to which the malignant cells have spread (Izumi and Ozawa, 2000). 
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Stage IV lymphomas can also include disease that has spread to the BM or 
the central nervous system (CNS). CNS involvement is more common in 
aggressive NHL, such as BL, and is associated with poor patient survival 
(Hollender et al., 2002). Most diagnoses occur at Stages III and IV (Ansell, 
2015) which can be detrimental to the patient’s prognosis due to the 
advanced spread of the disease. Detection at earlier stages is associated 
with better prognosis (Fields and Wrench, 2015), allowing monitoring of 
disease progression and early treatment. 
Historically, the emergence of NHL as a class of diseases arose from a 
study of Hodgkin’s Lymphoma (HL) patients where some patients did not 
present with the typical characteristics of HL, such as Reed-Sternberg cells, 
huge infiltration of immune cells and an ordered lymph node – by – lymph 
node progression. These diseases were first acknowledged by Henry 
Rappaport in 1956 who aimed to classify lymphomas other than Hodgkin’s 
(Lukes and Collins, 1975). Since then, several methods of classifying NHL 
have been developed, resulting in the World Health Organisation classifying 
NHLs as B cell or T/NK cell in origin, and the diagnosis of specific subtypes 
being derived from a variety of genetic and immunophenotypic findings 
(Good and Gascoyne, 2008), as well as the maturation stage of the cell of 
origin. The classification of NHLs, based on their stage in B cell 
differentiation, will be discussed in more detail in section 2.3.6.  
2.3.2 Burkitt’s Lymphoma 
BL is a highly aggressive subset of B cell NHL that can be classified as 
endemic (eBL), which is associated with Epstein-Barr Virus (EBV) infection 
and malaria in Africa, or sporadic (sBL) which only has a 1-2% association 
with EBV. Human Immunodeficiency Virus (HIV)-associated BL is another 
classification and is associated with the loss of a functioning immune system 
due to HIV infection in Acquired Immunodeficiency Syndrome (AIDS) 
patients (Brady et al., 2007). The development of eBL requires the 
complementary activity of the malaria parasite, Plasmodium falciparum, and 
the EBV virus and, as a result, accounts for very few cases in the UK. 
Plasmodium falciparum induces the production of Activation-induced 
Cytidine Deaminase (AID) in GC B cells, which promotes genetic 
rearrangement, translocations and DNA damage. This process is 
complemented by EBV’s ability to prevent DNA repair by blocking p53 
activity. Taken together, this suggests a complex relationship between a 
pathogen that promotes DNA damage in GC B cells and a pathogen that 
prevents DNA repair, giving rise to DNA mutation-prone B cells and a 
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greater risk of developing BL (Thorley-Lawson et al., 2016). Most BL cases 
in the UK and Western world are sBL and are treated with rituximab-based 
(αCD20 monoclonal antibody (mAb)) chemotherapy regimens with promising 
survival rates reported (Hoelzer et al., 2012), (Barnes et al., 2011). BL can 
develop resistance, leading to relapse (Pineda et al., 2015), emphasising the 
need for new therapies.   
2.3.3 Diffuse Large B Cell Lymphoma 
DLBCL is the most commonly diagnosed form of NHL in the Western world, 
accounting for 30-40% of all NHL diagnoses (De Paepe and De Wolf-
Peeters, 2007). DLBCL is characterised by the presence of malignant B cells 
and may present as the GCB subtype, comprised of malignant centroblasts 
(Sehn and Gascoyne, 2015), or the more aggressive ABC subtype, 
comprised of B cells that have arrested during their differentiation into 
plasma cells and transformed (Perry et al., 2012). DLBCL-ABC is less 
responsive to current standard of care (Alizadeh et al., 2000), warranting 
research into novel mechanisms of therapeutic intervention. 
In the majority of cases, the cause of NHL is unknown, however, >30% of 
DLBCL-GCB cases present with a translocation between chromosomes 14 
and 18 (t(14:18)), which induces overexpression of BCL-2 (Iqbal et al., 
2004). Interestingly, despite the fact that there are no recorded cases of 
DLBCL-ABC that present with the t(14:18) translocation, BCL-2 is 
upregulated by enhanced activation of the Nuclear Factor Kappa-Light-
Chain-Enhancer of Activated B Cells (NFkB) pathway that is characteristic of 
this disease (Davis et al., 2001). Upregulation of NFkB is associated with 
mutations in multiple genes, including the NFkB negative-regulator, A20, 
which is mutated or deleted in ~30% of DLBCL-ABC cells (Compagno et al., 
2009). Overexpression of the anti-apoptotic protein, MCL-1, is also 
commonly associated with aggressive DLBCL-ABC (Wenzel et al., 2013). 
Elevated expression of anti-apoptotic proteins, such as BCL-2 and MCL-1, 
induce resistance to chemotherapy and, as such, are detrimental to the 
success of NHL treatments (Mounier et al., 2003), (Phillips et al., 2015). 
2.3.4 Follicular Lymphoma 
FL, the second most common NHL in the Western world, is classically 
indolent and accounts for 20-30% of all NHL (Ciobanu et al., 2013). FL is 
characterised by malignant B cells in the follicles of the LN. BM involvement 
is prevalent in 50-60% of FL cases (Salles, 2007) and is associated with a 
reduced response to standard therapy. The indolent nature of some FL 
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cases permits a “watch and wait” strategy, whereby therapy is withheld 
pending the progression of the disease (Berget et al., 2014). In advanced FL 
(stages III or IV), rituximab is used either alone or in combination with other 
chemotherapeutic agents, such as cyclophosphamide, Doxorubicin, 
vincristine and prednisolone. FL patients on rituximab-based chemotherapy 
have a response rate of >90% and a complete remission rate of 20-60% 
(Hiddemann and Cheson, 2014). FL has a propensity to relapse and/or 
transform, years after therapy, into a more aggressive and resistant disease 
(Solal-Celigny et al., 2004). This further demonstrates the urgent need for 
novel treatment strategies to target drug-resistant malignant cells. 
2.3.5 Current Therapy 
The vast range of NHL subtypes is met by an equally diverse array of 
therapies that can be used in isolation or in combination with each other. 
The most prominent treatment regimens are chemotherapy, radiotherapy or 
monoclonal antibody (mAb) therapy.  
2.3.5.1 The R-CHOP Regimen 
The current standard of care therapy for patients with NHL is the R-CHOP 
regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin 
(Hydroxydaunomycin), Vincristine (Oncovin) and Prednisolone. 
Rituximab is a chimeric αCD20 mAb that selectively binds to CD20 on B 
cells of all stages of development, except plasma cells, which do not express 
CD20. Rituximab’s cytotoxicity is mediated by mechanisms such as 
Antibody-Dependent Cellular Cytotoxicity (ADCC), Antibody-Dependent 
Cellular Phagocytosis (ADCP), Complement-Dependent Cytotoxicity (CDC) 
and activation of caspase 3, which makes the cell sensitive to apoptotic cell 
death (Weiner, 2010). ADCC is the best characterised mechanism of cell 
death with data implicating a role for NK cells, whereby the FcγRIIIa on the 
NK cell binds to the Fc (fragment crystallisable) region on the CD20-bound 
mAb, inducing perforin/granzyme-mediated lysis of rituximab-opsonised cells 
(Rudnicka et al., 2013). FcγRI engagement by monocytes and macrophages 
(Uchida et al., 2004), and neutrophils (Hernandez-Ilizaliturri et al., 2003) can 
also eliminate rituximab-opsonised cells by ADCP. Rituximab is a first 
generation αCD20 antibody, and is proceeded by second generation mAbs, 
such as ocrelizumab, veltuzumab and ofatumumab, which are humanised to 
reduce immunogenicity, and third generation, such as GA101/obinutuzumab 
which is fully humanised and has a modified Fc region (Lim et al., 2010); 
obinutuzumab’s Fc region lacks a fucose molecule, increasing its affinity for 
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FcyRIII on NK cells and promoting enhanced ADCC (Gagez and Cartron, 
2014). 
Cyclophosphamide adds an alkyl group to the guanine base of DNA and 
inhibits DNA replication (El-Serafi et al., 2014). Doxorubicin intercalates with 
DNA and inhibits DNA synthesis. It also inhibits the actions of topoisomerase 
II and causes DNA breaks, which increases the ratio of pro- (for example 
Bax) vs. anti-apoptotic (for example BCL-2) proteins to promote apoptosis 
(Tacar et al., 2013). Vincristine acts by binding to tubulin, inhibiting the 
separation of chromosomes during mitosis and forcing the cell to undergo 
apoptosis (Rai and Wolff, 1996).  
Lastly, prednisolone irreversibly binds to glucocorticoid receptors α and β 
causing them to dimerize, traffic to the nucleus and interact with cellular 
DNA to regulate gene transcription. This involves the regulation of several 
immunoregulatory genes, such as the suppression of IL-2 (Walker et al., 
1987); inhibition of the immune response eases discomfort for the patient 
(Dorff and Crawford, 2013). 
While some lymphomas show promising survival rates with R-CHOP therapy 
(FL; 76% 5-year survival with (Press et al., 2013)), others have a much 
poorer prognosis (DLBLC-ABC; 25% 5-year survival (Sehn and Gascoyne, 
2015)). NHL cases can also relapse following R-CHOP treatment or develop 
resistance to the therapy (Chao, 2013). The aggressive nature of these 
lymphomas warrants further research into more effective novel areas of 
therapeutic intervention with the hope of improving patient survival. 
2.3.5.2 Radiotherapy 
Radiotherapy involves using cytotoxic radiation exposure, locally applied to 
malignant LNs, to ablate cancer cells. It is more commonly used to treat 
indolent subtypes, such as FL, and can be used in conjunction with 
chemotherapy for aggressive subtypes, such as DLBCL (Zimmermann et al., 
2016). Radiotherapy for NHL patients is tailored to suit the individual with 
most regimens involving daily exposure of 30-35Gy for 2-4 weeks (Tsang, 
R.W. and Gospodarowicz, 2005). Whole body radiotherapy can also be used 
to deplete the patient’s immune system in preparation for a stem cell 
transplant (Kahn et al., 2005). Despite the fact that radiotherapy is not the 
primary method of treating NHL, it remains a useful tool in the clinic for 
supplementing the efficacy of other therapies or preparing the patient for a 
stem cell transplant. 
2.3.5.3 Surgery 
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Surgery plays a diminished role in treating NHL due to the advancement of 
more specific chemical, biological and radioactive therapies in recent 
decades. Surgery remains an option to retrieve malignant tissue for biopsies, 
to remove small, localised disease that is affecting non-lymphatic organs 
such as the stomach or small bowel, and a splenectomy to remove a 
malignant spleen (Weledji and Orock, 2015). Splenectomies are largely 
reserved for patients with enlarged spleens due to Splenic Marginal Zone 
Lymphoma or lymphoma that has invaded, and enlarged, the spleen 
(Kennedy et al., 2018).  
2.3.6 The Lymph Node Environment 
While the primary focus of cancer research is on the cancer cells, the tumour 
microenvironment (TME) is a vital factor when investigating candidate 
treatments for efficacy. The TME comprises the cancer cells, their 
surrounding immune and stromal cells, including blood supply and nutrients. 
These neighbouring cells, while non-transformed, can inadvertently provide 
support to cancer cells, making them more difficult to treat. While this is very 
true for solid malignancies, haematological malignancies, which may 
comprise blood cells that circulate in the peripheral blood, can also home to 
locations in the body that provide a comparable support system, such as 
leukaemias which reside in the bone marrow, making them more difficult to 
treat. Research by Ilkow, et al., has highlighted the role of the TME when 
considering OV as a treatment option for solid malignancies and shown that 
the TME can actually assist the OV by diminishing the ability of the cancer 
cells to destroy the virus (Ilkow et al., 2015). this data highlights the 
importance of considering the TME when examining novel therapies for 
efficacy against cancer, such as NHL, which predominantly resides in the 
patient’s lymph nodes. 
The human body contains ~450 LNs that are interconnected by the 
lymphatic system, a complex network of vasculature, closely associated with 
the circulatory system. LNs provide densely packed, tightly regulated 
environments for migrating immune cells to interact, present their cognate 
antigen, mature and induce an immune reaction to foreign antigens. They 
also provide a microbe filter for the blood, allowing immune cells, such as 
dendritic cells, that have identified and ingested foreign microbes to migrate 
out of the blood and into the LN where they present their antigen to immune 
effector cells and stimulate an immune response. A schematic of a human 
LN is shown in Figure 2-2. 
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Figure 2-2: The structure of the human LN. 
The LN is comprised of segments known as lobules, of which there may be 
one or several per LN. Within each lobule, lies a B cell-rich follicle (white) 
which contains a densely-packed area of proliferating B cells known as the 
germinal centre (yellow). B cells migrate to this area upon entering the LN 
where they interact with follicular dendritic cells and other antigen presenting 
cells (APCs) and activate to become mature B cells during infection. The 
germinal centre and follicle are closely associated with the T cell-rich 
paracortex (blue) which allows T cells to interact with B cells, promoting their 
maturation and function. The paracortex itself, much like the follicle, is 
encapsulated in a layer of extracellular matrix and provides a location for 
migrating T cells to interact with APCs, which present antigens to T cells, to 
promote their activation and clonal expansion to combat foreign antigens. 
Beyond the paracortex are the macrophage- and plasma cell-rich medullary 
cords (red). It is to here that the maturing B cells will migrate from the 
follicles and complete their maturation into plasma cells before they release 
antibodies into the lymph to fight infection. The nodules are separated from 
each other by sinuses that are composed of extracellular matrix and follicular 
dendritic cells (Andrews, 2008), (Willard-Mack, 2006).  
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As previously mentioned (section 2.3.1), the classification of NHL is partially 
based on cellular characteristics, their stage in B cell development and 
location within the LN, such as the follicle for FL and BL, the dark zone of the 
germinal centre for DLBCL-GCB and light zone for DLBCL-ABC 
(Pasqualucci and Dalla-Favera, 2014). Figure 2-3 demonstrates the 
different B cell malignancies and where they arise during B cell 
development.  
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Figure 2-3: The emergence of malignancies during B cell development. 
This diagram shows the progression of a naïve B cell through the LN where 
it will undergo somatic hypermutation and class switching to form a B cell 
clone that targets a specific antigen. During these processes, errors in 
genetic rearrangement can result in the emergence of a malignant B cell 
clone. This can occur before the B cell enters the LN, such as with Chronic 
Lymphocytic Leukaemia (CLL), in the GC as a centrocyte, such as DLBCL-
GCB, or as a plasmablast, such as DLBCL-ABC. (Koues et al., 2015) 
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The LN plays a critical role in controlling the development and activation of 
immune cells and generating an immune response. Interactions between 
cells residing in the LN facilitate these events and can be hijacked by 
tumorigenesis. B cell: T cell interactions in the LN are important for B cell 
selection, maturation and proliferation (Janeway CA Jr, 2001). In particular, 
the CD40:CD40L interaction gives a strong pro-survival signal to developing 
B cells (Elgueta et al., 2009), allowing B cells to survive the maturation 
process. B cell: T cell interactions within the LN have been described 
previously to confer drug resistance to malignant B cells through 
manipulation of pro- and anti-apoptotic protein ratios (Romano et al., 1998), 
(Kater et al., 2004), (Kitada et al., 1999), (Romano et al., 1998). To simulate 
the B cell: T cell reaction in the LN, NHL cell lines can be co-cultured on 
CD40L+ fibroblasts (L929 murine fibroblasts transfected with human CD40L), 
which has previously been shown to induce resistance to Doxorubicin in 
Daudi, Raji, BJAB, BL36 and BL70 NHL cell lines (Voorzanger-Rousselot et 
al., 1998). The emergence of drug-resistant NHL poses a challenge to the 
efficacy of current treatments, warranting the need for alternate methods to 
eliminate drug resistant cells.  
2.4  Oncolytic Virotherapy 
Oncolytic (“cancer bursting”) viruses (OV) preferentially infect and kill 
malignant cells and/or manipulate the patient immune system to mount an 
anti-cancer immune response. The concept of harnessing the cytotoxic and 
immunogenic properties of viruses for selective use against malignant cells 
dates to the early 20th century when it was first observed that patients with 
solid tumours or leukaemia developed a brief or sustained remission 
following viral infection (Dock et al., 1904). The mechanisms behind this 
phenomenon were researched during the decades that followed. This 
research, alongside the characterisation of viral human pathogens and 
cancer and the advent of genetic manipulation, lead to the development of 
oncolytic virotherapy as a novel and promising therapy for several cancers 
(Kelly and Russell, 2007). 
Some OVs have been genetically modified to enhance their selectivity for 
malignant cells and their immunomodulatory effects. Talimogene 
Laherparepvec (T-Vec), an oncolytic Herpes Simplex Virus 1 (HSV-1) which 
was approved by the FDA for clinical use in 2015, has been genetically 
modified to lack the Infected cell protein 34.5 (ICP 34.5) gene and express 
granulocyte-macrophage colony-stimulating factor (GM-CSF), thus 
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prohibiting its replication in normal cells, such as neuronal cells, and 
activating the immune system, respectively (Randazzo et al., 1997). Other 
OVs such as Reolysin® (reovirus Type 3 Dearing) and CAVATAK™ 
(Coxsackievirus Type A21, CVA21) are naturally occurring human 
pathogens. These OV have not been genetically manipulated but have been 
selected due to their innate preferential targeting of malignant cells. Most of 
the healthy population has already been exposed to reovirus (Douville et al., 
2008) and less than 10% has been exposed to CVA21 (Israelsson et al., 
2011). Pre-exposure to either virus could result in neutralising antibodies or 
immune memory against them, potentially resulting in eradication by the 
patient’s immune system (Ferguson et al., 2012). However, replication-
competent reovirus has previously been retrieved from the blood and liver 
metastasis of colorectal cancer patients that received intravenous virus 
before surgery, despite the presence of pre-existing anti-reovirus antibodies 
(Adair et al., 2012). Moreover, a phase I clinical trial that examined the 
safety and tolerability of reovirus in patients with advanced cancers 
demonstrated viral localisation and replication in 3 out of 33 patient tumours, 
despite the presence of neutralising antibodies (Vidal et al., 2008). These 
findings demonstrate a potential use for reovirus, despite the presence of 
pre-existing immunity. 
2.4.1 Mechanism of action 
The primary mechanism of action of OVs was initially believed to be direct 
lysis of tumour cells which would result in the release of progeny viruses, 
thus perpetuating the oncolytic effect (Bauzon and Hermiston, 2014). Recent 
research has shown that this is not their sole mechanism of action, and OVs 
also target the tumour stroma and vasculature, and activate the innate and 
adaptive immune system to destroy malignant cells, thus providing a multi-
armed effect against the tumour (Lichty et al., 2014). The potential for 
immune modulation by OV therapy will be discussed further in section. 
2.4.1.1 Oncolysis 
A range of molecular and cellular factors will determine whether a malignant 
cell will be susceptible to OV infection, some of these are summarised in 
Table 2-2 and discussed below.  
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Virus Modifications Preferential infectivity 
NDV Strain 73T-R-
198; Altered 
fusion protein 
Preferential targeting of mammalian over avian 
cells, reducing risk of environmental damage if 
released (Cheng et al., 2016) 
HSV-1 Strain R5111; 
glycoprotein 
replaced with 
human IL-13 
Targets cancer cells that express elevated levels 
of IL-13Rα2 receptor on their surface (Zhou et 
al., 2002) 
Strain T-vec; 
viral ICP 34.5 
deleted, 
human GM-
CSF inserted 
Resulting virus is unable to infect healthy cells 
with normal antiviral response, preferentially 
targets malignant cells with a defective response 
(Randazzo et al., 1997) 
Poliovirus Strain PVS-
RIPO; coding 
region  
replaced with 
type 1 live 
attenuated 
vaccine strain 
Preferentially targets cancer cells that express 
elevated levels of CD155 (Ochiai, H. et al., 
2006) 
CVA21 n/a Over-expression of entry receptor ICAM-1 on 
tumour cells (Au et al., 2005) 
Reovirus n/a Deregulation of ras family proteins in tumour 
cells, resulting in defective antiviral signalling 
(Marcato et al., 2007) 
VSV n/a Unable to replicate in cells with functioning IFN 
response, instead infect IFN-deficient tumour 
cells (Hastie and Grdzelishvili, 2012) 
Vaccinia 
virus 
n/a Targets tumour cell antiviral response pathways 
(Colamonici et al., 1995) 
Insert human 
epidermal 
growth factor 
receptor 2 
(HER2) 
Targets HER2+ breast cancer tumour (Sharp 
and Lattime, 2016) 
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transgene 
Table 2-2: List of Oncolytic viruses being investigated at clinical and 
pre-clinical levels in various malignancies. 
This list provides an overview of the diverse range of oncolytic viruses that 
are being investigated in cancer research  
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2.4.1.1.1 Overexpression of Viral Entry Receptors 
OV often rely on overexpression of surface receptors on malignant cells for 
viral entry (Jhawar et al., 2017). These receptors are often highly expressed 
on cancer cells, making them more susceptible to OV infection than their 
non-transformed counterparts. T-Vec, as with the parental HSV-1 strain, 
utilises Herpesvirus Entry Mediator (HVEM) and nectin-1 and -2, which are 
overexpressed on a variety of cancer types (Kohlhapp et al., 2015), for viral 
entry. CVA21, a human enterovirus that targets cells in the upper airways, 
preferentially infects cancer cells that express enhanced levels of its 
attachment (Decay Accelerating Factor, DAF) and entry receptors 
(Intercellular Adhesion Molecule-1, ICAM-1) (Au et al., 2005). Echovirus 1, 
another enterovirus, targets ovarian cancer cells that display enhanced 
levels of integrin α2β1 on their cell surface (Shafren, D.R. et al., 2005). 
Similarly, an oncolytic recombinant poliovirus strain, that preferentially 
targets malignant glioblastoma multiforme (GBM) cells that express high 
levels of CD155 has been developed (Ochiai, H. et al., 2006). Importantly, 
as discussed in a review by Singh, et al., overexpression of a viral entry 
receptor, a receptor that may also be present on the surface of many healthy 
cells, is unlikely to be sufficient for preferential infection of malignant cells 
(Singh et al., 2012). Other mechanisms of OV tumour specificity are 
discussed below. 
2.4.1.1.2 Genetic Manipulation of Viruses 
The advent of the genetic manipulation of organisms has allowed viruses to 
be modified to alter their host tropism and pathogenicity. This can result in 
diminishing the cell tropism of a potentially dangerous virus, such as HSV-1, 
so that it only targets cancer cells. HSV-1 is one of the most studied viruses 
in this regard as numerous oncolytic strains of the virus, with various genetic 
modifications, have been developed (Sokolowski et al., 2015). HSV’s large, 
stable DNA genome is an ideal candidate for genetic modification, allowing 
genes to be deleted and added. HSV-1 also possesses an outer envelope 
that can be manipulated to enhance targeting of cancer cells. For example, a 
HSV-1 strain, which has had its glycoprotein gD replaced with human IL-13, 
targets cancer cells that express elevated levels of IL-13Rα2 receptor on 
their surface (Zhou et al., 2002).  
Newcastle Disease Virus (NDV), an avian paramyxovirus, is currently being 
investigated as an oncolytic agent in many tumours such as advanced renal 
and breast carcinoma (Omar et al., 2003). Due to its ability to target avian 
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species, the use of NDV carries some environmental risks, leading to the 
development of a genetically modified strain of NDV, with an altered fusion 
protein, which preferentially infects mammalian cells (Cheng et al., 2016). 
2.4.1.1.3 Defective Antiviral Response 
The antiviral response is a broad term that includes all aspects of the 
immune system’s ability to prevent viral infection. This response can be 
innate and fast-acting, such as the interferon (IFN) response (depicted in 
Figure 2-4) and NK cells which can detect and target virally-infected 
malignant cells through loss of MHC-I, or acquired and slower to develop, 
such as priming of virus-specific T cells that target virally-infected malignant 
cells or generating a humoral immune response where B cells produce 
neutralising antibodies against a virus. The IFN response is a common 
obstacle to viral infection and may prevent the application of IFN-sensitive 
OV to cancer cells with functional IFN signalling (Singh et al., 2012). 
The IFN response allows infected and neighbouring cells to communicate 
and prevent further viral replication. Infected cells detect Pathogen 
Associated Molecular Patterns (PAMPs), such as viral genetic material or 
bacterial components, by Pattern Recognition Receptors (PRRs), such as 
Toll-Like Receptors (TLRs) or other sensors of virus material (Takeuchi and 
Akira, 2010). TLRs, such as TLR7 and 8, recognise viral single-stranded 
RNA (ssRNA) in endosomes upon viral entry (Wang, J.P. et al., 2007), 
(Triantafilou et al., 2005) and TLR3 recognises double-stranded RNA 
(dsRNA), and has been implicated in detecting the genome of reovirus 
(Maitra et al., 2017). Coxsackieviruses can be detected by a variety of 
intracellular proteins such as Melanoma Differentiation-Associated protein 5 
(MDA5), which senses viral dsRNA during replication in the cytoplasm 
(Valaperti et al., 2013), and TLR7 and 8.  
Pathogen detection triggers signalling pathways that induce the expression 
of pro-inflammatory cytokines and the production of type 1 IFNs (Zhu and 
Mohan, 2010). Upon IFN release, IFN binds receptors on neighbouring cells, 
triggering a signalling cascade through Signal transducer and activator of 
transcription (STAT) molecules, such as STAT1, which induces the 
expression of Interferon-Stimulated Genes (ISGs) to inhibit propagation of 
viruses and other pathogens (Schneider et al., 2014). ISGs include Tripartite 
Motif-containing protein 5-α (TRIM5α), which binds to, and disrupts, 
retroviral capsids (Black and Aiken, 2010), tetherin, which sequesters new 
enveloped virus particles to the cell surface (Mahauad-Fernandez and 
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Okeoma, 2016), MHC-I and –II, which are involved in antigenic presentation, 
Protein Kinase R (PKR), which senses viral dsRNA and shuts down host cell 
protein translation (Sadler and Williams, 2007), and Oligoadenylate 
synthetase 1 (OAS1), which detects viral dsRNA and activates RNase L to 
degrade it. The IFN response in neighbouring non-infected cells results in a 
highly defensive, antiviral state preventing replication in these cells and 
limiting infection. 
Many cancers have defective IFN response pathways, due to the 
accumulation of mutations that render the pathway ineffective (Critchley-
Thorne et al., 2009). This provides an opportunity for OV to replicate freely 
without the constraints of host natural defences. Some OVs, such as 
Vesicular Stomatitis Virus (VSV), are sensitive to IFN, which protects healthy 
tissues that have retained the pathway, while the virus can replicate in and 
destroy IFN-defective malignant cells (Hastie and Grdzelishvili, 2012). 
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Figure 2-4: Defective IFN response facilitates OV replication in 
malignant cells. 
In healthy cells, a functioning IFN response will block viral replication and 
dissemination, as described. Dysfunction of these pathways have been 
reported in many cancers, providing OV with a vulnerability that can be 
exploited to target malignant cells while sparing healthy cells (Kaufman et 
al., 2015). 
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Some viruses have also evolved mechanisms to overcome functional IFN 
responses to allow viral replication.  For example, the V protein encoded by 
the avian paramyxovirus NDV can target the antiviral response by 
degradation of STAT1 molecules in avian cells, but not in human cells (Park 
et al., 2003), suggesting that cancer cells with deficient IFN signalling may 
be more susceptible to NDV-induced cell death (Fiola et al., 2006). 
Furthermore, the B18R protein encoded by Vaccinia virus is able to bind to 
IFN-α, thus blocking its ability to signal neighbouring cells (Colamonici et al., 
1995). A summary of how viruses can subvert the antiviral IFN response 
pathway is shown in Figure 2-5. 
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(a) 
(b) 
 
 
Figure 2-5: Viral mechanisms for evading the antiviral IFN response.  
(a) Proteins expressed by Influenza, Arenaviruses and paramyxoviruses can 
block virus-detecting PRRs, such as RIG-1 and MDA5, while RSV and 
Measles viruses inhibit TLR7 and 8 signalling. This results in defective viral 
detection and inhibits the induction of IFN proteins. (b) Japanese 
Encephalitis Virus, Dengue virus, Inluenza A, Hepatitis C Virus, Sendai 
Virus, Measles, Rubula virus and Hendraviruses inhibit downstream 
signalling of IFN receptors, resulting in a diminished antiviral response. 
(Devasthanam, 2014)  
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2.4.1.1.4 Mechanistic Target of Rapamycin (mTOR) 
Dysregulation of the Ras pathway confers sensitivity of malignant cells to 
oncolytic reovirus (Strong et al., 1998) and dysfunctional IFN signalling 
prevents the production of antiviral proteins, contributing to a favourable 
intracellular environment for OV replication (Wollmann et al., 2007). Another 
example of a pathway that is altered in cancer cells is the Mechanistic 
Target of Rapamycin (mTOR) pathway, which contributes to cell 
proliferation, nutrient sensing, transcription, translation, and cytoskeletal 
remodelling. MTOR’s reported hyperactivity in a variety of cancers (Saxton 
and Sabatini, 2017), its importance for NHL cell survival (Bhatt et al., 2010), 
and its frequent hijacking by viruses to control the stress response of cells 
(Le Sage et al., 2016), make it a possible determinant of OV susceptibility. 
2.4.1.1.4.1 Role of mTOR in Cellular Biology 
MTOR is a serine/threonine protein kinase that plays a major role in cell 
metabolism, growth and survival (Tan and Miyamoto, 2016) and is a key 
regulator of autophagy; the process by which cells degrade and recycle 
intracellular proteins during times of stress. MTOR is active in either of two 
functionally distinct protein complexes; mTOR Complex 1 or 2 (mTORC1 or 
mTORC2), as shown in Figure 2-6. 
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Figure 2-6: Components of mTORC1 and 2. 
MTORC1 consists of mTOR, Regulatory-associated protein of mTOR 
(Raptor), mammalian lethal with SEC13 protein 8 (mLST8), proline-rich Akt 
substrate of 40 kDa (PRAS40) and DEP domain-containing mTOR-
interacting protein (DEPTOR) (Ding et al., 2018). MTORC2 is composed of 
mTOR, mLST8, mammalian stress-activated protein kinase interacting 
protein 1 (mSIN1), DEPTOR, Rapamycin-insensitive companion of 
mammalian target of rapamycin (RICTOR) and Protein observed with Rictor 
(PROTOR), and regulates cell survival and cytoskeleton remodelling by 
downstream effectors such as Akt and members of the Protein Kinase C 
(PKC) family, respectively (Saxton and Sabatini, 2017).  (Figure obtained 
from (Guertin and Sabatini, 2009). 
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MTORC1 is a nutrient sensor that controls transcription and cap-dependent 
translation by phosphorylating downstream pathway components, such as 
S6 Kinase (S6K) or Eukaryotic translation initiation factor 4E-binding protein 
1 (4EBP1) (Showkat et al., 2014), under nutrient-rich conditions. Before 
activation by mTORC1, 4EBP1 is bound to Eukaryotic translation initiation 
factor 4E (eIF4E), preventing it from initiating translation; mTORC1 
phosphorylates 4EBP1, releasing eIF4E to initiate translation (Faller et al., 
2015). The second pathway downstream of mTORC1 signals through S6K 
which regulates ribosomal translation by phosphorylating S6 on ribosomes 
and initiating translation (Magnuson et al., 2012). MTORC2 has been 
identified as a prominent influencer of amino acid metabolism in cancer, 
allowing malignant cells to adapt to new conditions (Gu, Y. et al., 2017), and 
contributes to tumourigenesis by promoting lipid synthesis (Guri et al., 2017).  
2.4.1.1.4.2 Role of mTOR in viral replication 
Viruses rely heavily on cellular processes, such as transcription and 
translation, for replication (Walsh et al., 2013). MTOR’s control over 
pathways that affect these processes make it, and its downstream effector 
molecules, targets for viral manipulation. EBV’s Latent Membrane Protein 2A 
(LMP2A) activates upstream regulators of mTOR, such as 
phosphatidylinositol 3-kinase (PI3K)/Akt, resulting in enhanced translation of 
viral proteins (Moody et al., 2005). Adenoviruses express two proteins, E4-
ORF1 and E4-ORF4, which mimic growth factors and glucose, respectively, 
to activate mTOR, even in low-nutrient conditions (O'Shea et al., 2005). 
Viruses also mimic the downstream effectors of mTOR, for example, HSV-1 
expresses Infected Cell Protein 6 (ICP 6) which overrides 4EBP1’s control of 
RNA translation by acting as a chaperone for Eukaryotic initiation factor 4F 
(eIF4F) (Walsh and Mohr, 2006) to initiate translation. Other viruses, such as 
Respiratory syncytial virus (RSV), abrogate memory CD8+ T cell 
differentiation by phosphorylating and activating mTOR, thus impairing the 
ability of CD8+ T cells to develop immunological memory to RSV (de Souza 
et al., 2016).  
Autophagy, which is controlled by mTOR, can be essential or detrimental to 
viral replication, as the process is required by some viruses to replicate, 
such as Influenza A (Yeganeh et al., 2018), while also posing a risk to other 
viruses by degrading viral proteins (Levine, 2005). In the latter case, which is 
termed xenophagy, autophagy can be used as an antiviral response 
mechanism. Some viruses, such as CVA16 and other picornaviruses, have 
developed mechanisms to control autophagy, so that autophagic bodies are 
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produced within the cell to allow viral replication (Shi et al., 2015), (Klein and 
Jackson, 2011).  
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2.4.1.2 OV anti-tumour immunity 
An alternate mechanism of action of OV therapy is the activation of the 
patient immune system to mount a response against malignant or virally-
infected cells. This effect is summarised in Figure 2-7. 
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Figure 2-7: OV-induced immune response against malignant or virally-
infected cells. 
While the primary mechanism of action of OVs was believed to be direct 
cytotoxicity (1st panel), alternate mechanisms have been discovered. The 
presence of OV can activate NK cells to target malignant or virally-infected 
cells, or induce the secretion of cytotoxic cytokines to kill malignant cells 
(2nd panel). The rupture of malignant cells can result in the presentation of 
Tumour-Associated Antigens (TAAs) and OV antigens to T cells by APCs to 
stimulate an adaptive response (3rd panel). The benefits of this response 
include a systemic effect of memory circulating tumour- or OV-specific T 
cells, and their ability to target distant metastases (4th panel) (Labiotech.eu, 
2015).  
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Immunogenic cell death, as distinct from apoptosis, arises from the rupture 
of a dying cell, resulting in the release of its intracellular components. Upon 
release, these components may be detected by the immune system as a 
“danger signal”, resulting in the stimulation of an immune response to mop 
up and clear the debris from the dead cell. Immunogenic cell death can also 
arise during the late stages of a lytic viral infection, whereby the newly-
synthesised virions within an infected cell burst out, killing the cell and 
releasing themselves and the cellular components. This can result in an 
immune response to these viruses (Donnelly et al., 2013). This form of cell 
death can be instrumental in OV therapy, as it can result in an immune 
response against the virus and the cancer cells, contributing to the anti-
cancer effect. Such a response can be evaluated in vitro by examining the 
cells for non-apoptotic cell death by flow cytometry, release of nuclear 
proteins such as High mobility group box 1 (HMGB1) and release of 
Adenosine Triphosphate (ATP) (Kepp et al., 2014).  
Despite the co-existence of malignant B cells with normal immune cells, 
such as NK cells, T cells and dendritic cells (DCs), within the highly 
immunological environment of the LN, the patient immune system fails to 
obliterate the aberrant cells. The presence of these immune cells provides 
an arsenal for priming an immune response against NHL, however, the 
effects of immunosuppressive cells in the LN prevents recognition and 
destruction of the NHL cells. This will be discussed in more detail in section 
2.4.1.2.2. The duration of an OV-induced anti-cancer immune response can 
vary from short term innate responses, such as NK cell-mediated responses, 
to long term adaptive responses comprising immunological memory, such as 
T cell-mediated responses (Filley and Dey, 2017). This will be discussed in 
more detail in section 2.4.1.2.2. 
2.4.1.2.1 Innate immune responses 
The innate immune response is a broad range of cellular responses to 
antigenic assault, ranging from the IFN response, as described in 2.4.1.1.3, 
to NK cell-mediated responses. IFNs, in addition to stimulating the enhanced 
expression of ISGs, such as Tetherin and MHC-I, exert a range of effects on 
their target cells that aid their antiviral effects. These effects can include 
inducing cell cycle arrest to hamper viral replication (Sangfelt et al., 2000), 
inducing apoptosis in infected and malignant cells (Chawla-Sarkar et al., 
2003), and cell metabolism (Wu et al., 2016). IFNs also play a critical role in 
immune regulation, such as promoting class switching during B cell 
development and the production of a humoural immune response (van den 
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Broek et al., 1995), activating monocytes (Buchmeier and Schreiber, 1985) 
and elevating MHC expression to facilitate antigen presentation and promote 
T cell responses (Bernard Mach et al., 1996). 
An NK cell-mediated response can be achieved following OV treatment, 
whereby an infected cancer cell could be manipulated by the virus to 
decrease MHC I expression and subsequently block antigen presentation to 
T cells (Bhat et al., 2011). Inadvertently, this would result in the NK cell 
detecting the lack of MHC I expression (“lack of self”), resulting in NK-
mediated killing of malignant, virus-infected, cells (Woller et al., 2014). 
Moreover, OV, such as reovirus, can also activate NK cells, through 
stimulating monocytes to produce IFN-α, to target non-infected malignant 
cells, as has been demonstrated in HMs, such as CLL (Parrish et al., 2015) 
and AML (Hall et al., 2012). Research by Miyamoto, et al., also 
demonstrated enhanced NK cell and granulocyte infiltration into established 
lung cancer tumours following intratumoral treatment with Coxsackievirus B3 
(CVB3) in female BALB/c nude mice (Miyamoto et al., 2012). The decision 
by an NK cell to kill results in the trafficking of intracellular granules to the 
cell surface where the contents are released (known as degranulation) into 
the extracellular space to attack the target cell. Cytolytic granules contain 
perforin, a glycoprotein that inserts itself into the target cell membrane and 
oligomerises to form a pore (Osinska et al., 2014), and multiple proteases, 
such as Granzyme B, a serine protease that enters the cell via the perforin 
pore and initiates a proteolytic cascade resulting in apoptosis of the target 
cell (Lord et al., 2003). Interestingly, perforin alone can kill the target cells by 
causing it to lyse (Waterhouse et al., 2006). Alternatively, NK cells can 
deliver death signals to target cells via interactions between Fas (First 
apoptosis signal) Ligand and TRAIL (TNF-related apoptosis-inducing ligand) 
on the NK cell surface, or secreted tumour necrosis factor-α (TNF-α), with 
their cognate receptors on the target cell. These interactions result in the 
activation of the caspase cascade and directly trigger apoptosis (Zamai et 
al., 1998). 
Virus infection can also result in infected and neighbouring cells secreting 
cytokines, for example, the alphavirus M1 stimulates the secretion of  IL-8, 
IL-1A, and TRAIL, which induced cell death in hepatocellular carcinoma and 
colorectal cancer cell line models (Cai et al., 2017). This indirect cytotoxicity 
towards malignant cells is known as bystander killing. 
Reovirus has displayed immunogenic properties, including activation of  
innate immunity, such as enhancing NK cell-mediated targeting of anti- 
35 
 
 
epidermal growth factor receptor (αEGFR) antibody (cetuximab)-coated 
colorectal cancer cell lines (Zhao, X. et al., 2015), inducing the IFN response 
against AML cells (Hall et al., 2012) and inducing CD8+ antigen-specific T 
cells  to target melanoma LN metastases in a C57BL/6 mouse model 
(Prestwich, R. J. et al., 2008). Innate immune responses are potent tools in 
targeting malignant cells, however, an adaptive T cell-mediated response 
can provide a more durable anti-cancer effect. 
2.4.1.2.2 Adaptive Immune responses 
Oncolysis results in the release of antigens of viral or cellular origin which 
can be ingested and presented by professional APCs, such as DCs, to 
developing T cells. This can lead to an antigen-specific T cell response that 
can recognise and target malignant cells (Howells et al., 2017). This has 
been demonstrated in multiple animal models including: a FVB/N mouse 
model of breast cancer that used a GM-CSF- and human epidermal growth 
factor receptor 2 (HER2)-expressing vaccinia virus to induce cytotoxic CD8+ 
T cell targeting of a HER2+ breast cancer tumour (Sharp and Lattime, 2016); 
and a Syrian (golden) hamster model of pancreas ductal adenocarcinoma 
that demonstrated CD8+ T cell-dependent antitumour response in wild-type 
adenovirus type 5-treated animals (Li, X. et al., 2017). Healthy CD4+ and 
CD8+ T cells are functional and capable of destroying NHL cells, lending 
hope to the possibility that the patient’s immune cell arsenal could be utilised 
to fight the malignancy (Yang, Z.Z. et al., 2006a), (Yang, Z.Z. et al., 2006b).  
CD8+ cytotoxic T cells fail to destroy NHL cells due to the presence of 
immunosuppressive regulatory T cells (Tregs) (Yang, Z.Z. et al., 2006b). 
Treg populations in NHL result in an inhibited adaptive T cell-mediated 
immune response and the persistence of the malignant cells (Wang, Jing 
and Ke, 2011). Recent research has shown that OV can alleviate the 
immunosuppressive effects of Tregs; examples include oncolytic adenovirus 
that decreases tumour-infiltrating Tregs in a syngeneic glioblastoma 
multiforme (GBM) mouse model (Qiao et al., 2015), oncolytic HSV-1, which 
reduced Treg populations in melanoma patient tumours following 
intratumoural injection (Kaufman et al., 2010), and  reovirus, which 
decreased numbers of tumour-residing Tregs in a C57BL/6 ovarian cancer 
model (Gujar, S. et al., 2013). Taken together, these findings implicate a role 
for OV in priming an adaptive anti-cancer immune response by alleviating 
the immunosuppressive effects of Tregs and promoting T cell-mediated 
targeting of malignant or virally-infected cells. 
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2.4.1.2.3 Combinations with Immunomodulatory Drugs 
The ability of OV to promote anti-cancer immune responses is being 
investigated in combination with immunomodulatory drugs, such as mAbs. 
MAbs specifically bind to their target antigen, resulting in blocking of an 
interaction between malignant cells and immune cells, such as PD-L1 
(Programmed death-ligand 1) on malignant cells signalling to PD-1 
(Programmed cell death protein 1) on immune cells to inhibit immune cell 
targeting of malignant cells. MAbs have shown efficacy against a range of 
solid and haematological malignancies, for example, the αPD-1 antibody, 
pembrolizumab, lead to a progression-free survival rate in 38% of melanoma 
patients vs 16% in those that received chemotherapy (carboplatin and/or 
paclitaxel) (Ribas et al., 2015). MAbs can also mark the mAb-coated 
malignant cells for immune destruction, as previously discussed with 
rituximab (section 2.3.5.1).  
Rituximab binds to CD20 on malignant B cells and, coupled with its direct 
effects, such as downregulating the B Cell Receptor (BCR) (Kheirallah et al., 
2010) and inducing apoptosis (Pedersen et al., 2002), stimulates anti-tumour 
immunity against them by ADCC, CDC and possibly ADCP (Oflazoglu and 
Audoly, 2010). Given that rituximab achieves its efficacy by activation and 
utilisation of the immune system, and OVs can activate the immune system 
(Aurelian, 2016), combinations of OV and mAbs to treat a variety of cancers 
are being investigated. Previous work by Parrish, et al., showed that in vitro 
reovirus treatment enhanced rituximab-mediated NK cell ADCC against ex 
vivo CLL (Parrish et al., 2015). The enhanced effects of this combination 
could be investigated in other B cell malignancies such as NHL where 
rituximab is already part of the current standard of therapy. Despite low NK 
cell numbers in the LN (Bajenoff et al., 2006), it may be possible to induce 
the trafficking of NK cells to LN during OV therapy, as has been 
demonstrated in mouse models in which virus infection, for example, 
influenza (Duan et al., 2017) and ectromelia virus (ECTV) (Parker et al., 
2007), can stimulate NK cell trafficking to the LN.  
Current immunotherapy strategies, including rituximab, are successful 
against NHL, providing scope for further harnessing of the immune system 
with OV therapy. The possibility for the immune system to eradicate 
malignant cells in the LN suggests that OV therapy, alone or in conjunction 
with immunomodulatory drugs, may harness the potential of anti-tumour 
immunity.  
2.4.1.3 OV in B Cell Malignancies 
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Previous work on OV therapy in the context of NHL has shown that some 
NHL cell lines in isolation are sensitive to reovirus oncolysis, while others are 
resistant (Alain et al., 2002). This could present a challenge for treating NHL 
with reovirus as some patients may remain resistant to OV direct oncolysis, 
however this does not preclude a role for reovirus-induced immunotherapy. 
Other OVs have been investigated in pre-clinical research for efficacy 
against B cell malignancies. Table 2-3 summarises these findings (Angelova 
et al., 2017).  
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B cell 
Malignancy 
OV Outcome References 
Multiple 
Myeloma 
Reovirus Reovirus induced autophagy-
dependent apoptosis in a myeloma 
cell line (RPMI 8226) 
(Thirukkumara
n, C. M. et al., 
2013) 
VSV VSV induced cell death in myeloma 
cell lines and primary patient cells, 
but not PBMCs. 
(Lichty et al., 
2004) 
Myxoma Intravenous myxoma virus reduced 
myeloma burden in female Balb/C 
mice by 70-90% through direct 
oncolysis and priming of a CD8+ T 
cell-mediated response. 
(Bartee et al., 
2016) 
Vaccinia Vaccinia virus induced replicative cell 
death in myeloma cell lines 
(Deng et al., 
2008) 
Adenovirus Ad 5 induced cell death in most 
myeloma cell lines and primary 
patient cells 
(Senac et al., 
2010) 
CVA21 CVA21 induced replicative cell death 
in myeloma cell lines and purged 
patient BM biopsies of up to 98·7% of 
CD138+ plasma cells. 
(Au et al., 
2007) 
NHL HSV-1 HSV-1 replicated in 1/3 NHL lines (Esfandyari et 
al., 2009) 
Reovirus Reovirus exhibited significant purging 
of NHL cells from patient blood, but 
not healthy PBMCs. 
(Thirukkumara
n, Chandini M. 
et al., 2003) 
Reovirus induced cell death in 6/9 
NHL cell lines and 21/27 primary 
patient samples, but not PBMCs. 
(Alain et al., 
2002) 
Adenovirus Adenovirus induced cell death in all 
primary MCL samples. 
(Medina et al., 
2005) 
Measles Replication-competent measles virus 
induced tumour regression in 
established human lymphoma 
xenografts in Balb/C mice 
(Grote et al., 
2001) 
CLL VSV BCL-2 inhibitors sensitised primary 
CLL cells, but not PBMCs, to VSV 
oncolysis. 
(Tumilasci et 
al., 2008) 
Reovirus Reovirus promotes rituximab-
mediated ADCC of CLL targets 
(Parrish et al., 
2015) 
B-lineage-ALL Measles Measles virus-loaded BM-derived 
mesenchymal stromal cells deliver 
virus to ALL cell targets in a SCID 
mouse model  
(Castleton et 
al., 2014) 
B-
lymphoblastic 
leukaemia 
Adenovirus IL-24-expressing Adenovirus5 
induced cell death in human B-
lymphoblastic leukaemia and 
lymphoma cell lines and patient cells 
(Qian et al., 
2008) 
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Table 2-3: List of B cell malignancies that have been investigated as 
potential targets for OV therapy. 
The data shows a wide range of OVs have been investigated against a 
variety of B cell malignancies, with promising results against cell lines, 
primary patient material and in vivo models. 
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Table 2-3 demonstrates the interest in the use of OV to treat a variety of B 
cell malignancies. While these studies have yielded promising data into the 
efficacy of OV against HMs, most studies have only examined these cells in 
isolation, and have not investigated roles for the immune response, or the 
TME. These data have demonstrated reovirus susceptibility in some BL cell 
lines, however, more research is needed to characterise the susceptibility of 
DLBCL cell lines to reovirus infection, the role of the (TME) in reovirus 
oncolysis of NHL cells, and reovirus’ ability to potentiate an anti-NHL 
immune response. Other than investigating the susceptibility of multiple 
myeloma cells, no other data on the efficacy of CVA21 in the context of B 
cell malignancies have been reported.   
2.4.2 REOLYSIN®/Reovirus 
2.4.2.1 Origins and Discovery 
Reolysin® is the proprietary formulation of the Type 3 Dearing (T3D) strain 
of reovirus (Respiratory Enteric Orphan virus) and is produced by Oncolytics 
Biotech Inc. It is a non-manipulated member of the Reoviridae family and 
has a small dsRNA genome and an icosahedral capsid. The reovirus 
genome is comprised of 10 segments that encode for structural and non-
structural proteins that are necessary for its infection and replication (Shatkin 
et al., 1968). Reovirus was first identified as a novel oncolytic agent by 
Hashiro, et al., who described how the virus preferentially infected and killed 
malignant cells but not non-transformed cells (Hashiro et al., 1977), leading 
to further research into its potential as an oncolytic agent. Historically, the 
proprietary strain of Reolysin was propagated in murine L cells to provide a 
bioselected strain of the virus, i.e., one that has been passaged multiple 
times through one homogeneous cell line to create a more consistent 
formulation of the virus than what would be isolated from patients (Duncan et 
al., 1978). 
2.4.2.2 Pathogenic Significance and Virulence 
Reovirus is a common human pathogen that causes a mild enteric or 
respiratory illness in young children (Rosen et al., 1960). Exposure to the 
T3D strain of reovirus is widespread, with some studies reporting up to 90% 
seropositivity for neutralising antibodies against the virus (Minuk et al., 
1985). The primary receptor for reovirus is Junctional Adhesion Molecule A 
(JAM-A) that is ubiquitously expressed in endothelial and haematological 
cells throughout the body (Sugano et al., 2008). The role of JAM-A in 
reovirus infection has previously been investigated by the transfection of 
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Chinese Hamster Ovary (CHO) cells with JAM-A, -B and –C. These 
experiments demonstrated that only cells expressing JAM-A were 
permissive to reovirus infection (Campbell et al., 2005). JAM-A plays a vital 
role in several cellular processes such as tight junction formation and 
leukocyte migration, and its dysregulation in cancer is advantageous for 
tumour progression (Zhao, C. et al., 2014). Elevated JAM-A expression is 
not implicated in enhancing reovirus’ preferential infection of malignant cells, 
however, reovirus is thought to preferentially target malignant cells with 
activated Ras signalling (Marcato et al., 2007), elevated in many cancers 
(Downward, 2003). Another factor that contributes to reovirus susceptibility 
is enhanced levels of cathepsin B and L, which aid virus uncoating to allow 
replication, as reported in an in vivo glioma model (Alain et al., 2007). 
Enhanced cathepsins B and L expression were reported when tumour cells 
were grown in vivo and not in vitro, illustrating the importance of considering 
the TME in OV therapy. Although activation of the Ras pathway is infrequent 
in NHL cells (Ahuja et al., 1990), activating mutations in factors downstream 
of this pathway, such as ERK and p38, have been reported in NHL (Kurland 
et al., 2003), (Kawauchi et al., 2002), (Jazirehi et al., 2004), suggesting NHL 
cells as a good target for reovirus oncolysis. The presence of the JAM-A 
receptor on B cells (Xu et al., 2017) and the previously mentioned 
immunogenic potential of reovirus (section 2.4.1.2.1) make it a worthwhile 
candidate OV for NHL treatment. 
2.4.2.3 Progress in Clinical Trials 
Reolysin® is a promising candidate for oncolytic virotherapy due to its 
preference for transformed cells and high tolerability, only inducing low 
grade adverse effects in patients (Comins, C. et al., 2010), (Lolkema et al., 
2011), (Karapanagiotou et al., 2012). Reovirus has also been reported to 
induce an increase in CD4+ T cells, CD8+ T cells, NK cells and cytokine 
production in heavily pre-treated patients with advanced cancers, who had  
received surgery, radiotherapy or chemotherapy, prior to reovirus treatment 
(White et al., 2008). A table showing some examples of reovirus clinical trials 
is shown below (Table 2-4). 
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Disease Combinations Phase Trial numbers Results 
Gliomas N/A I NCT00528684 No dose-limiting 
toxicity, 1/12 
patients remained 
disease free for >6 
years (yrs) (Forsyth 
et al., 2008) 
Pancreatic 
Cancer 
Carboplatin/ 
Paclitaxel 
II NCT01280058 No significant 
enhancement of 
progression-free 
survival with 
reovirus vs drugs 
alone (4.9 vs 5.2 
months) (Noonan et 
al., 2016) 
Head and 
Neck 
Cancers 
Carboplatin/ 
Paclitaxel 
II NCT00753038 4/13 patients had 
partial response, 
2/13 had stable 
disease for >12 
weeks (Karnad et 
al., 2011) 
Carboplatin/ 
Paclitaxel/ 
Placebo 
III NCT01166542 Not reported 
Melanoma N/A II NCT00651157 Virus was well-
tolerated, viral 
replication was 
detected in 2/15 
patients (Galanis et 
al., 2012) 
Carboplatin/ 
Paclitaxel 
II NCT00984464 Partial response in 
3/14 patients 
(Oncozine, 2013) 
Myeloma N/A I NCT01533194 Virus was well-
tolerated (Sborov et 
43 
 
 
al., 2014) 
Lung 
Cancer 
 
Carboplatin/ 
Paclitaxel 
 
 
II NCT00861627 11/37 partial 
responses, 20/37 
stable diseases 
(Villalona-Calero et 
al., 2016) 
II NCT00998192 12/25 partial 
responses, 10/25 
stable diseases 
(Mita et al., 2013) 
Pemetrexed/ 
Docetaxel 
II NCT01708993 Virus was well-
tolerated, no 
enhancement of 
progression-free 
survival with 
reovirus vs drugs 
alone (2.96 vs 2.83 
months) (Morris et 
al., 2016) 
Prostate 
Cancer 
Docetaxel and 
Prednisone 
II NCT01619813 Poorer overall 
survival in virus and 
drug combination 
arm, vs drug alone 
(Eigl et al., 2017) 
Breast 
Cancer 
Paclitaxel II NCT01656538 Combination arm 
showed improved 
overall survival vs 
drug alone arm 
(17.4 vs 10.4 
months) (Erum 
Naqvi, 2013) 
Table 2-4: Clinical trials investigating reovirus alone or in combination 
with other therapies for the treatment of various cancers. 
Reovirus has been investigated alone and in combination with other 
therapies as a potential treatment for a wide range of malignancies, with 
some promising results.  
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Table 2-4 demonstrates the diverse applicability of reovirus in treating a 
variety of cancers. Most of these trials are in solid malignancies, however, 
reovirus was well-tolerated by patients with multiple myeloma (Sborov et al., 
2014), but reported minimal effects on disease stability (4-8 months stable 
disease in 3/12 treated patients). Ongoing clinical trials are currently 
investigating reovirus in combination with Bortezomib and Dexamethasone 
for relapsed or refractory myeloma (ClinicalTrials.gov, 2015c) and in 
combination with lenalidomide or pomalidomide against relapsing myeloma 
(ClinicalTrials.gov, 2017c). 
2.4.3 CAVATAK™/Coxsackievirus Type A21 
2.4.3.1 Origins and Discovery 
Coxsackievirus Type A21 (CVA21) is a non-enveloped member of the 
Enterovirus C species of the picornavirus family. It has a linear single-strand 
positive-sense RNA genome that is 7.4kb long (Bruu, 2013) . CVA21 is one 
of 23 Coxsackievirus Type A viruses (1-22 and 24).  
CAVATAK™ is a non-manipulated clinical-grade formulation of CVA21. It is 
one of several aetiological agents of the common cold (Xiao et al., 2001). 
Similarly to Reolysin, CAVATAK was purified by routine passage in human 
ICAM-1-transfected rhabdomyosarcoma (ICAM-1-RD) cells to obtain a 
formulation of the virus that would be more homogenous than clinically-
isolated virus samples (Shafren, D.R. et al., 2004). ICAM-1, the CVA21 entry 
receptor, is a member of the immunoglobulin superfamily with roles in cell 
signalling (Hubbard and Rothlein, 2000), endothelial transmigration 
(Rahman and Fazal, 2009) and endocytosis (Muro et al., 2003) and is widely 
expressed on both endothelial and immune cells, including B cells (Yashiro, 
2008). DAF, the CVA21 attachment receptor, is a negative regulator of the 
complement system and acts by blocking the formation of the membrane 
attack complex (MAC) by inhibition of the C3 and C5 convertases (Kinoshita, 
1998). ICAM-1 is expressed at high levels on lymphoma B cells in 
comparison to healthy B cells (The Human Protein Atlas, 2017) and DAF is 
highly expressed on a number of tumour types as a mechanism of 
complement resistance (Jurianz et al., 1999), including NHL (Terui et al., 
2006), suggesting a strong rationale for using CVA21 to target NHL B cells. 
It is important to note that, while some clinical isolates of CVA21 do not 
always rely on both receptors to infect cells, the Kuykendall strain, which is 
the subject of these experiments, requires both receptors for successful 
infection (Newcombe et al., 2004).  
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Preclinical work has shown that CVA21 kills prostate cancer cell lines that 
expressed ICAM-1 (Berry et al., 2008), reduces tumour burden in human 
breast cancer xenografts (Skelding et al., 2009) and can reduce tumour 
burden and increase survival in a syngeneic mouse model of melanoma 
where B16 murine myeloma cells had been transfected with human ICAM-1 
(Shafren, D. et al., 2014). Although research into the use of CVA21 to target 
HMs is at an early stage, CVA21 has efficacy as an oncolytic agent against 
myeloma cell lines that express both ICAM-1 and DAF, can target BM-
derived primary patient MM cells and has no cytotoxicity against healthy 
lymphocytes (Au et al., 2007). Taken together, these data implicate CVA21 
as a highly toxic agent against myeloma cells, and as a potential ex vivo 
purging agent.  
2.4.3.2 Pathogenic Significance and Virulence 
CVA21 is one of hundreds of aetiological agents of the common cold and 
primarily infects upper respiratory tract epithelial cells (Shafren, D.R. et al., 
2004). Initially found to cause mild upper respiratory tract infections (URTIs) 
(Lennette et al., 1958), it is not expected to pose a significant risk as a 
pathogen to the public and has received a biosafety level of 2 from the 
ATCC (ATCC, 2017). This rating is designated to agents that pose a mild 
risk to the public and environment. 
2.4.3.3 Progress in Clinical Trials 
CAVATAK™ has been tested in several trials for various solid malignancies. 
It has successfully progressed through 5 phase one trials for bladder cancer 
in combination with Mitomycin C, non-small cell lung cancer in combination 
with pembrolizumab (anti-PD1 antibody), advanced melanoma in 
combination with pembrolizumab, melanoma in combination with ipilimumab 
and as a single agent for prostate cancer. CAVATAK™ has also completed 
a phase II trial for late stage melanoma where 63 patients with stage IIIc or 
IV melanoma received 10 intratumoural (IT) injections of CAVATAK™ 
across 18 weeks. This study showed 6-month progression-free survival in 
22.5% of patients, surpassing (Andtbacka et al., 2015). This progress 
through a phase II trial shows promise for CAVATAK™’s possible 
acceptance as an approved therapy for melanoma. A summary of trials that 
examine the safety and efficacy of CAVATAK is shown in Table 2-5. 
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Disease Combinations Phase Trial Numbers Results 
Melanoma Pembrolizumab I NCT02565992 Recruiting, 18/23 
disease control rate 
(Ann W. Silk, 2017) 
Ipilimumab I NCT02307149 Recruiting, 
combination well-
tolerated, 14/18 
disease control rate 
(Viralyitics, 2016) 
I NCT03408587 Recruiting 
N/A II NCT01227551 22/57 Immune-related 
Progression-Free 
Survival (Andtbacka et 
al., 2015) 
I NCT02316171 Virus well-tolerated, 
evidence of replication, 
apoptosis and 
inflammation in TME. 
(Nicola E Annels, 
2015) 
I NCT02043665 Virus was well-
tolerated 
(ClinicalTrials.gov, 
2016) 
Bladder 
Cancer 
Mitomycin C I NCT02043665 Virus was well-
tolerated 
(ClinicalTrials.gov, 
2016) 
Pembrolizumab I NCT02824965 Recruiting 
Lung Cancer Pembrolizumab I NCT00636558 Virus was well-
tolerated, some 
evidence of replication 
(Pandha et al., 2015b)  
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Table 2-5: Clinical trials investigating CVA21 alone or in combination 
with other therapies for the treatment of various cancers. 
CVA21 has been investigated alone and in combination with other therapies 
as a potential treatment for a wide range of malignancies, with some 
promising results. 
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As previously mentioned, no published research has demonstrated CVA21-
induced cell death of NHL cell lines or primary patient material, however, 
CVA21 has induced cell death in other cancer types such as multiple 
myeloma (Au et al., 2007), melanoma (Au et al., 2005), breast cancer 
(Skelding et al., 2009), and prostate cancer (Berry et al., 2008), but no cell 
death in healthy donor PBMCs (Au et al., 2007). CVA21 and closely-related 
viruses have also demonstrated immunogenic properties in cancer models. 
Examples include,  immunogenic cell death in CVA21-treated bladder 
cancer cells, and a role for CD4+ T cells in targeting a murine C57/BL6 
bladder cancer model (Annels et al., 2018), and CVB3-mediated NK cell 
infiltration and elimination of human non-small-cell lung carcinoma (NSCLC) 
in a nude BALB/c xenograft model (Miyamoto et al., 2012). CVA21’s ability 
to preferentially target malignant cells, coupled with its demonstrated 
immunomodulatory potential, make it an exciting candidate for the treatment 
of NHL. 
2.5 Aims of the study 
This study aimed to investigate, by use of cell lines and primary patient 
material in isolation and in an NHL TME model, and an animal model for 
reovirus-mediated NK cell trafficking to the LN, the potential to use oncolytic 
virotherapy for the treatment of NHL, focusing on the efficacy of CVA21 and 
reovirus for the treatment of Burkitt’s lymphoma, Diffuse Large B Cell 
Lymphoma-Germinal Centre B Cell Subset and Diffuse Large B Cell 
Lymphoma-Activated B Cell Subset. These NHLs were chosen due to their 
aggressive nature and high prevalence in patients. These studies will be 
undertaken to investigate novel and exciting avenues of therapeutic 
intervention to target resistant and aggressive NHL cells. More specifically, 
this study aimed to: 
1. Compare two candidate OVs (reovirus and CVA21) for their ability to 
directly kill NHL cells by oncolysis and examine their efficacy against 
drug resistant malignant cells co-cultured with TME support. Reovirus 
and CVA21 were selected due to their impressive performance in 
clinical and pre-clinical trials to date, the elevated expression of 
ICAM-1 on NHL cells and the immunogenic potential of both viruses. 
2. Investigate the specificity of CVA21 for malignant cells and 
characterise the cellular determinants responsible for CVA21 
sensitivity. 
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3. Investigate the potential to use OVs, CVA21 and reovirus, to stimulate 
an anti-NHL immune response. 
4. Validate the efficacy of CVA21 and reovirus against NHL using 
primary NHL samples. 
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Chapter 3: 
Materials and Methods 
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Chapter 3 
3.1 Cell Culture  
3.1.1 Cell lines  
Ramos, Raji, SU-DHL-4 and OCI-LY19 cells were kindly supplied by Dr. 
Reuben Tooze and Dr. Gina Doody from Experimental Haematology (Leeds 
Institute of Cancer and Pathology - LICAP). U2932, OCI-LY3, L929, MEL-
624 and SK-MEL-28 cells were purchased from American Type Culture 
Collection (ATCC). Genotypic validation of Ramos, Raji, OCI-LY19, SU-
DHL4, OCI-LY3 and OCI-LY10 was conducted in-house by Short Tandem 
Repeat (STR) profiling and compared with the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ) database by Dr. Claire Taylor. 
The results from the STR profiling are shown in Figure 9-1 to Figure 9-6 
(Chapter 9).  
All cell lines were maintained at 37oC in a humidified atmosphere containing 
5% CO2 (Sanyo). Ramos, Raji, OCI-LY19, SU-DHL4, U2932, CD40L+ L929 
cell lines and parental L929 cells were maintained in sterile Roswell Parks 
Memorial Institute 1640 medium (RPMI 1640 – Sigma Aldrich) 
supplemented with 10% volume/volume (v/v) heat-inactivated (56oC for 
30minutes (mins)) Foetal Calf Serum (FCS – Life Technologies). OCI-LY3 
cells were maintained in RPMI 1640 supplemented with 20% v/v FCS. SK-
MEL-28 and MEL-624 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM – Sigma Aldrich) supplemented with 10% v/v FCS. For 
routine maintenance, once the cells had reached 80-90% confluence, the 
adherent cell lines (SK-MEL-28, MEL-624, CD40L+ L929 and parental L929) 
were washed in sterile Phosphate Buffered Saline (PBS – Oxoid) before 
being incubated with 1X Trypsin (Sigma Aldrich; 10X Trypsin was diluted 1 
in 10 with HBSS and stored at -20oC) to detach the adherent cells. Cells 
were then resuspended in fresh medium and a proportion transferred to a 
new tissue culture flask with fresh medium added as required. All tissue 
culture flasks were purchased from Corning unless stated otherwise. All cell 
lines were checked daily and split between 1:10-1:20 ratio once they had 
reached >80% confluence. Cell lines were maintained for ~20 passages to 
minimise variability and genetic drift. Viable cells were enumerated using 
Trypan blue (Beckman Coulter) exclusion, followed by cell counting on a 
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haemocytometer (Hawksley), for calculating seeding densities for 
subsequent assays.  
3.1.2 Cryopreservation 
Cell lines or primary patient cells were centrifuged at 400g for 5mins and 
resuspended in freezing medium (90% RPMI-1640 and 10% Dimethyl 
sulphoxide (DMSO, Sigma) for cell lines, and 50% human serum (Sigma), 
40% RPMI-1640 and 10% DMSO for human primary patient cells). Cell 
suspensions were aliquoted at 5x106/mL for cell lines and 10x106/mL for 
primary patient material, in 1mL in a 1.2mL cryovial (Nunc, Sigma-Aldrich), 
and transferred to polystyrene boxes which were then placed at -80oC 
overnight before being transferred to liquid nitrogen (LN2). All centrifugation 
was carried out using an Eppendorf Centrifuge 5810R, unless otherwise 
stated. 
Frozen cell stocks were retrieved from LN2 storage and thawed in a 37oC 
water bath and added dropwise, using a 3mL Pasteur Pipette (Fisher), to 
10mL of their respective media (pre-warmed to 37oC). Cell suspensions 
were pelleted by centrifugation at 400g for 5mins and the supernatant 
discarded, Cells were resuspended in 7mL of media, before being 
transferred to T25 flasks and allowed to rest overnight. Cells were monitored 
the following day by light microscopy, and a sample analysed by Trypan blue 
exclusion to give an estimate of cell viability. U2932s and OCI-LY3s were 
cultured in RPMI 1640 containing FCS at 20% and 30%, respectively, for the 
first week to aid their recovery. Once the cultures had been established, 
cells were harvested by centrifugation and place in RPMI 1640 containing 
10% and 20% FCS, respectively, for routine culture. 
3.1.3 Isolation of Human Mononuclear Cells from Peripheral 
Blood and Lymph Nodes 
Lymph Node Mononuclear Cells (LNMCs) were isolated from LN biopsies of 
suspected cases of lymphoma which were supplied by the Haematological 
Malignancy Diagnostic Service (HMDS, Level 3, Bexley Wing, St. James’ 
University Hospital (SJUH), Leeds). Ethical approval for the use of human 
LN samples was received from the NHS/HSC Research and Development 
offices / Research Ethics Committee (reference number: 14/WS/0098). Due 
to the non-sterile techniques used to harvest patient NHL LN biopsies, LN 
sample medium (RPMI 1640 and 10% (v/v) FCS) was further supplemented 
with Penicillin (50units/mL)/Streptomycin (50μg/mL) (Life Technologies). 
LNMCs were isolated from fresh samples by density centrifugation over 
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Lymphoprep™ (Axis Shield) (800g for 20mins, acceleration 6, brake 0). A 
3mL Pasteur Pipette was used to aspirate the cell layer from the top of the 
Lymphoprep™ and isolated cells were washed in Hank’s Balanced Salt 
Solution (HBSS – Sigma Aldrich) three times (600g for 10mins, acceleration 
6, brake 6) before being assessed for cell viability using Trypan blue 
exclusion. Cells were resuspended at 2x106 cells/mL in RPMI-1640 
supplemented with 10% v/v FCS and Penicillin (50units/mL)/Streptomycin 
(50μg/mL). Cell numbers varied and not all samples yielded enough cells for 
immunophenotyping or viability assays. Cells that were not used 
immediately were frozen in LN2 for longer term storage.  
Peripheral blood mononuclear cells (PBMCs) were isolated from the whole 
blood of healthy donors with informed verbal consent by density 
centrifugation over Lymphoprep™ and prepared as described above for 
LNMCs. Cells were cultured at 2x106 cells/mL in RPMI-1640 supplemented 
with 10% v/v FCS. 
3.1.4 Cell culture decontamination and disposal 
1% Virkon (DuPont UK Ltd.) was used to disinfect cell lines and LN sample 
waste, and 10% Distel (Tristel Solutions Ltd.) was used for whole blood 
waste products. Materials were decontaminated for a minimum of 60mins in 
their respective decontaminant. 
3.1.5 NHL Co-cultures 
Murine L929 cell lines, stably transfected to express human CD40L, were 
used to simulate the B cell (CD40) – T cell (CD40L) interaction thought to 
occur in the LNs (Clodi et al., 1998a). Parental, non-transfected L929 cells 
were used as a CD40L-negative control for these experiments.  Both cell 
lines were trypsinised, harvested into 50mL Falcon tubes which were placed 
on ice, and irradiated with 50 Gray (Gy), 50mins at 1Gy/min Metrix NDT X-
ray Irradiator. The cells were then retrieved from the irradiator, returned to 
culture and left overnight to allow them to adhere to the flask/well.  
On day 2, NHL cells lines, healthy donor PBMCs or NHL LNMCs were 
added to L929 feeder layers at fixed ratios (3x105 NHL cell lines: 2x105 L929 
cells per 2cm2 or 2x106 primary cells: 2x105 L929 cells per 2cm2) in fresh 
media and returned to the incubator overnight. Controls were cultured in 
identical volumes and cell densities, in adjacent wells with no feeder layer. 
Cells were routinely cultured on the feeder layers for 24hrs before being 
used in experiments. 
54 
 
 
3.1.6 Cell Treatments 
3.1.6.1 Oncolytic Viruses 
3.1.6.1.1 Coxsackievirus Type A21 (CVA21) 
CAVATAK™, the clinical-grade formulation of CVA21, was provided by 
Viralytics ltd. Clinical vials were stored at -80oC for long term storage. For 
use, vials were thawed and aliquoted before being re-frozen at -80oC. In-use 
vials were kept at 4oC for no more than 24hrs due to the instability of the 
virus resulting in a loss of potency over time. CVA21 was also propagated 
in-house using the identical Kuykendall strain of CVA21, purchased from 
ATCC (#VR-850). CVA21 was added directly to cell culture medium at the 
required plaque-forming unit (pfu) per cell (pfu/cell) following quantification of 
viral titres using plaque assay (Section 3.1.6.1.1.2). 
3.1.6.1.1.1 CVA21 Propagation and Purification 
CVA21 Kuykendall Strain was propagated using MEL-624 cells and purified 
by density ultra-centrifugation; MEL-624 cells were used to propagate 
CVA21 due to their susceptibility at low doses. 
On day 1, 12.5x106 MEL-624 cells were seeded in T150 tissue culture flasks 
in 20mL DMEM supplemented with 10% v/v FCS, and Penicillin 
(50units/mL)/Streptomycin (50μg/mL). The cells were placed at 37oC 
overnight. On day 2, the MEL-624 flasks were checked for 90% confluence 
and inoculated with CVA21 at 0.0005 pfu/cell and returned to the incubator 
for 72hrs.  
On day 4, solutions were prepared for density centrifugation using Optiprep 
(Sigma). 0.1M EDTA (Sigma), 1M Tris (Sigma) and 1M NaCl (Sigma) were 
prepared, filtered using a 0.22m filter and stored at 4oC.  
Subsequently, Solution B (100mL) was prepared using 50mL ddH2O, 30mL 
1M Tris stock solution and 3mL 0.1M EDTA. The pH was adjusted to pH7.4 
using 5M Hydrochloric acid (HCl, Sigma) and the volume made up to 100mL 
with ddH2O prior to filtration and storage at 4oC. 
Solution C (100mL) was then prepared using 50 mL ddH2O, 10mL 1M NaCl, 
5mL 1M Tris and 0.5mL 0.1M EDTA. The pH was adjusted to 7.4 with 5M 
HCl and the volume was made up to 100mL with ddH2O prior to filtration and 
storage at 4oC. 
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To prepare Solution D, 20mL of 60% Optiprep was added to 5mL of Solution 
B and used to prepare different concentrations of Optiprep as outlined 
below: 
• 15% Optiprep: 3mL Solution D + 7mL Solution C 
• 23% Optiprep: 4mL Solution D + 6mL Solution C 
• 28% Optiprep: 6mL Solution D + 4mL Solution C    
• 35% Optiprep: 7mL Solution D + 3mL Solution C 
2.5mL of each concentration was then gently layered on top of one another, 
beginning with the highest percentage of Optiprep at the bottom and the 
lowest at the top, in two ultracentrifuge tubes (Beckman Coulter 344059; 
Tube, Thinwall, Ultra-Clear™, 13.2 mL, 14 x 89 mm). The gradients were 
then wrapped in parafilm, gently laid on their sides and kept at 4oC 
overnight. 
On day 5, the MEL-624 cells were examined under light microscope for 
cytopathic effect (CPE), with typically 50-80% of cells detaching from the 
flask upon agitation. The media was removed from the flasks, transferred to 
50mL Falcon tubes (Corning) and centrifuged at 400g for 10mins. The 
supernatants were harvested from each falcon tube and amalgamated while 
the cell pellets were discarded. The amalgamated supernatant was filtered 
through a 0.22µm filter unit (Corning). The filtrate was distributed equally 
among an even number of 94mL Beckman Coulter heat-seal tubes (Tube, 
Thinwall, Polypropylene, 94 mL, 38 x 102 mm). The tubes were filled to 
maximum capacity and heat-sealed using Beckman Tube Topper (Beckman 
Coulter). The tubes were weighed to assure an equal distribution of weight 
(to within 0.1g difference) and placed in a Ti45 rotor (Beckman Coulter) for 
ultracentrifugation using a Beckman Optima L-80 Ultracentrifuge (Beckman 
Coulter) (150,000g, 2hrs, 4oC). The tubes were subsequently removed from 
the ultracentrifuge, the sealed nib was removed with a scalpel (Swann-
Morton) and 20mL media was aspirated and discarded. Following this, the 
tops of the tubes were cut off using a scalpel and the media discarded. The 
virus pellets were resuspended in PBS and amalgamated in less than 1mL. 
The virus formulation was then equally distributed onto Optiprep gradient 
tubes and approximately 1mL of solution C added, leaving a 3mm gap at the 
top of each tube. The Optiprep tubes were loaded into a SW41Ti swing rotor 
(Beckman Coulter) for ultracentrifugation (160,000g, 1hr 30min, 4oC). After 
centrifugation, the virus was extracted from the gradients by removal of 
approximately 1mL of supernatant, ~8cm from the bottom of the tube, and 
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CVA21 stocks were aliquoted in 25µL volumes and stored at -80oC. A 
representative diagram of the virus-loaded Optiprep gradients is shown in 
Figure 3-1. 
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Figure 3-1 Representative Optiprep gradients before and after 
ultracentrifugation. 
Virus was loaded onto optiprep gradients. Following ultracentrifugation, the 
virus preparation loaded on top of the gradient separates into a low debris 
band (above the 35% gradient), a high debris band (above the 15% 
gradient) and the CVA21 band estimated to be between the 15 and 23%. 
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3.1.6.1.1.2 CVA21 Plaque Assay 
CVA21 infectious particles were enumerated by plaque assay on MEL-624 
cells. On day 1, 9x105 MEL-624 cells were seeded in 2mL media per well of 
a 6-well plate (Corning) and left to adhere overnight. On day 2, MEL-624 
cells were examined under light microscope for 95% confluence. Stock 
samples of CVA21 were serially diluted by a factor of 10 from 10-3 to 10-10 
(25µL of each dilution into 225µL of media). The media was aspirated from 
the MEL-624 wells and 100µL of each virus dilution was then added with 
500µL serum-free DMEM to duplicate wells of 95% confluent MEL-624 
monolayers and incubated at 37oC for 2hrs. After 2hrs, the virus dilution 
samples were aspirated and 2mL overlay media was gently added to each 
well. Overlay medium comprised of a 1:1 ratio of 3% Carboxymethylcellulose 
(CMC, in sterile ddH20, Sigma) and 2xDMEM (pH7.6 adjusted with sodium 
bicarbonate, Sigma) supplemented with 20% FCS, creating a 1.5% CMC: 
1xDMEM-10% FCS solution. Following addition of the CMC overlay media, 
the plates were returned to the incubator for a further 72hrs. On day 5, the 
CMC overlay was gently aspirated, and the wells were washed in 1mL PBS. 
The PBS was subsequently aspirated, and the cells were fixed in 1mL 1% 
Paraformaldehyde (PFA; Sigma) in PBS for 20mins. The PFA was removed 
and the monolayers were stained with 300µL 1% methylene blue in PBS 
(Sigma) for 10mins before the methylene blue was discarded and the plates 
were rinsed gently with water. Plates were left to dry and plaques were 
counted in wells where 10-90 plaques were present. To calculate pfu/mL, 
the plaque count was averaged from duplicate wells and this figure was 
multiplied by the appropriate dilution factor, and then multiplied by 10 to give 
the plaque count per millilitre, because 100µL of the virus dilution was used.  
3.1.6.1.1.3 CVA21 50% Tissue culture Infective Dose (TCID50) 
TCID50 assays were used to measure virus replication in NHL, PBMC and 
LNMC samples. On day 1, 6x103 SK-MEL-28 cells were seeded in 100µL 
DMEM supplemented with 10% FCS into flat-bottomed 96-well plates and 
left overnight. On day 2, virus samples were serially diluted 10-fold (100µL of 
each dilution in 900µL of media) from 10-1 to 10-10 and 100µL of each dilution 
was added to octuplicate wells of the SK-MEL-28 cells. The plates were 
returned to the incubator for 5 days. On day 7, media was aspirated, and the 
wells were washed with 200µL PBS. Cells were then fixed (100L 4% PFA) 
for 10mins at room temperature before staining in 1% methylene blue 
solution (30L/well, 5mins, room temperature). Excess methylene blue was 
removed using running water and the plates were left to dry. Wells that 
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stained blue were deemed to contain viable cells and therefore no infectious 
virus, while wells that did not stain were deemed to be devoid of cells due to 
lytic replication of the virus causing CPE. The number of wells where CPE 
had occurred was counted for each dilution and this data was analysed 
using the Reed-Muench method (Reed, L.J. and Muench, 1938) which 
calculated the TCID50 for that sample. TCID50 values were used to calculate 
the fold increase in viral replication at appropriate time points after CVA21 
treatment. 
3.1.6.1.1.4 Ultraviolet irradiation of CVA21 
Stock virus was diluted in 100µL PBS in 1 well of a 48-well plate (Corning). 
The virus was subjected to 3mins of UV exposure (Stratalinker® UV 
Crosslinker). Virus inactivation at this time point was validated by plaque 
assay. Control, non-UV-exposed CVA21 was transported and stored 
identically to the UV-inactivated CVA21. 
3.1.6.1.2 Reovirus 
Clinical grade Reolysin was provided by Oncolytics Biotech Inc. and stored 
at -80oC. Bottles were thawed and aliquoted into 1.2mL cryovials and re-
frozen at -80oC. These vials were thawed as required and the virus 
concentration (pfu/mL) was quantified by plaque assay on L929 cells in an 
identical protocol to the CVA21 plaque assay. Reolysin aliquots were stored 
at 4oC for up to 4 weeks due to the stability of reovirus particles. 
3.1.6.1.3 Rapamycin 
Rapamycin (Selleckchem), a potent mTORC1 inhibitor, was used alongside 
DMSO-treated and untreated controls to measure the effects of mTORC1 
blockade on CVA21 cytotoxicity, proliferation and cell cycling in NHL cell 
lines. A stock solution of 100µM was prepared by reconstituting in DMSO. 
This was aliquoted and stored at -20oC. 
3.1.6.1.4 ICAM-1 Blockade 
A human anti-ICAM-1 (αICAM-1, Biolegend) antibody was used to block 
ICAM-1 on NHL cell lines. NHL cell lines were seeded at 3x105 cells/mL in 
multi-well plates (Corning) and αICAM-1 antibody or IgG1 isotype control 
antibody was added in escalating concentrations ranging from 1µg/mL to 
20µg/mL. The cells were returned to the incubator for 30mins prior to 
treatment with CVA21. 
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3.1.7 Flow Cytometry – Fluorescence activated cell sorter 
(FACS) 
Flow cytometry assays were performed using an Attune® Acoustic Focusing 
Cytometer (Applied Biosystems). 
 
3.1.7.1 LIVE/DEAD™ Cell Viability 
Cells were harvested into FACS tubes (Falcon), washed in 2mL PBS and 
pelleted by centrifugation (400g, 5mins, room temperature). The supernatant 
was discarded, and the cell pellet was resuspended in the residual volume 
and stained with LIVE/DEAD™ Fixable Yellow Dead Stain (Life 
Technologies); 0.5μL of LIVE/DEAD™ stain diluted in 0.5mL PBS, was 
added to each tube or 0.5mL PBS (without LIVE/DEAD™ stain) as a 
negative control. Samples were incubated at 4oC, in the dark for 30mins, 
washed in 2mL PBS and pelleted by centrifugation (400g, 5mins). The 
supernatant was discarded, and the cell pellet was resuspended in 300μL 
1% PFA (4oC), prior to data acquisition and analysis by Flow Cytometry. 
3.1.7.2 Extracellular Marker Staining 
All extracellular staining and analysis was conducted using a similar 
protocol. Cells (cell lines, LNMCs, PBMCs) were harvested into FACS tubes 
and washed in 2mL FACS buffer (0.1% Sodium Azide (Sigma Aldrich), 1% 
FCS in PBS) and cells were pelleted by centrifugation (400g, 5mins). The 
supernatant was discarded, and cell pellets were resuspended in residual 
volumes. Fluorescently-conjugated antibodies were added (5 or 10μl per 
1x106 cells) and cells were left at 4oC, in the dark for 30mins. Samples were 
subsequently washed in 2mL FACS buffer,  pelleted by centrifugation (400g, 
5mins), and the cells were fixed in 300μL 1% PFA. Cells were then analysed 
by Flow Cytometer at a constant flow rate. Forward Scatter/Side Scatter 
(FSC/SSC) plots were used to identify cell populations of interest prior to 
analysis. Marker expression was quantified using histogram plots along with 
mean fluorescence intensity (MFI), as appropriate. FACS antibodies used 
are detailed in Table 3-1. 
3.1.7.3 Intracellular Phosflow™ Staining 
Phosflow™ staining was performed as per the manufacturer’s 
recommendations. Treated cells were harvested into FACS tubes and 
washed in 2mL FACS buffer prior to centrifugation (600g, 10mins). 
Extracellular staining to identify specific cell populations (e.g. CD20 on B 
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cells) was performed at this point, if required (detailed in section 3.1.7.2). 
Samples were washed in 2mL FACS buffer, centrifuged (600g, 10mins) and 
resuspended in 1mL warmed media and 1mL Cytofix™ (BD Biosciences). 
The tubes were incubated at 37oC for 12mins in the dark to fix the cells. The 
cells were then centrifuged (600g, 8mins) and the supernatant was 
discarded. Tubes were vortexed to resuspend the cell pellets and 1mL 
chilled Perm Buffer III (BD Biosciences) was added to each tube; cells were 
vortexed again and placed at 4oC, in darkness for 30mins. Cells were then 
washed twice in 2mL FACS buffer (centrifugation at 600g for 8mins), and 
cell pellets were resuspended in residual volumes. Antibodies p-S6, p-
4EBP1, p-STAT1 and isotype controls were diluted 1 in 10 with FACS 
Buffer (10µL Antibody: 90µL FACS buffer per 1x106 cells) and 100µL was 
added to the respective FACS tubes. The cells were incubated in darkness 
for 60mins at room temperature before being washed in 2mL FACS buffer 
and pelleted by centrifugation (600g, 10mins). After the supernatant was 
discarded the cell pellet was resuspended in 500L FACS buffer and data 
acquired by flow cytometer. FACS antibodies and volumes used are detailed 
in Table 3-1. 
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Target Species Fluorophore Clone Volume µL 
/1x106cells 
Provider 
IgG1 Mouse 
BALB/c 
PE EMR8-5 5µL BD 
IgG2B Mouse 
C57BL/6 
PE 2H7 5µL BD 
MHC I Mouse 
BALB/c 
PE EMR8-5 5µL BD 
CD3 Mouse 
BALB/c 
PE SP34-2 10µL BD 
CD3 Mouse 
BALB/c 
FITC UCHT1 5µL BD 
CD19 Mouse FITC HIB19 5µL BD 
CD19 Mouse PE HIB19 5µL BD 
CD20 Mouse 
C57BL/6 
PE 2H7 5µL BD 
CD20 Mouse VioBlue LT20 5µL Miltenyi 
Biotec 
IFN-α/β 
receptor 
Mouse APC 85228 5µL R & D 
Systems 
ICAM-1 
(CD54) 
Mouse 
BALB/c 
PE HA58 5µL BD 
DAF 
(CD55) 
Mouse PE IA10 5µL BD 
p-
STAT1 
Mouse PE 4a 10µL BD 
p-S6 Mouse 
BALB/c 
PE N7-548 10µL BD 
p-
4EBP1 
Mouse 
BALB/c 
PE M34-
273 
10µL BD 
CD56 Mouse PE p282 
(H19) 
5µL BD 
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CD56 Mouse FITC B159 5µL BD 
CD69 Mouse 
BALB/c 
FITC L78 5µL BD 
CD107a Mouse 
BALB/c 
FITC H4A3 10µL BD 
CD107b Mouse FITC H4B4 5µL BD 
Nectin-2 Mouse PE R2.525 5µL BD 
CD40L 
(CD154) 
Mouse 
BALB/c 
PE 89-76 5µL BD 
JAM-A Mouse 
BALB/c 
PE M.Ab.F1
1 
5µL BD 
Tetherin Rat PE eBio927 10µL eBiosciences 
Table 3-1 List of Anti-Human Antibodies 
Table lists the anti-human antibodies that were used for flow cytometry-
based analysis, their animal of origin, fluorophore, clone, volume per test 
and manufacturer.  
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3.1.7.4 Cell Proliferation Assays 
CFSE (Carboxyfluorescein succinimidyl ester, Thermofisher Scientific) 
fluorescent dye was used to measure the proliferation of NHL cell lines, 
whereby maximal fluorescence was recorded upon cell staining on day 0 
and subsequent cell divisions resulted in diminishing CFSE fluorescence on 
daughter cells (as shown in Figure 3-2). 
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Figure 3-2 Representative diagram of the principles of CFSE staining. 
Parent cells are stained with CFSE on day 0 (maximal fluorescence). 
Subsequent cell divisions result in the halving of CFSE staining, and 
fluorescence, between daughter cells. Cell proliferation can be inferred from 
diminishing CFSE fluorescence by flow cytometry. 
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On day 0, 2x106 cells were washed in 2mL PBS and pelleted by 
centrifugation (400g, 5mins). CFSE was reconstituted in DMSO and used at 
a concentration of 500nM to stain the cells. For comparison, unstained 
controls were also prepared. The cells were then incubated at 37oC for 
20mins, washed in 10mL medium at room temperature for 5mins before 
being centrifuged (400g, 5mins), resuspended at 3x105 cells/mL and seeded 
at 0.5mL per well in 48-well plates. After 3hrs in culture, prior to treatment, 
unstained and stained samples were analysed for CFSE fluorescence to 
quantify maximal CFSE fluorescence prior to cell proliferation. Treated and 
untreated CFSE-labelled and CFSE-unlabelled cells were harvested at 24hr 
intervals and CFSE intensity was quantified by flow cytometry. 
3.1.7.5 Cell Cycle Analysis 
NHL cells were harvested and fixed in ice cold 70% ethanol (Sigma) and 
incubated at 4°C for a minimum of 30mins. The cells were then stained with 
propidium iodide (PI, Sigma, 1mg/mL) at 50µg/mL in PBS in the presence of 
100ng/mL RNAse (Sigma), to remove contaminating RNA, for 30mins. The 
samples were then washed twice in PBS and cells pelleted by centrifugation 
(400g, 5mins) and immediately analysed by Attune® Accoustic flow 
cytometer using the BL-2 fluorescence channel set to a linear scale. For 
assessment of cell cycle phase, cells that are 4n (tetraploid, G2/M) have 
double the fluorescence of cells that are 2n (diploid, G1), as depicted in 
Figure 3-3. 
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Figure 3-3 Representative histogram of Propidium Iodide Analysis. 
PI-stained cells were analysed by flow cytometry on a linear scale. Cells in 
G1, S and G2M phase of the cell cycle are labelled according to the PI 
intensity and correlating DNA content. 
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3.1.7.6 NK cell Degranulation Assay 
HDPBMCs (untreated or OV-treated; CVA21 or reovirus) were resuspended 
at 2.5x106 per mL and cell line targets (unlabelled, isotype-labelled or mAb-
labelled.) at 2.5x105 per mL. HDPBMCs and cell lines were co-cultured at a 
fixed effector to target ratio of 10:1 (5x105:5x104) in 400µL of media in FACS 
tubes at 37oC for 1hr. During this time a master mix was prepared containing 
αCD3 and αCD56 antibodies for identification of NK cells (CD3-CD56+), and 
CD107a and CD107b, for assessment of NK degranulation. Brefeldin A 
(Sigma; 1mg/mL stock) was also included at 50µg/mL to prevent CD107a/b 
recycling into the cell. The master mix recipe per tube is shown in Table 3-2. 
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Item Per tube (µL) 
CD3 VioBlue (Miltenyi) 2 
CD56 PE (BD) 2 
CD107a FITC BD) 4 
CD107b FITC (BD) 4 
Brefeldin A (Sigma) 0.5 
RPMI-10% FCS 87.5 
Total 100 
Table 3-2 Master mix recipe per tube for NK cell degranulation assay. 
Table shows the relative volumes of antibodies, Brefeldin A and media per 
tube used to detect NK cell degranulation. 
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After 1hr co-culture, 100µL of the master mix was added to each tube and 
the FACS tubes were returned to the incubator for a further 4hrs. After 4hrs, 
the cells were washed in 2mL FACS Buffer, pelleted by centrifugation (400g, 
10mins) and fixed in 300µL 1% PFA. The samples were stored at 4oC and 
protected from light until acquisition and analysis by flow cytometer; 
degranulating NK cells were identified as CD3-CD56+CD107a/b+. 
3.1.8 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISAs were used to measure the production of interferon-α (IFN-α) in cell-
free supernatants in response to OV treatment.  
On day 1, NUNC 96 well MAXISORP flat-bottomed plates (Thermo 
Scientific) were coated with 100μL per well anti-human IFN-α capture 
antibody (stock concentration of 1mg/mL, Mabtech, MT1/3/5), diluted 1 in 
250 in coating buffer; 10x coating buffer (1M NaHCO3 (BD Laboratory 
Supplies, Poole, UK) pH8.2) was diluted 1 in 10 (1x coating buffer, 0.1M 
NaHCO3, pH8.2) using ddH20 prior to use. The plates were wrapped and left 
at 4oC overnight. 
On day 2, the plates were washed 3 times with 300µL 0.05% Tween (Sigma) 
in PBS (PBS-Tween) with a SkanWash 300 (Gemini BV Laboratory) and 
blocked using 200μL of blocking solution (10% v/v FCS in PBS) per well for 
2hrs at room temperature. The plates were then washed 3 more times with 
300µL PBS-Tween. IFN-α standards (Biolegend) were prepared by diluting 
the stock in RPMI to give a top standard of 5000pg/ml with halving dilutions 
used to give a standard range down to 78.125pg/ml. Samples were then 
added to the wells in triplicate at 100µL per well. The plates were wrapped 
and left at 4oC overnight. 
On day 3, the plates were washed 6 times in 300µL PBS-Tween with a 
SkanWash 300 and the anti-h IFN-α detection antibody (1mg/mL, Mabtech, 
MT2,4,6) was prepared as a 1 in 1000 dilution in blocking solution, added at 
100μL per well and left at room temperature for 2hrs. The plates were then 
washed a further 6 times in 300µL PBS-Tween/well and 100μL Extravidin 
(Sigma; stock concentration of 5mg/mL) was added to each well after a 
1:5000 (in PBS-Tween) dilution.  Plates were left for 1hr at room 
temperature, during which time the substrate solution (p-nitrophenyl 
phosphate (pNpp) in Tris-buffered saline (TBS) (Sigma) at 1mg/ml in 20mL 
ddH2O) was prepared and protected from light. Following the Extravidin 
incubation, the plates were washed 3 times again in PBS-Tween, and 3 
times with H2O, and 100μL of substrate solution was added to each well. 
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The wells were incubated in darkness at room temperature for 20mins and 
optical density was then determined using a plate reader (Multiskan Ex, 
Thermo Scientific) and 405nm filter. The Optical Density (OD) values of the 
wells were calculated as the mean of the triplicate wells, minus the media 
only control. The IFN-α standards were used to generate a standard curve, 
using Microsoft Excel, and the resulting equation was subsequently used to 
calculate the concentration of IFN-α in each of the samples tested, using 
their observed OD values. 
3.1.9 In vivo experiments 
In vivo animal experiments were performed at the St. James’ Biomedical 
Service (SBS). All experiments were approved by Home Office and 
standards of care were based on UKCCCR Guidelines for the welfare and 
use of animals in cancer research (Workman et al., 2010). Experiments were 
carried out on non-tumour-bearing male C57BL/6 mice. 
6 male C57BL/6 mice aged 6-8 weeks were inoculated with 100 µL PBS or 
108 pfu reovirus in 100µL PBS (3 mice/group) via tail vein injection. Inguinal, 
axillary, and brachial LN were dissected from the C57BL/6 mice 24hrs post-
infection. The LN were then transferred to a mixture of Liberase™ (Sigma), 
HBSS and DNAse (Sigma) to allow digestion of the LN and release of the 
LNMCs. 
Murine LNMCs were enumerated by Trypan Blue exclusion and 1x106 viable 
cells were transferred to FACS tubes. Cells were stained with CD3e and 
NK1.1 antibodies (Table 3-3) as described previously (section 3.1.7.2) and 
NK cells were enumerated by flow cytometry. NK cells were defined as 
CD3e-NK1.1+ and expressed as a percentage of the total LN cell population. 
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Target Species Fluorophore Clone Volume µL 
/1x106cells 
Provider 
CD3e Hamster PE BM10-37 2 BD 
NK1.1 Mouse FITC PK136 2 Biolegend 
Table 3-3: Anti-Mouse Antibodies 
Table shows antibodies used to identify murine NK cell from C57/BL6 mice. 
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3.2 Statistics 
GraphPad Prism (version 7.04) software was used to analyse data and 
perform paired, two-tailed student’s t-test, one-way and two-way Analyses of 
Variance (ANOVAs), and Pearson’s tests as required. If the resulting p-value 
was less than 0.05 then the difference was deemed statistically significant. 
Microsoft Excel was used to generate standard curves for ELISAs. 
  
74 
 
 
 
 
 
 
 
 
 
Chapter 4: 
Efficacy of CVA21 and reovirus 
against Non-Hodgkin Lymphoma 
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Chapter 4  
4.1 Introduction 
OVs can target cells by direct oncolysis, whereby they replicate in malignant 
cells and release their progeny virions by rupturing the cell membrane 
(Zeyaullah et al., 2012). This chapter details the comparison of two 
candidate OV, reovirus and CVA21, in terms of the expression of their entry 
receptors, due to the reliance of both OV on the availability of their receptors 
for cell entry and infection, and their ability to induce cell death of NHL B cell 
lines while sparing healthy B cells.  
Previous work by Kim, et al., has shown that reovirus is a poor lytic agent 
against the Burkitt’s lymphoma (BL) cell lines, Ramos and Raji (Kim et al., 
2010). The work described in this chapter expands upon this study to test 
the susceptibility of other NHL cell lines to reovirus, namely the DLBCL cell 
lines, SU-DHL-4 and OCI-LY19 of the GCB subset, and U2932 and OCI-LY3 
of the ABC subset. Currently there are no studies investigating the efficacy 
of CVA21 against NHL. 
Importantly, CD40:CD40L engagement is associated with activation of 
germinal centre B cells under normal production of a humoral immune 
response and provides a strong pro-survival signal to B cells (Elgueta et al., 
2009), and has also been associated with drug resistance in NHL models 
(Voorzanger-Rousselot et al., 1998). Moreover, given the reported increase 
in ICAM-1 expression on CD40L-stimulated B cells (Shinde et al., 1996), the 
effects of the CD40:CD40L interaction on OV receptor expression and 
susceptibility in NHL cell lines and healthy B cells, and sensitivity of NHL cell 
lines to vincristine-induced cell death were also investigated. Under the 
medical name Oncovin®; vincristine inhibits microtubule formation and 
affects cell division (prophase), causing intracellular cell stress and 
apoptosis (Jordan and Wilson, 2004). Vincristine was investigated due to its 
prominent role as a component of the R-CHOP regimen and its potency at 
inducing apoptosis (Groninger et al., 2002), a process that is reportedly 
diminished by stimulation of CD40 (Lee, S.W. et al., 2012), potentially 
resulting in reduced efficacy of the drug. 
Overall, the results reported in this chapter investigate the direct oncolytic 
potential of CVA21 and reovirus against NHL.   
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4.2 Results 
4.2.1 Oncolytic Virus Receptor Expression on NHL cell lines. 
Infection of a target cell by a virus involves a carefully orchestrated 
interaction between the virus and the host cell surface to facilitate entry into 
the intracellular compartment. This process requires expression of viral entry 
receptors on the surface of the target cell to enable virus binding and entry 
(Marsh and Helenius, 2006). CVA21 requires DAF and ICAM-1 (Shafren, 
D.R. et al., 1997b) to enter target cells, while reovirus uses JAM-A, 
therefore, the expression of these proteins was examined on a panel of 6 
NHL cell lines (Figure 4-1, Figure 4-2).  
Figure 4-1 shows representative histogram plots for αICAM-1 (a-f), αDAF 
(g-l) and αJAM-A (m-r) (all light grey) antibody staining on NHL cell lines 
overlaid with isotype antibody-stained controls (dark grey). This data shows 
that the OV receptors ICAM-1, DAF and JAM-A are widely expressed on 
most NHL cell lines tested. To quantify this expression, the MFI of antibody-
stained cells was expressed as a fold change above isotype-stained cells, 
Figure 4-2. ICAM-1 (a) is highly expressed on Ramos, Raji, SU-DHL-4, 
U2932 and OCI-LY3 cell lines, with a range of 10- to 120-fold increase in 
MFI, but very low on OCI-LY19 cells, with only a 2-fold increase. DAF (b) is 
expressed on all cell lines, ranging from 10- to 30-fold increased MFI. JAM-A 
(c) expression on NHL cell lines ranges from 27- and 20-fold increase in MFI 
on U2932 and Ramos cells, respectively, to a 5-fold increase on Raji and 
OCI-LY19 cells, and only a 2-fold increase on SU-DHL-4 and OCI-LY3.
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Figure 4-1 Histogram plots showing OV Receptor expression on NHL cell lines. 
Ramos, Raji, SU-DHL-4, OCI-LY19, U2932 and OCI-LY3 NHL cell lines were harvested and analysed for surface expression of the 
CVA21 entry receptor, ICAM-1 (a-f), co-receptor, DAF (g-l), and reovirus receptor, JAM-A (m-r), by flow cytometry. Receptor 
expression is illustrated by representative histogram plots overlaying isotype (negative control) in dark grey and receptor staining in 
lighter grey. Results shown are representative of n=3 independent experiments
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Figure 4-2 Quantification of OV Receptor Expression on NHL cell lines. 
Ramos, Raji, SU-DHL-4, OCI-LY19, U2932 and OCI-LY3 NHL cell lines 
were harvested 24hrs post-passage and analysed for surface expression of 
OV receptors by flow cytometry. ICAM-1 (a), DAF (b) and JAM-A (c) 
expression was measured as the fold increase in MFI of receptor antibody-
stained cells above isotype antibody-stained controls. Data shows the mean 
of n=3 independent experiments + SEM. 
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4.2.2 Efficacy of reovirus against NHL 
Reovirus has previously demonstrated potent lytic abilities against a range of 
solid malignancies, as well as an ability to target HMs, such as myeloma 
(Thirukkumaran, C. M. et al., 2012), and NHL (Alain et al., 2002), where it 
induced cell death in some myeloma and NHL cell lines, and primary 
myeloma, NHL and CLL samples, while others were resistant. To examine 
the efficacy of reovirus in targeting a wider variety of NHL cell lines, including 
DLBCL lines, Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) 
and OCI-LY3 (f) cell lines were treated with increasing doses of reovirus for 
up to 72hrs and analysed for viability every 24hrs by LIVE/DEAD™ staining 
and flow cytometry. Figure 4-3 shows that reovirus cytotoxicity is limited in 
all cell lines tested, with Raji and U2932 cells exhibiting 20 and 30% cell 
death after treatment with 10pfu/cell at 72hrs, respectively. SU-DHL-4 and 
OCI-LY19 cells demonstrated a small (10% above background cell death), 
yet significant increase in cell death after treatment with reovirus at 
10pfu/cell by 72hrs, while Ramos and OCI-LY3 cells remained resistant. 
This data shows that, despite JAM-A expression, not all cells were 
susceptible to reovirus oncolysis, suggesting alternate determinants of 
reovirus susceptibility. 
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Figure 4-3 Cytotoxicity of reovirus against NHL cell lines. 
Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) and OCI-LY3 (f) 
cell lines were treated with 0.1, 1 and 10 pfu/cell reovirus for 24, 48 and 
72hrs. At each time point, cells were analysed for viability by flow cytometry 
using LIVE/DEAD™ staining. Data shows the means of n=3 independent 
experiments + SEM. Significance was determined by two-way ANOVA.   
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4.2.3 Efficacy of CVA21 against NHL 
Using LIVE/DEAD™ staining and analysing cells by flow cytometry, the 
cytotoxic effects of CVA21 on NHL B cell lines was determined. Figure 4-4 
shows that CVA21 induced cell death in Ramos (a), Raji (b), SU-DHL-4 (c), 
U2932 (e) and OCI-LY3 (f) cell lines in a dose- and time-dependent manner. 
The cell lines displayed varying degrees of susceptibility to CVA21, with Raji, 
SU-DHL-4 and OCI-LY3 cells showing significant death by 48 and 72hrs at 
as little as 0.01pfu/cell, while cell death of Ramos and U2932 increased up 
to 72hrs with maximal death at 1 pfu/cell. By contrast, OCI-LY19 (d) cells 
remained completely resistant to the virus, even at 96hrs (data not shown), 
in keeping with the low expression of ICAM-1 on the surface of this cell line.  
The lowest dose of CVA21 represents a ratio of 0.01 CVA21 particles per 
NHL cell (or 100 cells per infectious CVA21 particle). This suggests that 
CVA21 is replicating and releasing progeny viruses to infect and kill 
neighbouring cells. To test this, cell-free supernatants were harvested from 
0.01 and 0.1pfu/cell-treated samples and analysed for viral titre by TCID50 
assay (Figure 4-5). Figure 4-5 shows increased viral titre above input levels 
in Ramos, Raji, SU-DHL-4, U2932 and OCI-LY3 cell lines confirming viral 
replication within these cells. 
To confirm that viral replication was required for CVA21-induced cell death 
of NHL cell lines, UV-inactivated (replication-deficient) CVA21 was used. 
Figure 4-6 (a) shows representative plaque assays of non-UV and UV-
inactivated CVA21, demonstrating that 3mins of UV exposure is sufficient to 
completely abrogate CVA21-induced plaque formation on MEL-624 cells. 
NHL cell lines Ramos (b), Raji (c), SU-DHL-4 (d), U2932 (e) and OCI-LY3 (f) 
were then treated with non-UV and UV-inactivated CVA21 for up to 48hrs 
and analysed for viability. This data demonstrates that UV-inactivated 
CVA21 was unable to induce cell death, highlighting the importance of viral 
replication for CVA21-induced cell death.  
As previously discussed, CVA21 relies on DAF as its binding receptor and 
ICAM-1 as its entry receptor (Shafren, D.R. et al., 1997b). Previous research 
has outlined how both receptors are required for cell entry by the Kuykendall 
strain of CVA21 (Newcombe et al., 2004), highlighting that, although clinical 
isolates can vary in their receptor requirements, the Kuykendall strain is 
dependent on the availability of both receptors. To examine whether CVA21 
relies on ICAM-1 to infect and kill NHL B cell lines, an αICAM-1 antibody was 
used to block ICAM-1 on NHL cell lines and cell death was measured 
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following CVA21 treatment.  Figure 4-7 shows the efficacy of CVA21 against 
Ramos (a), Raji (b), SU-DHL-4 (c), U2932 (d) and OCI-LY3 (e) cells that 
have not been treated with antibody (white bars), treated with the isotype 
control antibody (grey bars), or the αICAM-1antibody (black bars). αICAM-1-
treated Ramos, SU-DHL-4 and U2932 cells showed complete abrogation of 
CVA21-induced cell death, while αICAM-1-treatment of Raji and OCI-LY3 
cells showed a significant reduction in CVA21-induced cell death at lower 
viral doses only. It is possible that the Raji and OCI-LY3 cells were not 
completely protected by the αICAM-1 antibody as these cells grow as 
aggregates in culture, hindering antibody binding. However, it is also 
possible that infection is not solely dependent on ICAM-1 in these cell lines. 
These data demonstrate that, as with other cancer models, ICAM-1 is 
essential for CVA21-induced oncolysis.  
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Figure 4-4 Cytotoxic effects of CVA21 against NHL cell lines.  
Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) and OCI-LY3 (f) 
cell lines were treated with 0.01, 0.1 and 1 pfu/cell CVA21 for 24, 48 and 
72hrs. At each time point, cells were analysed for viability by flow cytometry 
using LIVE/DEAD™ staining. Data shows the mean of n=3 independent 
experiments+ SEM. Statistical significance was determined by two-way 
ANOVA. 
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Figure 4-5 CVA21 replication in NHL cell lines. 
Ramos (a), Raji (b), SU-DHL-4 (c), U2932 (d) and OCI-LY3 (e) cells were 
treated with CVA21 for 72hrs. Cell free supernatants were taken at 0hrs as 
input (white bars) and again at 72hrs (black bars). Supernatants were then 
analysed for virus titre by TCID50 assay. Results show the mean from n=4 
independent experiments + SEM. Statistical significance was determined by 
paired, two-tailed student’s t test.  
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Figure 4-6 Viral replication is required for CVA21-induced death of NHL 
lines. 
(a) Representative plaque assay result from live (Non-UV) and UV-
inactivated CVA21 (3 min UV exposure) on MEL-624 cells. Ramos (b), Raji 
(c), SU-DHL-4 (d), U2932 (e) and OCI-LY3 (f) cells were treated with non-
UV and UV-inactivated CVA21 in increasing doses for up to 48hrs. Cell 
viability was assessed by flow cytometry using LIVE/DEAD™ viability dye. 
Data shows the m an of n=3 independent experiments + SEM. Statistical 
significance was determined by two-way ANOVA.  
No UV                           + UV 
                  
(a) 
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Figure 4-7 ICAM-1 blockade abrogates CVA21-induced cell death of 
most NHL cell lines. 
Ramos (a), Raji (b), SU-DHL-4 (c), U2932 (d) and OCI-LY3 (e) cells were 
cultured alone (white bars) or with an isotype control (grey bars) or αICAM-1 
(black bars) antibody. The cells were then treated with increasing doses of 
CVA21 and analysed for virus-induced cell death after 48hrs using 
LIVE/DEAD™ viability dye by flow cytometry. Data shows the mean of n=3 
independent experiments+ SEM. Statistical significance was determined by 
two-way ANOVA. 
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4.2.4 Correlating OV receptor expression with susceptibility 
to infection 
The NHL cell lines used in these investigations differentially expressed the 
OV receptors and varied in their susceptibility to either virus. Therefore, an 
important question is whether susceptibility to either virus correlated with 
viral receptor expression. This would serve as the simplest explanation for 
the differing susceptibility between the cell lines tested. To examine this, the 
mean fold increase in MFI of OV receptor expression, above the isotype 
control, was plotted against the mean percentage cell death, after 
subtraction of background cell death, for each NHL cell line. For CVA21, the 
mean percentage cell death observed at 0.1pfu/cell at 48hrs was chosen to 
best illustrate the variation between the cell lines. For reovirus, cell death 
induced by 10pfu/cell at 72hrs was selected, as reovirus-induced cell death 
occurred in some cell lines at this time point. Figure 4-8 shows OV receptor 
expression plotted against susceptibility, as well as significance values (p) 
and a measure of how well the data fits the regression line (r2).  
In Figure 4-8 (a), ICAM-1 expression on OCI-LY19, Ramos and Raji cells 
showed that low, medium and high expression appeared to correlate with 
virus-induced cell death, however, this pattern was only observed in these 
three cell lines and SU-DHL-4, U2932 and OCI-LY3 cell lines displayed high 
cell death at this time point and comparatively low ICAM-1 expression. 
Taken together, these data yielded an r2 value of 0.1596 and showed no 
correlation between CVA21-induced cell death and ICAM-1 expression of 
NHL cell lines, as shown by Pearson’s Test.  
DAF expression (Figure 4-8 (b)) yielded an r2 value of 0.00277, suggesting 
no correlation between DAF expression and CVA21-induced cell death. 
Similarly, in Figure 4-8 (c), an r2 value of only 0.3685 demonstrates no 
correlation between JAM-A expression and reovirus sensitivity. Taken 
together, this data demonstrates that susceptibility to either virus does not 
correlate with the expression levels of their respective entry receptors in 
these 6 NHL cell lines. 
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Figure 4-8 Correlation of OV receptor expression with virus-induced 
cell death: 
Baseline OV receptor expression, as determined by mean MFI over isotype 
control MFI, was plotted against susceptibility to OV, as determined by the 
percentage cell death above untreated controls for Ramos, Raji, SU-DHL-4, 
OCI-LY19, U2932 and OCI-LY3 cells. For CVA21, data for 0.1pfu/cell after 
48hrs was used, whilst for reovirus, 10pfu/cell for 72hrs was used. Data 
shows the mean percentage cell death and receptor expression from n=3 
independent experiments. Statistical analysis was determined by Pearson’s 
test with resulting r2 values deemed to show a correlation if they were close 
to 1 and p values showing statistical significance of the trend, where p<0.05 
denotes significance. 
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4.2.5 Validating the CD40L+ L929 co-culture as a model of 
Chemo-Resistance 
As discussed previously, tumours cannot be accurately modelled by two-
dimensional cell culture systems whereby cancer cells are grown in isolation 
in nutrient-rich media and stable, optimised conditions. Due to the high 
complexity of the NHL LN, it is not yet sustainable to control for every 
possible contributing factor within the TME in vitro. However, careful 
selection of highly influential signals allows elements of cell: cell cross talk, 
and their effects on the efficacy of novel therapies, to be measured. For 
these studies, CD40L was chosen because it provides support and survival 
signals to malignant B cells and can induce resistance to classical 
chemotherapy agents (Korniluk et al., 2014). CD40L stimulation of NHL B 
cells has also been associated with increased anti-apoptotic signals and 
resistance to chemotherapy in vitro (Voorzanger-Rousselot et al., 2006), 
suggesting a potential problem for current therapies.  
Firstly, to validate the expression of CD40L on the CD40L+L929 cell lines, 
CD40L+ and parental L929 cells were analysed for CD40L expression by 
flow cytometry. The parental cells lacked CD40L expression while the 
CD40L-transfected cells expressed CD40L, demonstrated by enhanced 
αCD40L antibody staining above the isotype control (Figure 4-9). CD40 
expression on the NHL cell lines was also confirmed by flow cytometry (n=2, 
data not shown). 
Next, to confirm that CD40:CD40L interactions induced a drug-resistant 
phenotype, the effect of CD40L stimulation on the sensitivity of NHL cells to 
chemotherapy was investigated. Ramos (a), SU-DHL-4 (b) and U2932 (c) 
cells were cultured alone, or on the CD40L+L929 and parental L929 feeder 
layers for 24hrs and treated with vincristine, a key component of the R-
CHOP chemotherapeutic regimen for the treatment of NHL. Figure 4-10 
demonstrated that vincristine-treated NHL cell lines, in isolation, undergo cell 
death by 48hrs (blue bars). Importantly, co-culture of Ramos, SU-DHL-4 and 
U2932 cells on the CD40L+L929 cells significantly inhibited vincristine-
induced cell death. Moreover, NHL cells cultured on the parental L929 cells 
were not protected from vincristine-induced cell death, although this was not 
significant for U2932 cells. This data demonstrates that CD40L stimulation 
induced drug resistance to conventional NHL therapies. 
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CD40L (CD154) expression on CD40L+ L929 cells:  
 
 
 
 
 
 
 
 
Figure 4-9 Validating CD40L (CD154) Expression on CD40L+L929 cell 
lines. 
Parental and CD40L+ L929 cells were stained with an isotype control or 
αCD40L (CD154) antibody. CD40L expression was subsequently 
determined by flow cytometry. Data shows a representative overlay 
histogram of parental L929 isotype control (red), parental L929 αCD154 
antibody-stained (purple), CD40L+L929 isotype control (blue), CD40L+L929 
αCD154 antibody-stained (yellow). Data is representative of n=2 
experiments.  
  
CD40L (CD154) Expression 
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Figure 4-10 Resistance to Vincristine in NHL B cell lines. 
NHL B cell lines, Ramos (a), SU-DHL-4 (b) and U2932 (c) were cultured 
alone, or on the CD40L+L929 or parental L929 cells for 24hrs before being 
treated with increasing concentrations of vincristine for 48hrs and analysed 
for viability using LIVE/DEAD™ staining and Flow Cytometry. Data shows 
mean cell death of n=3 independent experiments + SEM, following 
subtraction of untreated control values. Statistical significance was 
determined by two-way ANOVA.  
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4.2.6 The effects of CD40L stimulation on OV receptor 
expression 
Initial experiments examining OV receptor expression were repeated 
following CD40L stimulation to determine if CD40L stimulation alters OV 
receptor expression. Previous research by Shinde, et al., has demonstrated 
that ICAM-1 expression is upregulated on B cells upon CD40L expression 
(Shinde et al., 1996). The effect of CD40L stimulation on ICAM-1 
expression, and subsequent changes in susceptibility to CVA21, was 
investigated after promising research showed enhanced ICAM-1 expression 
in CD40L-stimulated CLL cells which correlated with enhanced susceptibility 
to CVA21 (Gina Scott – personal communication). NHL B cell lines were 
cultured in isolation or co-cultured on CD40L+L929s, or parental L929s, for 
24hrs before being harvested and analysed for the expression of OV 
receptors by flow cytometry. Figure 4-11 shows that CD40L stimulation 
significantly enhanced ICAM-1 expression on Ramos (a), SU-DHL-4 (c), 
OCI-LY19 (d) and U2932 (e) cells. However, although ICAM-1 expression 
was increased by CD40L stimulation in Raji (b) and OCI-LY3 (f) cells, this 
increase was not statistically significant. Co-culture with the parental L929 
cells did not significantly affect the expression of ICAM-1 on any NHL cell 
line. Furthermore, CD40L stimulation did not induce any significant changes 
in DAF expression (Figure 4-12) or in JAM-A expression (Figure 4-13).  
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Figure 4-11 Effect of CD40L stimulation on ICAM-1 expression on NHL 
cell lines 
Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) and OCI-LY3 (f) 
were cultured alone or on CD40L+L929 or parental L929 cells for 24hrs 
before being harvested and stained with an isotype control or an αICAM-1 
antibody. Surface ICAM-1 expression was measured by flow cytometry and 
expressed as fold increase in MFI above isotype antibody-stained control 
levels. Data shows the mean of n=4 independent experiments + SEM, 
significance was determined by unpaired, two-tailed student’s t test. 
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Figure 4-12 Effects of CD40L stimulation on DAF expression on NHL B 
cell lines:  
Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) and OCI-LY3 (f) 
were cultured alone or on CD40L+L929 or parental L929 cells for 24hrs 
before being harvested and stained with an isotype control or αDAF 
antibody. Surface DAF expression was measured by flow cytometry and 
expressed as fold increase in MFI above isotype control levels. Data shows 
the mean of n=4 independent experiments + SEM. Significance was 
investigated by unpaired, two-tailed student’s t test, but no significance was 
detected.  
95 
 
 
A
lo
n
e
C
D
4
0
L
L
9
2
9
0
1 0
2 0
3 0
4 0
R a m o s
F
o
ld
 i
n
c
re
a
s
e
 M
F
I
A
lo
n
e
C
D
4
0
L
L
9
2
9
0
1 0
2 0
3 0
R a ji
F
o
ld
 i
n
c
re
a
s
e
 M
F
I
A
lo
n
e
C
D
4
0
L
L
9
2
9
0
2
4
6
S U -D H L -4
F
o
ld
 i
n
c
re
a
s
e
 M
F
I
A
lo
n
e
C
D
4
0
L
L
9
2
9
0
2
4
6
8
1 0
O C I-L Y 1 9
F
o
ld
 i
n
c
re
a
s
e
 M
F
I
A
lo
n
e
C
D
4
0
L
L
9
2
9
0
1 0
2 0
3 0
4 0
5 0
U 2 9 3 2
F
o
ld
 i
n
c
re
a
s
e
 M
F
I
A
lo
n
e
C
D
4
0
L
L
9
2
9
0
5
1 0
1 5
O C I-L Y 3
F
o
ld
 i
n
c
re
a
s
e
 M
F
I
(a ) (b )
(c ) (d )
(e ) ( f )
 
Figure 4-13 Effects of CD40L stimulation on JAM-A expression on NHL 
B cell lines: 
Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) and OCI-LY3 (f) 
were cultured alone or on CD40L+L929 or parental L929 cells for 24hrs 
before being harvested and stained with an isotype control or αJAM-A 
antibody. Surface JAM-A expression was measured by flow cytometry and 
expressed as fold increase in MFI above isotype control levels. Data shows 
the mean of n=4 independent experiments + SEM, significance was 
investigated by unpaired, two-tailed student’s t test, but no significance was 
detected.  
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4.2.7 Effect of CD40L stimulation on CVA21-induced cell 
death 
ICAM-1 expression is required for CVA21 infection (Newcombe et al., 2004) 
and is increased by CD40L stimulation of NHL cell lines (Figure 4-11), 
therefore, the effects of CD40L stimulation, and subsequent ICAM-1 
upregulation, on CVA21-induced cell death were determined. NHL cell lines 
were cultured in isolation or in co-culture with CD40L+L929 and parental 
L929 cells for 24hrs before being treated with CVA21 for 24hrs.  
Figure 4-14 shows that CVA21 treatment induced cell death in a dose-
dependent manner, in the 4 candidate NHL cell lines tested (Ramos, Raji, 
SU-DHL-4 and U2932; (a)-(l)), when cultured alone (blue bars); comparable 
with the data shown in Figure 4-4. CVA21-induced cell death was increased 
significantly after CD40L stimulation in Ramos at 1pfu/cell (c) and U2932 
cells at 0.1 pfu/cell (k). No change in CVA21 susceptibility was observed on 
the parental L929 feeder layer. This data suggests that enhanced ICAM-1 
expression, due to CD40L stimulation, can increase CVA21-induced cell 
death in some cell lines. Further experiments could clarify the role of CD40L 
stimulation, and subsequent ICAM-1 upregulation, in enhancing CVA21-
induced cell death by blocking ICAM-1 on CD40L-stimulated NHL cells by an 
αICAM-1 blocking antibody or siRNA knockdown of ICAM-1, and measuring 
the ability of CVA21 to kill the NHL cells. 
Identical experiments were also conducted with reovirus, however, there 
was no increase in cell death of NHL cells that were co-cultured with CD40L 
(data not shown). Despite the unchanged JAM-A expression on NHL cells 
following CD40L stimulation, these experiments were conducted as previous 
research had demonstrated a role for the TME in enhancing OV-induced cell 
death of malignant cells (Ilkow et al., 2015). Due to the limited cell death 
observed in NHL cell lines, suggesting that they are only mildly susceptible, 
reovirus was not investigated further as a lytic agent but was investigated in 
the context of priming an anti-NHL immune response (Chapter 6) and 
targeting primary NHL cells (Chapter 7). 
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Figure 4-14 CD40L stimulation of NHL B cells enhances CVA21-
induced cell death in some cell lines: 
NHL cell lines Ramos (a)-(c), Raji (d)-(f), SU-DHL-4 (g)-(i) and U2932 (j)-(l) 
were cultured alone (blue) or on CD40L+ (red) or parental L929 (orange) cell 
lines for 24hrs. CVA21 was added at increasing doses and cells were 
cultured for a further 24hrs. Cells were then harvested and analysed for 
viability using LIVE/DEAD™ staining and flow cytometry. Cell death is 
expressed as the percentage dead cells above respective untreated 
controls. Data shows the mean of at least n=3 independent experiments + 
SEM, significance was determined by two-tailed, paired student’s t test.  
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4.2.8 Specificity of CVA21 for malignant B cells. 
Previous work in this chapter has shown the ability of CVA21 to kill NHL cell 
lines. It is difficult to distinguish transformed B cells from non-transformed in 
the NHL LN by flow cytometry; therefore, healthy peripheral blood B cells 
were used to determine the effects of CVA21 on non-malignant B cells, and 
the effects of CD40L stimulation on their susceptibility. 
Healthy donor B cells (in the context of PBMCs) express a significantly lower 
level of ICAM-1 than the NHL cell lines Ramos, Raji, SU-DHL-4, U2932 and 
OCI-LY3, Figure 4-15. However, the level of expression was comparable to 
the CVA21-resistant OCI LY19 (Figure 4-1, Figure 4-2). CD40L stimulation 
of healthy donor B cells significantly increased ICAM-1 expression on these 
cells, but this remained significantly lower than levels observed on the 
Ramos, Raji and SU-DHL-4 cell lines (Figure 4-15).  
In order to investigate whether enhanced ICAM-1 expression on healthy B 
cells made them susceptible to CVA21, and whether CVA21 can kill healthy 
donor B cells in the context of a mixed cell population, PBMCs were cultured 
alone, on CD40L+L929 or on parental L929 cells and treated with CVA21 for 
up to 120hrs. Figure 4-16 demonstrates that CVA21 did not induce 
significant cell death under any growth condition tested. The majority of 
samples (4 of 7) remained completely resistant to CVA21-induced cell death, 
even after CD40L stimulation and enhanced ICAM-1 expression, and 
minimal cell death was detected in the remaining samples. 
Cell-free supernatants from CVA21-treated healthy donor PBMC samples 
were subject to TCID50 assays to examine whether viral replication was 
supported in non-malignant cells. Figure 4-17 indicates that the high viral 
titres at the start of the experiment (input), diminished by the 120hr time 
point (a). The input titres for both doses were normalised to 100% in (b) and 
the 120hr results expressed as a percentage of this. This data shows a 
significant decrease in CVA21 titre in healthy PBMC samples, suggesting 
that virus replication was not taking place. 
Lastly, replication was measured in healthy donor samples that had been 
cultured alone, on CD40L+L929 or on parental L929 feeder layers, Figure 
4-18. Viral titre appeared to be higher in healthy B cells cultured on both 
feeder layers at 120hrs, however, this was not significantly higher than 
observed in the B cells cultured alone. Taken together, these data suggest 
that CVA21 is unable to replicate in, or kill, healthy donor B cells, even when 
ICAM-1 expression is enhanced by CD40L stimulation.  
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Figure 4-15 ICAM-1 Expression on NHL B cells vs Healthy B cells  
Healthy donor PBMCs were cultured alone and on CD40L+ and parental 
L929 feeder layer for 24hrs. ICAM-1 expression was then measured on the 
surface of CD19+ or CD20+ B cells in each culture by flow cytometry. This 
result was then expressed as the fold increase in MFI over the isotype MFI. 
For comparison, data is plotted with the ICAM-1 expression data of the NHL 
cell lines Ramos, Raji, SU-DHL-4, OCI-LY19, U2932 and OCI-LY3 from 0. 
Data shows the mean from n≥3 independent experiments ± SEM. Statistical 
significance was determined by paired, two-tailed student’s t test.  
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Figure 4-16 CVA21 induced cell death of healthy donor B cells.  
Healthy donor PBMCs were cultured alone or on the CD40L+L929 or 
parental L929 feeder layers. The cells were then treated with CVA21 and 
returned to culture for 120hrs. The cells were stained with αCD20 or αCD19 
antibodies for identification of B cells and analysed for viability using 
LIVE/DEAD™ exclusion by flow cytometry. Cell death is represented as the 
percentage of LIVE/DEAD™-positive B cells minus the untreated control. 
Results show the mean of n≥4 independent experiments ± SEM. Statistical 
significance was analysed by two-way ANOVA, but no significance was 
detected.  
  
CVA21 (pfu/cell) 
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Figure 4-17 Replication of CVA21 in healthy PBMCs: 
Healthy donor PBMCs were treated with CVA21 for up to 120hrs. Cell-free 
supernatants were taken at 0hrs as input (white bars) and again at 120hrs 
(black bars) when cell death was analysed. Virus titre of the supernatants 
was then determined by TCID50 assay. (a) Shows virus titre at input and 
120hrs, and (b) shows this data after both input doses were normalised to 
100% and the 120hr data was expresses as a ratio of this. Results show the 
mean from n=4 independent samples + SEM. Statistical significance was 
determined by paired, two-tailed student’s t test. 
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Figure 4-18 Replication of CVA21 in healthy CD40L-stimulated and non-
stimulated PBMCs:  
Healthy PBMCs were isolated from fresh blood and cultured on the 
CD40L+L929 or parental L929 feeder layers for 24hrs. CVA21 was then 
added to the co-culture for 120hrs. Sample supernatants were taken at 0hrs, 
for virus input, and again at 120hrs when cell death was being measured. 
Supernatants were analysed for virus titre by TCID50 assay. Data shows the 
means of n=4 healthy donors, significance was analysed by two-way 
ANOVA, but no significance was detected. 
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4.3 Discussion 
The aim of this research was to examine whether CVA21 and reovirus can 
kill NHL cell lines. Previous research on the ability of reovirus to target HMs 
has demonstrated its potential as both a lytic and immunogenic agent by 1) 
enhancing NK cell targeting of rituximab-coated CLL cell lines (Parrish et al., 
2015), 2) stimulating NK cell targeting of, and causing direct killing of, AML 
cells (Hall et al., 2012) and CLL cells (Parrish et al., 2015), and 3) inducing 
direct lysis of cell lines and tumour destruction by immune activation in a 
multiple myeloma model (Thirukkumaran, C. M. et al., 2012). Reovirus is 
also being investigated in clinical trials for the treatment of relapsed or 
refractory myeloma in combination with the proteasome inhibitor, 
Bortezomib, and the corticosteroid, Dexamethasone (ClinicalTrials.gov, 
2015c), and with immunomodulatory drugs, Lenalidomide or Pomalidomide 
(ClinicalTrials.gov, 2017c). Conversely, the efficacy of CVA21 against HMs 
is less characterised, but some research has demonstrated its ability to kill 
myeloma cell lines directly and purge myeloma-contaminated BMs upon 
exposure ex vivo (Au et al., 2007). These data demonstrate the potential of 
CVA21 as an anti-HM agent and highlight the requirement for more HM-
oriented OV research. It should be acknowledged that the research shown in 
this chapter is derived from cell lines and primary healthy PBMCs that were 
cultured and treated with reovirus and CVA21 in vitro, making comparisons 
with effects in animals or patients difficult, as the OVs could be exerting their 
efficacy by a variety of mechanisms, such as activation of the immune 
response or destruction of the tumour stroma or vasculature in vivo, which 
would not be observed in vitro. 
The CVA21 receptors, ICAM-1 and DAF, and reovirus receptor, JAM-A, 
have distinct roles in the development and function of normal healthy B cells. 
JAM-A expression on NHL B cells plays a role in cell migration and invasion 
and is associated with poor survival in both DLBCL patients (Xu et al., 2017), 
and multiple myeloma patients (Solimando et al., 2018), warranting research 
into the use of reovirus to target these cells. Enhanced ICAM-1 on LN-
residing B cells interacts with Lymphocyte Function-associated Antigen 1 
(LFA-1) on T cells to provide a co-stimulatory signal for B cell activation 
(Holland and Owens, 1997), and increased DAF expression has been 
observed on B cells during the early stages of B cell development to protect 
them from complement-dependent cytotoxicity (CDC) (Terstappen et al., 
1992). DAF expression on NHL B cells is being targeted by other forms of 
therapeutic intervention, such as antibody blockade of DAF in combination 
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with rituximab to potentiate CDC in NHL (Federica et al., 2005). High ICAM-
1 and DAF expression on NHL cells presents CVA21 with an advantage in 
targeting malignant B cells compared to healthy B cells. This outlines the 
importance of matching OV to malignancies that may be more susceptible to 
viral targeting. High ICAM-1 expression is also associated with other tissue 
types, such as the gut epithelium (Veres et al., 2001), potentially posing a 
risk of gastric infection in CVA21-treated patients. While no patients have 
presented with serious gastric symptoms in any CVA21-based clinical trials 
to date, tissues that express high ICAM-1 could be monitored in CVA21-
treated patients to pre-empt the onset of adverse reactions to the virus. 
All NHL cell lines expressed the reovirus receptor, JAM-A, making virus 
entry into the cell possible, however, reovirus demonstrated a poor ability to 
induce cell death in NHL cell lines (Figure 4-3). Reovirus was previously 
shown to selectively target NHL cell lines with deficient p53 activity, for 
example, Ramos cells, that have an intact p53 response, were not 
permissive to reovirus infection, whilst the p53-deficient Raji cells were (Kim 
et al., 2010). This data is congruous with results in this chapter that showed 
Ramos cells were resistant to reovirus while Rajis were susceptible, as were 
U2932 cells which also harbour mutant p53 (Amini et al., 2002). However 
SU-DHL-4 and OCI-LY19 cells reportedly possess wildtype p53 (Wang, F. et 
al., 2011), (Morin et al., 2011), (Drakos et al., 2011),  but were susceptible to 
reovirus infection, suggesting that, while susceptibility to reovirus may be 
partially dependent on p53 deficiency, there are likely other, as yet 
undefined factors involved. The reported mutation or loss of p53 in 23% of 
DLBCL cases (Xu-Monette et al., 2012), (Leroy et al., 2002) suggests a 
potential use for reovirus in targeting primary NHL cells. Overall this data 
suggests that the presence of its entry receptor, JAM-A, although necessary, 
is not sufficient to make cells permissible to infection.  
Previously, CVA21 has demonstrated potent lytic killing in a variety of cancer 
models such as melanoma, multiple myeloma, breast cancer, prostate 
cancer and lung cancer (Bradley et al., 2014). Data presented in this chapter 
demonstrates that CVA21 was highly toxic to Ramos, Raji, SU-DHL-4, 
U2932 and OCI-LY3 cell lines, but not OCI-LY19 cells, most likely due to the 
virus’ dependence on co-expression of DAF and ICAM-1, the latter of which 
is expressed at very low levels on OCI-LY19 cells. Stable transfection of 
ICAM-1 into OCI-LY19 cells and measuring their susceptibility to CVA21 
infection could be used to examine this further. This has previously been 
investigated using an AML cell line, KG-1, which expressed low levels of 
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ICAM-1; stable transfection with human ICAM-1 conferred susceptibility to 
CVA21 (manuscript submitted). Previous research has also shown that 
murine L929 cells transfected with human ICAM-1 were rendered 
susceptible to CVA21 infection (Shafren, D.R. et al., 1997a). Shafren et al., 
also demonstrated that ICAM-1 blockade abrogated CVA21-induced cell 
death in ICAM-1+ L929 cells, validating the results observed in 0 which 
demonstrated that ICAM-1 blockade inhibited CVA21-induced cell death in 
NHL cell lines. This result highlights the importance of ICAM-1 in CVA21 
infection. It is currently unknown whether ICAM-1 receptor density is 
important for CVA21 infection, however, the lack of cytotoxicity in CVA21-
treated ICAM-1-low OCI-LY19 cells demonstrates that low levels of ICAM-1 
prevent infection. 
While the effects of DAF blockade by αDAF antibodies on CVA21-induced 
cell death of NHL cells was not investigated, research by Johannsen, et al., 
demonstrated inhibition of a bioselected DAF-dependent strain of CVA21 
(CVA21-DAFv, generated by multiple passaging of the Kuykendall strain of 
CVA21 through DAF-positive, ICAM-1-negative rhabdomyosarcoma (RD) 
cells) by αDAF antibodies (Johansson et al., 2004). It is also important to 
note that the blockade of DAF, a negative regulator of the complement 
cascade, could trigger complement-mediated cytotoxicity of the αDAF 
antibody-coated cells. This is unlikely however, due to the destruction of 
complement proteins during the heat-inactivation of FCS. 
It is important to note that lytic cell death is not the only mechanism of action 
of OV. Although OCI-LY19 cells can resist CVA21 lytic cell death, and most 
cell lines were resistant to reovirus-induced cell death, it may be possible for 
either virus to target them indirectly through the induction of an anti-tumour 
immune response. This has been reported for multiple OV, for example, 
HSV-1 promoted immune cell infiltration and targeting of a HSV-1-resistant 
melanoma model (Miller and Fraser, 2003), reovirus enhanced NK and T cell 
numbers in patient tumours (White et al., 2008), Coxsackievirus B3 
enhanced granulocyte and NK cell-mediated elimination of lung 
adenocarcinoma xenografts (Bhat and Rommelaere, 2015) and VSV 
enhanced IL-28 secretion in the TME, induced NK ligand expression on 
tumour cells and enhanced NK cell killing of these cells (Wongthida et al., 
2010). Research by Prestwich, et al., also demonstrated reovirus-induced 
elimination of murine melanoma cells that was immune-mediated and 
independent of viral oncolysis or replication (Prestwich, Robin J. et al., 
2009). Investigating the potential for these effects, that were largely 
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observed in in vivo models, is beyond the scope of in vitro research, 
however, the ability of either virus to induce immune cell targeting of the 
NHL cell lines will be the focus of Chapter 6. 
CVA21 replicated significantly in susceptible NHL cell lines (Figure 4-5), 
suggesting that cell death was replication-dependent, as confirmed by UV-
inactivation of CVA21 which inhibited cytotoxicity (0). Oncolysis would be 
beneficial to OV therapy as it perpetuates the virus within the TME, leading 
to the continual destruction of malignant cells or the induction of an immune 
response against the cancer (as discussed in section 2.4.1.2). While the 
properties of this lytic cell death were not investigated in this research, this 
could be analysed by the use of confocal microscopy to elucidate whether 
the cells have ruptured in the latter stages of viral infection. Interestingly, 
research into the use of VSV has shown that it remains toxic to leukaemia 
cell lines despite UV-inactivation (Tsang, J.J. and Atkins, 2015), the 
mechanism of this remains undefined, but could be due to the production of 
cytotoxic cytokines. Therefore, while CVA21-induced cell death of NHL cell 
lines is replication-dependent, other viruses do not require replication to 
induce cell death. Moreover, research by Batenchuk, et al., demonstrated a 
reduction in AML blasts from the peripheral blood of two patients following 
treatment with UV-inactivated Rhabdoviruses (Batenchuk et al., 2013). This 
effect was attributed to a combination of replication-independent cytolysis 
and T cell-mediated apoptosis of malignant cells. Taken together, both 
papers demonstrate a replication-independent role for viruses in targeting 
cancer cells. 
As previously discussed, tumours are comprised of neighbouring cells 
(immune cells and fibroblasts) that can provide supporting signals to 
malignant cells. The LN in NHL is no exception to this as it is comprised of 
immune cells, such as T cells and macrophages, and fibroblasts that provide 
a complex network of signals to malignant B cells (Scott and Gascoyne, 
2014). Mimicking the TME in vitro is essential to understand the efficacy of 
OV against cancer. To this end, the CD40:CD40L interaction between B 
cells and T cells was investigated for its effect on the efficacy of CVA21 
against LN-residing NHL cells. Although, to date, the TME has not been 
reported to enhance susceptibility of tumour cells to CVA21, this has been 
demonstrated in other OV models; VSV, which infects CAFs, induces 
neighbouring cancer cells to downregulate components of their antiviral 
response, such as RIG-I, thus increasing the susceptibility of the cancer 
cells to viral infection (Ilkow et al., 2015). The role of the TME can also be 
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detrimental to OV therapy as research by Liu, et al., demonstrated an 
enhanced antiviral state was induced by Interferon-β-secreting CD68+ 
macrophages residing in ovarian and breast tumours (Liu et al., 2013), 
resulting in diminished susceptibility of cancer cells to VSV. These findings 
suggest that other aspects of the NHL TME should be investigated to further 
characterise the impact of the TME on CVA21 efficacy against NHL; for 
example, interferon-secreting cells, such as plasmacytoid Dendritic Cells, 
can be present in the LN (Diacovo et al., 2005), and may stimulate a similar 
antiviral response. 
The use of a CD40L+L929 feeder layer co-culture to model the CD40:CD40L 
interaction in the LN, has previously been used to investigate the effects of 
this interaction on B cell activation, where it induced resistance to anti-IgM-
induced apoptosis in WEHI-231 murine lymphoma cells (Leopoldo et al., 
2001), and resistance to Doxorubicin in Daudi, Raji, BJAB, BL36 and BL70 
NHL cell lines (Voorzanger-Rousselot et al., 1998), warranting its use as a 
model of drug-resistance. CD40L stimulation has also been achieved by 
other methods, such as CD40L+3T3 cells and soluble CD40L trimers, that 
have induced chemotherapeutic resistance in CLL (Younes et al., 1998), 
(Romano et al., 1998), (Kitada et al., 1999) and MCL (Clodi et al., 1998b) 
models. 
Results presented in this chapter showed that CD40L stimulation induced 
vincristine resistance in NHL cell lines, suggesting that CD40:CD40L 
interactions could reduce vincristine’s efficacy in vivo, and increase the risk 
of patient relapse following treatment. Therefore, strategies such as OV, 
which may target drug-resistant cells, and thus eradicate residual disease, 
are important. Data presented in Figure 4-11 illustrates that CD40L 
stimulation significantly enhanced ICAM-1 expression on Ramos, SU-DHL-4, 
OCI-LY19 and U2932 cell lines, and healthy donor B cells. This coincided 
with enhanced CVA21-induced cell death in Ramos and U2932 cells (Figure 
4-14), but not in healthy B cells (Figure 4-16), which remained resistant. 
These data demonstrate the ability of CVA21 to target drug-resistant NHL 
cells, suggesting a potential to eradicate untreatable neoplastic cells, but not 
healthy LN-residing B cells. Research into the ability of CVA21 to target 
chemotherapy-resistant cells in other cancer types also reported CVA21-
induced cell death of chemotherapy-resistant melanoma cell lines (Au et al., 
2005), validating OV therapy as a potential strategy to complement current 
treatment methods.  
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Leopoldo, et al., also reported enhanced ICAM-1 expression after CD40L 
stimulation of murine lymphoma cell line WEHI-231 (Leopoldo et al., 2001), 
supporting the ICAM-1 upregulation observed in NHL cell lines following 
CD40L stimulus. It is important to note that while comparing healthy B cells 
with NHL cell lines, the enhanced ICAM-1 on CD40L-stimulated healthy B 
cells was still significantly lower than baseline ICAM-1 on Ramos, Raji and 
SU-DHL-4 cells, but not the U2932 and OCI-LY3 cells, which were highly 
sensitive to CVA21. Cumulatively, these data show that, while ICAM-1 is 
essential for CVA21 infection, alternate mechanisms can determine 
susceptibility to the virus. These determinants will be investigated further in 
Chapter 5. 
The inability of CVA21 to infect and kill healthy PBMCs has been previously 
demonstrated by Au, et al., who reported CVA21’s ability to target myeloma 
cell lines, but not healthy PBMCs (Au et al., 2007). In agreement with this, 
CVA21 replication was not detectable in healthy B cells (Figure 4-17), 
contrary to the high levels of replication observed in the neoplastic NHL cell 
lines (Figure 4-5). Similarly, reovirus does not induce cell death in healthy 
lymphocytes (Alain et al., 2002). Reovirus and CVA21 have been used in a 
range of clinical trials (Thirukkumaran, C. M. et al., 2010), (White et al., 
2008), (Gollamudi et al., 2010), (Pandha et al., 2015a), (Andtbacka et al., 
2015), where they have not displayed significant adverse events, indicating 
tolerability in patients and a lack of off-target effects against healthy cells. 
Overall this research has compared two candidate OV, reovirus and CVA21, 
for their ability to target NHL B cells. CVA21 was confirmed as a highly 
potent lytic agent against NHL B cells, while reovirus was less potent. For 
this reason, reovirus was no longer investigated as a lytic agent against NHL 
cells. CVA21-induced cell death of NHL cells was dependent on ICAM-1 and 
viral replication in malignant cells, and healthy B cells remained 
comparatively resistant. Other potential determinants of susceptibility to 
CVA21 will be the subject of future chapters. 
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Chapter 5: 
Effect of antiviral IFN and mTOR 
signalling on CVA21 cytotoxicity 
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Chapter 5  
5.1 Introduction 
The aim of the research conducted in this chapter was to investigate (1) the 
role of host antiviral immunity in susceptible malignant B cell lines and 
resistant healthy donor B cells, and (2) the role of the mechanistic Target of 
Rapamycin (mTOR) protein complex, and the pathways it controls, in CVA21 
sensitivity.  
The innate antiviral response allows infected cells, or those neighbouring 
infected cells, to communicate with one another and prevent further viral 
replication. Viruses, however, are constantly evolving to generate new 
means of overcoming this antiviral response. This was investigated in the 
context of NHL by analysing the expression of a small number of ISGs after 
IFN-α and/or virus treatment to examine (1) whether the cells are responsive 
to IFN treatment and (2) whether CVA21 employs mechanisms which can 
abrogate IFN signalling. This may identify additional cellular determinants 
required for CVA21-induced death of malignant NHL cells.  
The mTOR pathway is reportedly activated in a variety of cancers, including 
NHL (Schatz, 2011), (Westin, 2014), (Rahmani et al., 2014). MTOR is a 
serine/threonine protein kinase that works with several other proteins in one 
of 2 possible complexes; mTOR Complex 1 or 2 (mTORC1 or mTORC2). 
MTORC1 functions as a nutrient sensor that regulates transcription and 
translation (Showkat et al., 2014) while MTORC2 regulates cell survival and 
cytoskeleton remodelling (Saxton and Sabatini, 2017). As previously 
discussed, hijacking of mTOR activity is a hallmark of the replication cycles 
of many viruses (Chapter 2 section 2.4.1.1.4.2), highlighting it as a 
potentially important factor in determining the susceptibility of malignant cells 
to OVs. Because of the ability of rapamycin to inhibit mTORC1, a pathway 
known to be dysregulated in NHL cells, the effect of rapamycin on CVA21 
cytotoxicity and NHL proliferation was investigated.  
The findings of this chapter may facilitate the development of 
complementary combination strategies to enhance CVA21 efficacy in more 
resistant cancer models and help identify other cancer models which may 
benefit from CVA21 therapy.  
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5.2 Results 
5.2.1 NHL cell lines are not protected by IFN-α despite 
functional IFN signalling 
The type I IFN response is one of the first lines of antiviral defence. 
Therefore, it was hypothesised that NHL cell lines, which were highly 
susceptible to CVA21 infection, and healthy PBMCs, which were resistant, 
may differ in their IFN production and downstream signalling pathways, 
following CVA21 treatment. To test this, NHL cell lines and healthy PBMCs 
were treated with CVA21 for 48hrs and cell supernatants were analysed for 
the presence of IFN-α by ELISA. Figure 5-1 shows that no IFN-α was 
detected in Ramos, Raji, SU-DHL-4, OCI-LY19, U2932 or OCI-LY3 cell lines 
following treatment with CVA21. However, healthy donor PBMCs (n=4) 
showed a significant dose-dependent increase in IFN-α production in 
response to CVA21, outlining an important difference between isolated NHL 
cell lines and mixed PBMCs following CVA21 treatment. It is important to 
note that PBMCs differ from NHL cell lines considerably, due to their non-
transformed state, their limited growth and division in culture and the 
presence of a mix of cell types that will respond differently to the presence of 
CVA21, i.e., non-B cells in the PBMC culture could be producing antiviral 
factors that render the healthy B cells resistant to CVA21, an effect that 
would not be replicated in isolated NHL cell lines. Isolated B cells could not 
be used to compare with NHL cell lines due to the poor survival of isolated B 
cells in vitro within 72hrs (data not shown). 
Although NHL cell lines did not produce IFN-α in response to CVA21 it was 
important to investigate if IFN-α, produced from possible neighbouring cells, 
could protect NHL cells against CVA21 infection. NHL cell lines were treated 
with recombinant human IFN-α (rhIFN-α) for 1hr before the addition of 
CVA21. The aim of this experiment was to use rhIFN-α treatment as a 
surrogate for viral detection and IFN-α secretion induced during the host 
(PBMC) antiviral response. This method was previously observed to induce 
significant protection from CVA21 using the AML cell line, KG-1 (Louise 
Müller, personal communication; data not shown). Figure 5-2 illustrates that 
Ramos (a), Raji (b), SU-DHL-4 (c), U2932 (d) and OCI-LY3 (e) cells were 
not protected from CVA21-induced cell death by rhIFN-α. This finding was 
expanded upon in subsequent experiments which involved treating healthy 
donor PBMCs with CVA21, harvesting the virus-conditioned media (CM), 
and culturing the NHL cells with CVA21 in the presence or absence of CM. 
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Upon assessment of cell viability, CVA21 cytotoxicity was still observed, 
suggesting that the NHL cells were not protected by IFN-α, or other antiviral 
cytokines produced by PBMC in response to CVA21 treatment (data not 
shown).  
RhIFN-α pre-treatment did not protect NHL cell lines from CVA21 infection 
and oncolysis, while it did protect the KG-1 AML cells (LM: manuscript 
submitted), suggesting a possible dysfunction of the IFN pathway in NHL cell 
lines. The first step in the investigation of IFN signalling in neoplastic B cells 
was assessment of IFN-α/β receptor expression and its ability to respond to 
IFN-α treatment. The expression of the IFN-α/β receptor on NHL cell lines 
and healthy B cells, as a normal control, was analysed by flow cytometry. 
Figure 5-3 demonstrates that, Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 
(d), U2932 (e) and OCI-LY3 (f) all expressed the IFN-α/β receptor (red) 
above isotype control levels (grey). Although the expression varied between 
cell lines, levels were comparable with that of healthy B cells, which also 
showed high expression of the IFN-α/β receptor (g-i). 
Next, to investigate if engagement of IFN-α/β receptors by IFNs induced 
downstream signalling, intracellular Phosflow™ cytometry was used to 
detect STAT1 phosphorylation in response to rhIFN-α treatment. A 
preliminary time course of the p-STAT1 experiment showed that the signal 
diminishes after the first hour of IFN treatment (data not shown). Figure 5-4 
shows STAT1 phosphorylation was increased in 4 out of the five NHL cell 
lines tested (Ramos, Raji, SU-DHL-4 and U2932), in response to IFN-α 
treatment, although this was only significant in U2932 cells. No p-STAT1 
was observed in OCI-LY3 cells upon rhIFN-α treatment. Moreover, STAT1 
phosphorylation was not significantly different in NHL cells from those 
observed in the healthy donor B and T cells, as determined by student’s T 
test. Collectively, these data suggest that most NHL cell lines express 
functional IFN receptors that are responsive to IFN. However, rhIFN-α 
treatment did not induce STAT1 phosphorylation in OCI-LY3 cells which 
expressed the IFN-α/β receptor, which was unexpected.  
The functionality of the IFN response pathway was further investigated by 
treating NHL cells with rhIFN-α for 72hrs, followed by analysis for the 
expression of two surface-expressed ISGs; tetherin and MHC-I. MHC-I and 
tetherin were chosen as candidate ISGs for these pilot experiments due to 
their rapid detection by flow cytometry, the reported ability of CVA21 to 
target MHC-I during infection (UniProt, 2008), and the 72hr time point was 
chosen as previous research by Arellano-Garcia, et al., demonstrated 
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enhanced MHC-I at this time (Arellano-Garcia et al., 2014). Figure 5-5 (a) 
shows significant induction of MHC-I in SU-DHL-4 cells only, and a small 
upward trend in expression in Ramos and healthy B cells. By contrast, 
tetherin expression was significantly increased in Ramos, SU-DHL-4 and 
U2932 cell lines following rhIFN-α treatment, Figure 5-5 (b). OCI-LY3s 
showed no induction of either ISG above untreated levels, as expected given 
the lack of STAT1 phosphorylation observed in Figure 5-4. Interestingly, the 
induction of tetherin and MHC-I on NHL cell lines was not significantly 
different than that observed in healthy B cell controls, demonstrating no 
significant difference in their downstream IFN signalling. Taken together, 
these data suggest that, while the NHL cell lines are responsive to IFN 
treatment, IFN signalling does not protect them from CVA21-induced cell 
death and therefore does not offer a further explanation for the differential 
sensitivity of malignant B cells over healthy B cells. While this research 
focussed on MHC-I and Tetherin as candidate ISGs, further research is 
being conducted that will examine the effects of CVA21 and IFN-α on the 
expression of a wider range of ISGs. 
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Figure 5-1 Interferon-α production by NHL cell lines and healthy 
PBMCs in response to CVA21 treatment. 
Ramos, Raji, SU-DHL-4, OCI-LY19, U2932 and OCI-LY3 cell lines and 
healthy donor PBMCs were treated with CVA21 for 48hrs before analysis of 
supernatant for IFN-α secretion by ELISA. Data shows n=3 independent 
experiments for the NHL cell lines and n=4 independent healthy PBMC 
samples ± SEM. Significance was determined using a paired, two-tailed 
student’s T test.  
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Figure 5-2 IFN-α pre-treatment of NHL cell lines does not abrogate 
CVA21-induced cell death. 
Ramos (a), Raji (b), SU-DHL-4 (c), U2932 (d) and OCI-LY3 (e) cell lines 
were pre-treated with rhIFN-α (5000pg/mL) for 1hr before being treated with 
CVA21. Cells were cultured for 24hrs before being harvested and assayed 
for viability using LIVE/DEAD™ viability dye. Data shows the mean + SEM 
for n=3 independent experiments. Statistical analysis was determined by 
two-way ANOVA.
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Figure 5-3 Interferon-α/β receptor expression on NHL cell lines and 
healthy B cells. 
Ramos (a), Raji (b), SU-DHL-4 (c), OCI-LY19 (d), U2932 (e) and OCI-LY3 (f) 
cell lines were analysed by flow cytometry for surface expression of the IFN-α/β 
receptor. Receptor expression is illustrated by representative histogram plots 
overlaying IFN-α/β staining (red) and the matched isotype control (grey) (a-f). 
Lymphocytes were identified by FSC/SSC (g) and healthy donor B cells by 
CD20 expression (h). Healthy donor B cell IFN-α receptor expression (i) is 
illustrated by a representative histogram plot overlaying IFN-α/β receptor 
staining (blue) and isotype control (green). All data is representative of n=2 
independent experiments.  
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Figure 5-4 STAT-1 phosphorylation in NHL cell lines and healthy B cells in 
response to rhIFN-α treatment. 
NHL cell lines, Ramos (blue), Raji (red), SU-DHL-4 (green), U2932 (orange) 
and OCI-LY3 (black), and Healthy PBMC T cells (open circles) and B cells (grey 
squares) were analysed for STAT1 phosphorylation 30 min after rhIFN-α 
treatment (5000pg/mL). STAT1 phosphorylation MFI was normalised to the MFI 
of treatment-matched isotype controls and the graph illustrates the ratio to 
untreated samples. Data from individual experiments is shown, ± SEM. 
Significance was determined by paired, two-tailed student’s T test. 
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Figure 5-5 Induction of MHC-I and tetherin expression in response to 
rhIFN-α treatment. 
Ramos (blue), Raji (red), SU-DHL-4 (green), U2932 (orange) and OCI-LY3 
(black) cell lines, as well as 4 healthy donor B cells (grey; in the context of 
PBMCs) were treated with 5000pg/mL rhIFN-α and analysed for surface 
expression of MHC-I (a) and tetherin (b). Results are normalised to treatment-
matched isotype controls and expressed as ratios relative to untreated samples.  
Data from n=4 independent experiments is shown ± SEM. Significance was 
determined by paired, two-tailed student’s T test. 
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5.2.2 CVA21 inhibits the antiviral response in NHL cell lines but 
not healthy B cells in mixed PBMCs 
The ability of NHL cell lines to respond to IFN and induce antiviral ISGs 
suggests that the IFN pathway is functional, yet unable to inhibit CVA21-
induced cell death, as shown in Figure 5-2. One potential explanation for this is 
that CVA21 may inhibit IFN signalling in NHL cell lines, but not healthy donor B 
cells. To test this, NHL cell lines and healthy B cells (identified in the context of 
mixed PBMCs by flow cytometry) were treated with CVA21 for 16hrs before 
being treated with rhIFN-α for 24hrs; viable cells were then assessed for MHC I 
and Tetherin expression to determine whether IFN-induced ISG expression 
could be inhibited by CVA21. Figure 5-6 shows increased Tetherin expression 
in rhIFN-α-treated Ramos (a), SU-DHL-4 (b) and U2932 (c) cells, however, this 
appeared to be reduced upon CVA21 treatment in all three cell lines (n=2). 
Contrary to earlier figures, healthy donor B cells (d) showed no significant 
increase in Tetherin expression upon rhIFN-α treatment, however, in contrast to 
NHL lines, a significant increase in Tetherin expression was observed upon 
CVA21 treatment. Similarly, preliminary data shown in Figure 5-7 illustrates 
enhanced MHC-I expression by rhIFN-α treatment that is diminished by CVA21 
infection in SU-DHL-4 cells. Collectively, these data demonstrate that NHL cell 
lines are susceptible to CVA21 despite having a functional antiviral response. 
However, decreased ISG expression following CVA21 treatment suggests that 
CVA21 may inhibit the antiviral response in malignant NHL cells, but not in 
healthy cells.  It is possible that low ICAM-1 expression in healthy B cells may 
prevent sufficient CVA21 entry to overcome the natural host antiviral response. 
These data demonstrate the ability of CVA21 to manipulate the antiviral 
response of malignant cells and suggests this as a potential determining factor 
for CVA21 susceptibility.  
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Figure 5-6 CVA21 inhibits rhIFN-α-induced expression of Tetherin in NHL 
cell lines. 
Ramos (a), SU-DHL-4 (b), U2932 (c) cell lines and healthy donor B cells in the 
context of PBMCs (d) were pre-exposed to CVA21 for 16hrs before being 
treated with rhIFN-α for a further 24hrs. Samples were harvested and stained 
with an α-human Tetherin antibody prior to analysis by flow cytometry. Tetherin 
expression is displayed relative to isotype expression from treatment-matched 
samples. Results are from n=2 independent experiments for the NHL cell lines 
and n=3 donors for the healthy B cells. Data shows the mean + SEM, statistical 
significance was determined by two-way ANOVA. 
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Figure 5-7 CVA21 inhibits rhIFN-α-induced expression of MHC-I in SU-
DHL-4 cells. 
SU-DHL-4 cells were pre-exposed to CVA21 for 16hrs before being treated with 
rhIFN-α for a further 24hrs. Samples were then harvested and stained with an 
anti-human MHC-I antibody, prior to analysis by flow cytometry. MHC-I 
expression is displayed relative to isotype expression from treatment-matched 
samples. Results are from n=2 independent experiments. Data shows the mean 
+ SEM.  
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5.2.3 MTOR inhibition impairs CVA21-induced cell death in NHL 
cells 
A literature search of the pathways that are often dysfunctional in NHL cells 
identified upregulated mTOR signalling as a common trait in NHL B cells 
(Schatz, 2011). To investigate a potential relationship between mTOR activity 
and susceptibility to CVA21, NHL cell lines were investigated for their mTOR 
activation status and the effect of mTOR inhibition on CVA21 susceptibility. NHL 
cell lines were analysed for basal mTORC1 activity by intracellular Phosflow™ 
cytometry for the phosphorylation of the downstream targets S6 and 4EBP1. 
These samples were analysed alongside healthy donor B cells as non-
transformed controls. Figure 5-8 (a) shows significant mTOR activity in Ramos, 
SU-DHL-4 and OCI-LY3 cells. This is in contrast with the healthy donor B cells 
(in PBMCs) which appeared to display lower mTOR activity (n=2). Similarly, for 
p-4EBP1 (b), mTOR activity is active in Ramos, SU-DHL-4 and U2932 cells and 
appears to be lower in the healthy B cells. 
Having identified that mTOR signalling is active in most cell lines, but not 
healthy B cells, the role of mTOR in CVA21 infection and oncolysis was 
investigated.  NHL cell lines were treated with rapamycin for 1hr prior to being 
treated with CVA21 for 72hrs and quantification of cell death. Figure 5-9 
demonstrates that cell death induced by CVA21 was significantly reduced in the 
presence of rapamycin in Ramos (a), SU-DHL-4 (c) and U2932 (d) cells, but not 
the Raji (b) cells. To ensure that the doses of rapamycin used were sufficient to 
inhibit mTOR activity, NHL cell lines were treated with rapamycin for 24hrs and 
analysed for S6 and 4EBP1 phosphorylation. Phosphorylation of S6 was 
significantly inhibited by rapamycin in all NHL cell lines, Figure 5-10 (a), 
however, phosphorylation of 4EBP1 was not inhibited, Figure 5-10 (b), 
suggesting an important role for mTOR-regulated S6 activity in the sensitivity of 
these cells to CVA21. 
As previously described, CD40L stimulation increased ICAM-1 on most NHL 
cell lines and this coincided with enhanced susceptibility to CVA21 in two cell 
lines (sections 4.2.6 and 4.2.7). MTOR activity can also be increased upon 
CD40L stimulation (Dormond et al., 2008). NHL cell lines were cultured alone, 
or on CD40L+ L929s or parental L929s for 24hrs, harvested and analysed for p-
S6 and p-4EBP1 by Phosflow™ cytometry to test whether mTOR activity in 
NHL cell lines is enhanced upon CD40L stimulation.  CD40L has no significant 
effect on S6 phosphorylation levels, Figure 5-11 (a), and 4EBP1 
phosphorylation also remained unchanged in NHL cells after CD40L 
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stimulation, Figure 5-11 (b). These data showed no increase in mTOR activity 
upon CD40L stimulation, suggesting that enhanced mTOR signalling, in CD40L-
stimulated NHL, was not responsible for the enhanced CVA21 cytotoxicity 
shown in section 4.2.7, Figure 4-14.   
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Figure 5-8 MTOR Activity in NHL cell lines and healthy B cells. 
Ramos (blue), Raji (red), SU-DHL-4 (green), U2932 (orange) and OCI-LY3 
(black) cell lines, and 2 healthy B cells (grey; in the context of PBMCs) were 
cultured for 24hrs and analysed for baseline mTOR activity by 4EBP1 and S6 
phosphorylation. Isotype controls were normalised to 1 and matched p-S6 and 
p-4EBP1 expression was expressed as a ratio of isotype staining. Data shows 
the mean from n=4 independent experiments for cell lines and n=2 healthy 
donor samples + SEM. Significance was determined by paired, two-tailed 
student’s t test 
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Figure 5-9 Rapamycin diminishes CVA21-induced cell death in most NHL 
cell lines. 
NHL cell lines Ramos (a), Raji (b), SU-DHL-4 (c) and U2932 (d) were untreated 
(white bars) or pre-treated with DMSO (light grey), 50 or 100nM rapamycin 
(dark grey and black bars, respectively) for 1hr before the addition of CVA21. 
The cells were then cultured for 72hrs, harvested and analysed for cell death 
using LIVE/DEAD™ viability dye by flow cytometry. Results are expressed as 
the percentage dead cells from n=4 independent experiments + SEM. Statistical 
significance was determined by two-way ANOVA. 
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Figure 5-10 Rapamycin inhibits S6 phosphorylation, but not 4EBP1 
phosphorylation. 
Ramos (blue), Raji (red), SU-DHL-4 (green), U2932 (orange) and OCI-LY3 
(black) cell lines were treated with rapamycin (Rapa) or DMSO for 24hrs. The 
cells were harvested, stained for intracellular p-S6 and p-4EBP1 and the MFI 
values calculated as a ratio relative to the isotype values. Data were then 
normalised to the untreated samples and the graphs illustrate fold change 
relative to untreated controls. Data shows the results from n=4 independent 
experiments + SEM. Statistical significance was determined by one-way 
ANOVA.  
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Figure 5-11 CD40L Stimulation does not enhance MTOR activity in NHL 
cell lines. 
Ramos (blue), Raji (red), SU-DHL-4 (green), U2932 (orange) and OCI-LY3 
(black) cell lines were cultured alone (UT) or on CD40L+L929 (CD40L) or 
parental L929 (L929) cells for 24hrs. The cells were harvested, stained for 
intracellular p-S6 and p-4EBP1 and the MFI values calculated as a ratio relative 
to the isotype values. Data were then normalised to the untreated samples and 
the graphs illustrate fold change relative to untreated controls. Data shows the 
results from n=4 independent experiments + SEM. Statistical significance was 
determined by one-way ANOVA.   
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5.2.4 Rapamycin has little effect on NHL cell cycle and 
proliferation 
Rapamycin has strong anti-proliferative effects due to its reported inhibition of 
translation, as shown in melanoma (Bundscherer et al., 2008) and T cell 
lymphoma cell lines (Zhao, Y.M. et al., 2008). As such, Rapamycin was 
investigated for its effects on NHL cell line proliferation using CFSE staining to 
determine if there is a role for mTOR inhibition in CVA21 cytotoxicity, beyond a 
more general block of cellular proliferation.  
NHL cell lines, Ramos (a), Raji (b), SU-DHL-4 (c), U2932 (d) and OCI-LY3 (e) 
were stained with CFSE and incubated with and without rapamycin (Figure 
5-12).  Flow cytometry after 24hrs revealed reduced fluorescence in control 
untreated cells (due to cell division) that was comparable with rapamycin-(blue) 
and DMSO- treated (purple) cells. However, by 48hrs, the CFSE fluorescence 
of the rapamycin-treated cells was greater than that of untreated cells or DMSO 
controls. This effect was even more pronounced by 72hrs, suggesting a slowing 
of cell proliferation by rapamycin, rather than complete cell cycle blockade. 
These results are quantified in Figure 5-13 and demonstrate a significant 
difference between CFSE fluorescence in untreated and rapamycin-treated 
cells at 72hrs (the time point shown in Figure 5-9) in Ramos (a), SU-DHL-4 (c), 
U2932 (d) and OCI-LY3 (e) cells, but not in Raji (b).  By contrast, no significant 
delays in proliferation were observed at earlier time points (24 or 48rs) following 
rapamycin treatment. Importantly, rapamycin also inhibited CVA21-induced cell 
death to a similar extent at 48hrs in Ramos, SU-DHL-4, U2932 and OCI-LY3 
cells (n=1, data not shown) when cell proliferation was not significantly inhibited 
suggesting that blockade of cell proliferation by rapamycin was not responsible 
for reduced CVA21 cytotoxicity.    
To further examine the effect of rapamycin on cell cycle progression, propidium 
iodide (PI) staining of DNA was used to assess the cell cycle status following 
rapamycin treatment, Figure 5-14. PI analysis of rapamycin-treated NHL cell 
lines at 72hrs showed no significant in cell cycle between treated and untreated 
samples.  
Collectively, these data demonstrate that rapamycin does not immediately block 
NHL cell proliferation or cause G1 cell cycle arrest; however, small, but 
significant delays in cellular proliferation were observed following rapamycin 
treatment after 72hrs. Given that only a small delay in cellular proliferation was 
observed with rapamycin in most cell lines, this suggests that the effect of 
rapamycin is not due to abrogation of cell proliferation but another function of 
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mTOR, which is important to support CVA21 replication and lysis.  The 
significance of mTOR in CVA21-induced cell death needs to be further defined 
and is the subject of ongoing laboratory investigations. 
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Figure 5-12 Rapamycin delays NHL cell line proliferation. 
NHL cell lines were left unstained (red) or stained with CFSE before being 
treated with rapamycin (blue), DMSO (purple) or left untreated (green). Cells 
were then analysed for fluorescence immediately and every 24hrs thereafter. 
The 0hr untreated CFSE-stained result was included in the 24, 48 and 72hr 
histograms in all cell lines to demonstrate the shift in fluorescence from the start 
of the experiment (0hr) to the other time points. Data shows representative 
histogram overlays of unstained, untreated, DMSO or rapamycin treated cells 
from n=4 independent experiments. 
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Figure 5-13 Rapamycin delays NHL cell line proliferation. 
NHL cell lines were stained with CFSE before being incubated with and without 
DMSO or rapamycin (50 and 100nM). CFSE fluorescence was then analysed 
by flow cytometry immediately and every 24hrs thereafter. Data shows the 
mean of n=4 independent experiments +SEM, analysed for significance by one-
way ANOVA.  
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Figure 5-14 Rapamycin does not cause G1 arrest. 
NHL cell lines were treated with rapamycin for 72hrs before being harvested 
and stained with Propidium Iodide and analysed by flow cytometry. The 
percentage of cells in G1 and S/G2/M phases of the cell cycle were then 
determined by DNA content (PI fluorescence). Data shows the results from n=3 
independent experiments ± SEM. Statistical significance was determined using 
one-way ANOVA, no statistically significant differences were observed.  
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5.3 Discussion 
This research aimed to investigate the role of the antiviral IFN response in 
preventing CVA21 infection, the ability of CVA21 to overcome this response and 
the role of mTOR in CVA21 infection. Vähä-Koskela, et al., have previously 
reviewed a variety of factors that impact the ability of oncolytic viruses to 
replicate in malignant cells, such as the role of a functional IFN response (Vaha-
Koskela and Hinkkanen, 2014). Identifying cellular factors responsible for 
CVA21 replication and oncolysis may enable patient stratification to target 
susceptible disease, such as using IFN-sensitive OV to target IFN-deficient 
cancers. 
IFN signalling can inhibit OV replication, shifting the preference of the OV 
towards malignant cells that lack a functional antiviral IFN response, such as 
NDV (Elankumaran et al., 2010), an oncolytic influenza virus (Muster et al., 
2004) and VSV (Stojdl et al., 2000). In this chapter, the absence of detectable 
IFN-α in NHL cell line cultures, versus the high levels of IFN-α in CVA21-
resistant PBMCs (Figure 5-1), offered a possible explanation for their sensitivity 
to CVA21. This result may be due to the diverse mix of cells within the PBMC 
samples which could produce IFN-α, while the homogenous cell line cultures 
could not. For example, PBMC incorporate many cell types that can produce 
IFN in response to a virus, such as B cells (Ward et al., 2016), T cells (Klimpel 
et al., 1990), NK cells (Arase et al., 1996), monocytes (Hansmann et al., 2008), 
and Plasmacytoid Dendritic Cells (Fitzgerald-Bocarsly, 2002). Plasmacytoid 
Dendritic cells (pDCs) have been implicated as the main producers of IFN-α in 
response to CVA21 by complimentary research conducted in the laboratory 
(Louise Müller: manuscript submitted). Interestingly, Ho, et al., reported that 
NHL patient lymphocytes have a diminished ability to produce IFN in response 
to antigenic assault (Ho et al., 1992), suggesting that a reduced IFN response in 
NHL patients. Moreover, it should be recognised that the production of IFN and 
other cytokines by OV in vivo can suppress tumour growth, as demonstrated by 
Samson, et al., who showed cytokine-mediated suppression of hepatocellular 
carcinoma tumours in NOD/SCID mice by UV-inactivated reovirus (Samson et 
al., 2018). 
 Pre-treating NHL cell lines with rhIFN-α did not protect them from CVA21 
cytotoxicity, while it did protect the AML cell line, KG-1 (Louise Müller: 
Manuscript submitted). Therefore, it was possible that NHL cells may be unable 
to respond to IFN treatment, however further investigations, measuring 
downstream STAT1 phosphorylation and ISG (MHC I and Tetherin) 
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upregulation, confirmed this was not the case. By contrast, OCI-LY3 cells, 
despite expressing the IFN-α/β receptor, did not respond to rhIFN-α treatment 
by STAT1 phosphorylation or ISG expression. 
Interestingly, research conducted on other Coxsackieviruses by Lind et al., and 
Horwitz, et al., have demonstrated protective roles for IFN-λ against CVB3 (Lind 
et al., 2016) and IFN-γ against CVB4 (Horwitz et al., 1999), respectively, 
highlighting the importance of considering the IFN response when applying 
CVA21 to a malignancy. IFN-γ alone, and in combination with IFN-α, were 
investigated for their effects on CVA21 susceptibility but did not protect NHL 
cells from infection (data not shown). Unfortunately, due to time constraints, 
NHL cell lines, or healthy donor PBMCs, were not analysed for the secretion of 
other pro-inflammatory cytokines in response to CVA21, however, future 
research could test for the secretion of other IFNs, such as IFN-β, -λ or –γ, and 
a wider variety of secreted pro-inflammatory cytokines which have been 
associated with resistance to other picornaviruses (Dotzauer and Kraemer, 
2012). For example, IFN-β has been implicated in resistance to CVB3 
(Deonarain et al., 2004), (Runkel et al., 1998), and other Coxsackievirus and 
picornaviruses have displayed sensitivity to IFNs such as CVA16 (Hand, Foot 
and Mouth Disease Virus - HFMDV), which is abrogated in mice treated with 
murine IFN (Sasaki et al., 1986), and Foot and Mouth Disease Virus (FMDV), 
which is sensitive to IFN-α, -β and -γ in swine models (Diaz-San Segundo et al., 
2010). 
The fact that the IFN signalling appeared functional in the NHL cells, but was 
not able to inhibit CVA21, suggested that the virus may interfere with the IFN 
pathway. To test this, expression of MHC-I and Tetherin was examined after 
rhIFN-α treatment in the presence or absence of CVA21. ISG expression in the 
NHL cell lines appeared decreased upon CVA21 treatment, but not in healthy B 
cells; blockade of IFN signalling by CVA21 could provide a mechanism by which 
NHL cells remain susceptible despite the presence of antiviral IFN. In support of 
this hypothesis, Lind et al., also demonstrated that CVB3 could inhibit the IFN-λ 
response in HeLa cells using the 2Apro protein, which cleaved TIR-domain-
containing adapter-inducing interferon-β (TRIF) and Induced by Phosphate 
Starvation1 (IPS1), involved in relaying signals from PRRs to the nucleus to 
induce IFN production. Similar blockade of downstream effectors of the antiviral 
interferon response has been demonstrated by the 3C protein of enteroviruses 
68 and 71 cleaving TRIF (Xiang et al., 2014), (Lei et al., 2011), and the 3Cpro 
protein of CVB3 cleaving MAVS and TRIF (Mukherjee et al., 2011), suggesting 
a common mechanism of picornaviruses in blocking the antiviral IFN response. 
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CVA21, like other picornaviruses, has also been reported to subvert the host 
antiviral response by encoding proteins that interfere with host protein 
expression (ViralZone, 2015). CVA21 expresses proteins such as 2B, 2BC and 
3A, which disrupt the trafficking of IFN receptors and MHC molecules to the 
surface by inhibiting the function of the Golgi apparatus (UniProt, 2008). 
Coxsackieviruses also manipulate transcriptional and translational machinery in 
the cell for their own replication (Hwang, H.Y. et al., 2007), leading to a more 
general shutdown of host protein expression in the infected cell. Interestingly, 
CVA21 ablated human myeloma in SCID mouse xenograft models (Hadac and 
Russell, 2006). This response was associated with systemic myositis resulting 
in the death of mice. However, inoculation of an adenoviral vector expressing 
human IFN-α, resulting in increased IFN-α concentrations (3000 pg/mL) in the 
blood, inhibited the adverse effects. Importantly, the presence of the IFN had no 
impact on tumour eradication, suggesting that CVA21 retained an ability to 
target malignant cells within the TME, despite the presence of IFN. Importantly, 
during the Phase II CALM study that investigated the efficacy of CVA21 to treat 
advanced melanoma, NanoString RNA analysis of 4 pre- and post-treatment 
samples demonstrated an induction of interferon-induced genes (Andtbacka et 
al., 2015). This result, coupled with the 38.6% durable response rate reported, 
suggests that CVA21 is effective despite the production of an antiviral IFN 
response. 
Following the investigation of the IFN pathway’s role in CVA21 infection, other 
factors that could influence infection, namely the mTORC1 pathway, were 
examined. Enhanced mTOR activity has been observed in NHL B cells (Schatz, 
2011), (Kuo et al., 2011), and due to its regulation of cell growth, proliferation 
and metabolism, may contribute the survival and propagation of malignant cells 
(Rahmani et al., 2014).  
Rapamycin, a macrolide compound derived from the Streptomyces 
hygroscopicus bacterium, blocks the formation of the mTORC1 complex by 
binding to the cytosolic protein, FKBP12 (FK506 binding protein 12), which then 
binds to the FKBP-rapamycin-binding (FRB) domain of mTOR and blocks its 
ability to function (Yang, H. et al., 2013). FKBP12 is not normally a component 
of mTORC1 but associates with the complex upon binding to rapamycin 
(Hausch et al., 2013). Rapamycin also inhibits mTORC2, but only at high doses 
and in certain tissue types (Schreiber et al., 2015). Importantly, rapamycin has 
been used in the clinic as a potent immunosuppressant for organ transplants, 
due to its ability to prevent B and T cell activation by inhibiting IL-2 production 
(Saunders et al., 2001). 
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Analysis of mTORC1 downstream targets, S6 and 4EBP1, allowed the selection 
of sub-toxic doses of rapamycin that inhibited mTOR activity. These doses 
completely blocked p-S6 signalling by 24hrs and significantly hampered CVA21 
cytotoxicity in Ramos, SU-DHL-4 and U2932 cell lines, but not Raji cells. This 
result has yet to be explained but could be investigated further by testing Raji 
cells for downstream redundancies in this pathway, FKBP12 levels, or 
components of the rapamycin binding domain in the complex. It is interesting to 
note that, as well as having no effect on Raji cell susceptibility to CVA21, 
rapamycin did not affect the proliferation of Raji cells. This finding is congruous 
with work by Gu, et al., that demonstrated the resistance of Raji cells to 
rapamycin (Gu, L. et al., 2015).  
MTOR blockade by rapamycin coincided with diminished CVA21-induced cell 
death in Ramos, SU-DHL-4 and U2932 cell lines, suggesting a possible role for 
mTOR activity in CVA21 replication. A literature search of pathways that 
contribute to the replication of viruses similar to CVA21 suggested a role for 
mTOR in the replication of CVB3 (Chen et al., 2014). However, contrary to the 
observations in this chapter, this research showed that mTOR blockade by 
rapamycin promoted CVB3 replication in HeLa cells. The reason(s) for this 
remain unknown but may be due to differences in mTOR utilisation between 
different types of Coxsackievirus, or differences in the cell types investigated. 
Similar to the effects of rapamycin on CVB3 replication, research by Beretta, et 
al., defined a role for rapamycin in enhancing the translation of viral proteins 
from two alternative picornaviruses, Polio and Encephalomyocarditis Virus, 
while blocking the translation of host proteins, in NIH 3T3 cells  (Beretta et al., 
1996). This effect may suggest a potential role for mTOR inhibition in enhancing 
viral replication in epithelial cells, but not NHL cells. This data showed inhibition 
of p-4EBP1 and cap-dependent translation of host proteins, following 5hrs of 
rapamycin treatment, while cap-independent translation of viral proteins was not 
inhibited. The fact that p-4EBP1 was not inhibited by rapamycin in the NHL cell 
lines may explain why enhanced CVA21-induced cell death was not observed in 
rapamycin-treated NHL cells. Rapamycin only inhibits p-4EBP1 during the first 
1-3hrs of treatment (Choo et al., 2008), suggesting that p-4EBP1 returned to its 
phosphorylated state shortly after CVA21 treatment. 
The fact that diminished CVA21-induced cell death was observed in NHL cells 
that responded to rapamycin with inhibited S6 phosphorylation, while neither S6 
phosphorylation nor CVA21 cytotoxicity were impacted in Raji cells, strongly 
implicates a role for the S6-dependent side of mTORC1 activity in the 
susceptibility of NHL cells to CVA21. Taken together, these data suggest a 
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potential link between mTORC1 activity and CVA21 susceptibility. This could be 
examined further by assembling a panel of rapamycin-resistant cell lines, similar 
to Rajis, and examining whether they remain susceptible to CVA21-induced cell 
death after rapamycin treatment. Alternative methods of mTORC1 blockade, 
such as genetic or pharmacological inhibition of specific downstream effectors 
of mTORC1, could also be used to further elucidate the role of the mTORC1 
pathway in CVA21-induced cell death and not one that is due to rapamycin.  
As previously discussed, rapamycin can slow the proliferation of cells due to its 
impact on translation by blocking mTOR activity (Bundscherer et al., 2008). The 
reliance of many viruses on highly-proliferative cells made it important to 
investigate cell proliferation and cell cycle to ensure that rapamycin was not 
inhibiting CVA21 cytotoxicity solely by blocking NHL proliferation. Rapamycin 
induced a statistically significant slowing of proliferation after 72hrs in Ramos, 
SU-DHL-4 and U2932 cells, but this was minimal and thus, unlikely to be the 
main contributory factor for the reduced toxicity of CVA21 in these cell lines. No 
change in proliferation was observed in NHL cell lines at 48hrs, which, coupled 
with inhibition of CVA21-induced cell death at this time point, indicates an ability 
of rapamycin to diminish CVA21 cytotoxicity irrespective of the drug’s anti-
proliferative effect. The effects of mTOR inhibition on the proliferation of feline 
fibroblastic cells were also examined by Mortola, et al., who demonstrated a 
role for Tacrolimus, a rapamycin-analogue, in inhibiting Feline 
Immunodeficiency Virus (FIV) replication. This inhibition was observed 
alongside a decrease in cell proliferation after 3 days (Mortola et al., 1998); the 
exact role of Tacrolimus’ antiproliferative effect on FIV replication was not 
elucidated, but was acknowledged as a potential factor. 
It is difficult to correlate mTOR activation with CVA21 susceptibility in other 
tumour models. However, similar to published research on NHL, mTOR 
signalling is enhanced in a subset of multiple myeloma patients (Guglielmelli et 
al., 2015), and CVA21 displays toxicity against multiple myeloma cells (Au et 
al., 2007). These findings suggest a possible link, in B cell malignancies at 
least, between enhanced mTOR activity and CVA21 susceptibility. 
Contrary to the findings in this chapter that show reduced CVA21 cytotoxicity in 
rapamycin-treated NHL cells, rapamycin is being investigated in combination 
with OV in several tumour models, and has demonstrated synergy with several 
OV, such as myxoma virus against glioblastoma multiforme (GBM) stem cells 
(Zemp et al., 2013). Rapamycin also enhanced tumour cell death and survival 
when used in combination with myxoma virus in an in vivo model of glioma (Lun 
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et al., 2010). Similarly, both everolimus (a rapamycin derivative) and rapamycin 
enhanced adenovirus targeting of, and replication in, a colon cancer model 
(Homicsko et al., 2005) and murine prostate cancer model (Jiang et al., 2013), 
respectively; these effects were attributed to a diminished antiviral response 
following mTOR inhibition. Research by Comin, et al., demonstrated the 
importance of the sequence in which rapamycin and OV is administered. In this 
research, a synergistic effect was observed when reovirus and then rapamycin 
were administered to a C57/BL6 murine melanoma model, however, pre-
treatment of cells in vitro with rapamycin and then reovirus resulted in impaired 
virus replication and apoptosis (Comins, Charles et al., 2018). This research 
highlights the importance of the sequential administration of treatments in 
cancer research. It is important to acknowledge that a direct comparison 
between the cell line studies in this chapter and these in vivo results is not 
possible, due to the multifaceted representation of the tumour that in vivo 
models provided versus isolated cell line cultures. Since the precise role of the 
antiviral response in CVA21 targeting of NHL cells will be the focus of future 
research in the laboratory, the role of mTOR activity in this response must also 
be investigated. To date, no literature has reported efficacy of a combination of 
rapamycin and OVs to treat HMs, but inhibition of the antiviral response by 
rapamycin, as demonstrated in the prostate and colon cancer models, could 
play a role. The beneficial effect of an OV/rapamycin combination in these solid 
malignancies differs from the observed rapamycin-induced inhibition of CVA21 
replication in NHL cell lines. This difference could reflect the different roles of 
mTOR for different OV, or differences between solid tumours and HMs. 
Overall, the work presented in this chapter has demonstrated that CVA21 
oncolysis is not inhibited by antiviral type I IFN signalling, and data suggests 
that CVA21 may interfere with the antiviral response pathways to enable 
replication. Moreover, a role for mTOR signalling in some NHL cell lines has 
been proved. Both factors, as well as a role for ICAM-1 expression, are 
important for CVA21 infection, but may not be the only relevant factors for 
CVA21 susceptibility. This data expands what is known about CVA21’s activity 
in NHL cells and suggests that CVA21 may be efficacious in other cancer 
models that have high mTOR activity. This will develop CVA21’s applicability to 
other cancer models, allowing researchers to target cancers that may be more 
responsive to CVA21 treatment.  
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Chapter 6: 
Investigating the potential of OV to 
induce an anti-NHL immune 
response.   
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Chapter 6  
6.1 Introduction 
The aim of the research discussed in this chapter was to investigate the ability 
of both reovirus and CVA21 to potentiate an NK cell-mediated anti-NHL immune 
response, whereby OV stimulate NK cells to kill NHL cells, and whether this 
could be enhanced by mAbs. This alternate mechanism of killing by OV would 
complement direct lytic killing or replace it if the cells were resistant to 
oncolysis. Several clinical trials have examined the efficacy of OV in 
combination with immune checkpoint mAb therapy, such as reovirus and the 
αPD-1 antibody, pembrolizumab, to treat advanced or metastatic pancreatic 
adenocarcinoma (ClinicalTrials.gov, 2015b), and CVA21 and pembrolizumab to 
treat advanced melanoma (ClinicalTrials.gov, 2015a). Reovirus, a poor lytic 
agent against NHL cell lines, was included in these investigations due to its 
established immunogenicity (Prestwich, Robin J. et al., 2009). To date, OVs in 
combination with mAbs are the subject of multiple clinical trials for cancers, 
such as vaccinia virus and the αPD-L1 antibody, durvalumab, against colorectal 
carcinoma (ClinicalTrials.gov, 2017a), CVA21 and the αCTLA-4 mAb, 
ipilimumab, against melanoma (ClinicalTrials.gov, 2014), and vaccinia virus and 
the αPD-1 mAb, REGN2810 against renal cell carcinoma (ClinicalTrials.gov, 
2017b). Research has shown that a combination of OV and mAbs can enhance 
NK cell targeting of malignant cells in vitro, such as combined reovirus and 
rituximab to kill CLL cells (Parrish et al., 2015) and  combined reovirus and 
cetuximab against colorectal cancer (Zhao, X. et al., 2015).  
The ability of CVA21 and reovirus to promote the elimination of NHL cells by NK 
cells was examined in this chapter. Specifically, this work looked at NK cell 
activation by CD69 expression, a member of the C-type lectin superfamily that 
is absent on resting NK cells and rapidly upregulated upon viral infection (Fogel 
et al., 2013) and is the earliest expressed marker on activated immune cells 
(Ziegler et al., 1994), as well as the ability of NK cells to degranulate against 
NHL cell line targets.  
Due to the established role for mAbs in NK cell-mediated degranulation, and the 
enhanced effect when used in combination with OV, reovirus and CVA21 were 
combined with the αCD20 mAb, BHH2 (the laboratory-grade version of 
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GA101/obinutuzumab) against NHL. BHH2’s effect was examined on NHL cell 
lines with the highest CD20 expression; Ramos, SU-DHL-4 and U2932. 
Moreover, as stimulation by CD40L induces drug resistance in some NHL cell 
lines (Section 4.2.5), potentially making current chemotherapy less effective, 
CD40L-stimulated NHL cells were also examined for their susceptibility to NK 
cell-mediated killing. Investigating the combination between OVs and an αCD20 
mAb was chosen due to the previously-mentioned impressive performance of 
Rituximab in the treatment of NHL, the presence of the CD20 target on NHL B 
cells and the ability of combined rituximab and reovirus to induce enhanced NK 
cell targeting of CLL B cells (Parrish 2015). NK cells are significant effectors in 
targeting NHL cells in patients (Sarkar et al., 2017), making them appropriate 
effector cells to investigate. It is important to note that other signalling 
molecules, on both NHL cell lines and NK cells, provide activatory and inhibitory 
signals to NK cells, the balance of which will determine whether the NK cells 
target the NHL cells for cell death. With this in mind, the expression of some NK 
ligands was also investigated on NHL cell lines. 
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6.2 Results 
6.2.1 OV-induced NK-mediated ADCC against NHL cells 
Figure 6-1 shows CD69 expression on untreated and OV-treated NK cells after 
48hrs. These data show a significant increase in CD69 expression on NK cells 
by both CVA21 and reovirus, demonstrating the strong immunostimulatory 
potential of both viruses.  
To further explore the effects of CVA21 and reovirus on NK cells, and to 
examine whether they recognise malignant cells, untreated and OV-treated 
PBMCs were co-cultured with NHL cells for 4hrs. Whole PBMCs were used 
instead of isolated NK cells as new research has shown that CVA21-induced 
NK cell activation and degranulation against AML targets is dependent on IFN-α 
production by pDCs in the peripheral blood (Louise Muller – manuscript 
submitted). Figure 6-2 shows that NK cell degranulation is significantly 
enhanced against Ramos (light grey), SU-DHL-4 (dark grey) and U2932 (black) 
cell lines when treated with reovirus. Similarly, CVA21-treated PBMCs 
demonstrated increased NK cell degranulation against all cell lines, however, 
this was not significantly higher than untreated NK cells upon co-culture with 
Ramos cells.  CVA21 was consistently, but not significantly, less effective than 
reovirus at simulating degranulation of NK cells against NHL cell targets. 
PBMCs were also treated with either OV and cultured with no NHL targets 
(white). This showed a small, insignificant, increase in spontaneous 
degranulation in the absence of targets. The ability of both OVs to activate NK 
cell degranulation against NHL cell lines demonstrated their immunogenic 
potential against NHL, warranting further investigation in combination with the 
αCD20 antibody, BHH2.  
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Figure 6-1 OV-induced activation of immune effector cells. 
PBMCs were isolated from healthy donor blood and cultured with reovirus or 
CVA21 for 48hrs. PBMCs were then harvested and stained with αCD3 and 
αCD56 antibodies, to identify NK cell populations (CD3-CD56+), and CD69 to 
measure phenotypic activation. Gating strategy identifying lymphocytes by 
FSC/SSC (a) and NK cells within this population as CD3-CD56+ (b). (c) and (d) 
show overlaid histogram plots of CD69 expression (black) with isotype antibody 
controls (grey) on untreated and reovirus-treated samples, respectively. In (e), 
fold increases in CD69 MFI above dose-matched isotype controls is plotted for 
CD3-CD56+ NK cells. Data shows mean of n=4 PBMC donors + SEM. 
Significance was determined by One-way ANOVA.   
(e) 
 
Untreated 
0.1 pfu/cell Reovirus 
0.  pfu/cell CVA21 
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Figure 6-2 OV-induced NK cell degranulation against NHL cell lines. 
Healthy donor PBMCs were cultured with reovirus or CVA21 for 48hrs before 
being used in a degranulation assay either alone or against NHL cell lines at a 
10:1 effector: target ratio. After 1hr the co-cultures were supplemented with 
αCD3 and αCD56 antibodies, to identify NK cells, αCD107a/b antibodies, to 
identify degranulating cells, and Brefeldin A to prevent internalisation of 
CD107a/b, and cultured for a further 4hrs.  (a) and (b) show NK cell detection. 
(c) and (d) show detection of degranulating (CD107+) NK cells from untreated 
and reovirus-treated samples, respectively.  NK cell degranulation was 
determined as %CD107+ NK cells and quantified in (e). PBMCs were cultured 
alone (white, spontaneous degranulation control), or co-cultured with Ramos 
(light grey), SU-DHL-4 (dark grey) or U2932 (black) cells. Data shows the mean 
of n=4 PBMC donors +SEM, significance was determined by two-way ANOVA. 
(e) 
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6.2.2 Enhancing OV-mediated NK cell killing with an αCD20 
mAb 
Previous research demonstrated a possible application of combined OV and 
mAbs to treat cancers, such as reovirus and rituximab for enhanced ADCC 
against CLL (Parrish et al., 2015). The established efficacy of rituximab and 
more recent αCD20 mAbs in treating NHL provides ideal candidate mAbs for 
combination studies with OV. 
NHL cell lines were screened for CD20 expression by flow cytometry in order to 
confirm CD20 expression. Figure 6-3 shows that all NHL cell lines analysed 
expressed CD20 to varying degrees, with OCI-LY19s and OCI-LY3s expressing 
the lowest (2-fold increase in MFI over isotype controls) and second lowest 
levels (5-fold increase), respectively. Ramos and Raji expressed comparably 
medium levels (80- and 50-fold, respectively); while U2932’s expression was 2-
fold higher (~160-fold increase). In comparison, SU-DHL-4s had the highest 
level of CD20 expression, displaying a 700-fold increase in MFI over isotype 
control cells. Ramos, SU-DHL-4 and U2932 were selected as the candidate 
NHL targets for the combination studies as representative cell lines of BL, 
DLBCL-GCB and DLBCL-ABC, respectively. 
PBMCs were treated with reovirus or CVA21, and NHL cell targets were 
opsonised with BHH2, the laboratory grade formulation of the αCD20 mAb, 
GA101, to examine the efficacy of combining these two treatment modalities. 
The cells were co-cultured at a 10:1 effector: target ratio and NK cell 
degranulation in the presence of NHL cell lines was analysed. The working 
hypothesis for this strategy is that BHH2-coating of NHL cells enhances their 
recognition by NK cells, and activating NK cells by pre-exposure to the OV 
makes them better equipped to eradicate NHL targets.  
Figure 6-4 shows degranulation (CD107a and b surface expression) of NK cells 
following co-culture with NHL targets (a; Ramos, b; SU-DHL-4, c; U2932) 
without opsonisation (white), or with an isotype matched control antibody (light 
grey) or the BHH2 mAb (dark grey). Figure 6-4 (a) shows NK cell degranulation 
against Ramos cell targets; a small increase in degranulation was observed 
against Ramos cells with no antibody (white) or the isotype (grey) when the 
PBMCs were treated with CVA21 or reovirus.  By contrast, NK cell 
degranulation was significantly increased against BHH2-coated Ramos cells 
(dark grey) in the absence of virus treatment, and was significantly enhanced 
following OV treatment of PBMCs. Figure 6-4 (b) demonstrates that both 
reovirus and CVA21 treatment of PBMCs significantly enhanced NK cell 
146 
 
degranulation against unlabelled (white) or isotype-labelled SU-DHL-4 targets 
(light grey), i.e. in the absence of BHH2. NK cell degranulation against BHH2-
opsonised SU-DHL-4 cells was increased compared to unlabelled or isotype-
labelled targets, demonstrating the ability of the BHH2 antibody to potentiate NK 
cell function; this degranulation was enhanced further by both reovirus and 
CVA21 treatment of PBMCs, however, this was not statistically significant. 
Figure 6-4 (c) showed that reovirus, but not CVA21, treatment of PBMCs 
induced significant degranulation against unlabelled (white) and isotype-labelled 
(light grey) U2932 targets. However, NK cell degranulation was enhanced in the 
presence of BHH2-coated U2932 cells (in the absence of OV) and appeared to 
be further increased upon OV treatment. Disappointingly, the enhanced NK cell 
degranulation observed with OV treatment was not statistically significant. 
These data demonstrated that both OVs, CVA21 and reovirus, and the BHH2 
antibody, can promote NK cell targeting of NHL targets. This effect can also be 
additive between viruses and mAb, as both OVs induced significantly higher 
degranulation against mAb-coated Ramos targets.  
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Figure 6-3 CD20 expression on NHL cell lines. 
NHL cell lines Ramos, Raji, SU-DHL-4, OCI-LY19, U2932 and OCI-LY3 were 
stained for CD20 expression and analysed by flow cytometry. CD20 expression 
is displayed as the fold increase in MFI of αCD20 antibody-labelled cells over 
isotype control antibody-labelled cells. Results show means from n=4 
independent experiments + SEM.   
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Figure 6-4 OV-mediated NK cell degranulation is enhanced by αCD20 
antibodies in some NHL cell lines. 
PBMCs were isolated from healthy donor blood and cultured with reovirus or 
CVA21 for 48hrs. NHL cell line targets Ramos (a), SU-DHL-4 (b) and U2932 (c) 
were untreated (white bars) or labelled with an isotype-matched control (light 
grey) or BHH2 (dark grey) at 5µg/mL for 30mins. PBMCs were co-cultured with 
cell line targets for 1hr at a 10:1 effector: target ratio. The co-cultures were then 
supplemented with a mix of αCD3 and αCD56 antibodies, to identify NK cells, 
αCD107a and b antibodies, to identify degranulating NK cells, and Brefeldin A 
to prevent re-internalisation of the CD107a and b and cultured for a further 4hrs. 
Degranulation was determined as %CD107+ NK cells. Data shows the mean of 
n=4 PBMC donors +SEM, significance was determined by two-way ANOVA.  
pfu/cell 
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6.2.3 The effects of CD40L on an OV-induced anti-NHL NK cell 
response 
Research in Chapter 4, section 4.2.5 demonstrated CD40L-dependent drug 
resistance in NHL cell lines, highlighting the need for alternate methods to 
eradicate these resistant cells. The ability of NK cells to recognise and kill target 
cells depends on the ratios of activatory and inhibitory NK ligands expressed. 
As described previously (Chapter 4, section 4.2.6), CD40L stimulation of NHL 
cell lines increased ICAM-1 expression. Previous research has demonstrated 
enhanced NK cell killing of AML targets due to increased ICAM-1 expression on 
the target surface (Parameswaran et al., 2016). Elevated ICAM-1 on NHL B 
cells in the LN could enhance NK cell: NHL interactions and potentiate NK cell 
killing. In addition, the interaction between a target cell and an NK cell involves 
signalling between multiple activatory and inhibitory ligands and their cognate 
receptors on the NK cell surface which determines the outcome of the target: 
NK cell interaction. Therefore, it was important to also investigate the effect of 
CD40L stimulation on the expression of NK cell activatory and inhibitory 
receptor ligands on NHL cell targets.  
NHL cell lines were screened for several activatory NK ligands, such as ICAM-
1, PVR (Poliovirus Receptor; CD155), Nectin-2 (CD112), MICA/B (MHC class I 
polypeptide-related sequence), ULBP-1 (UL16 binding protein 1), and ULBP-
2/5/6, and inhibitory ligands, such as MHC-I. NK ligand expression profiling 
showed an absence of most NK ligands, with the exception of Nectin-2 (CD112, 
which has a role in cell adhesion and tight junctions, (Lopez et al., 1998) and 
MHC-I (which is involved with antigen presentation to CD8+ cytotoxic T cells 
and recognition of self by NK cells, (Kratky et al., 2011). These ligands were 
taken forward for further investigation. In the context of NK cell killing, Nectin-2 
on target cells interacts with DNAM-1 (DNAX Accessory Molecule-1) on the NK 
cell surface, triggering its cytotoxic activity (Bottino et al., 2003). MHC-I, on the 
other hand, inhibits NK killing by interacting with killer cell immunoglobulin-like 
receptors (KIRs) and C-type lectin-like receptors, such as Ly49 (Sawicki et al., 
2001). Diminished MHC-I expression due to, for example, viral infection, can 
eliminate this inhibitory effect, thereby making virally-infected cells more 
susceptible to NK cell killing (Brandstadter and Yang, 2011). 
Figure 6-5 shows that NHL cell lines Ramos (a), Raji (b), SU-DHL-4 (c), OCI-
LY19 (d), U2932 (e) and OCI-LY3 (f) express low levels of the activatory NK 
ligand, Nectin-2. Upon CD40L stimulation, there was no significant change in 
Nectin-2 expression on any NHL cell line. Although there were small changes in 
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expression on Ramos and Raji cells, these effects were not significant. Co-
culturing the NHL cell lines on the parental L929 feeder layer had no effect on 
Nectin-2 expression. 
Figure 6-6 illustrates MHC-I expression on NHL cell lines; all cell lines 
expressed basal MHC-I in the Alone treatment (blue). Upon CD40L stimulation, 
MHC-I was significantly increased in Ramos and SU-DHL-4 cell lines and the 
expression trended towards an increase in all cell lines. MHC-I expression was 
not affected by co-culturing the NHL cell lines on the parental L929 feeder layer. 
The enhanced MHC-I expression on the Ramos and SU-DHL-4 cells could 
result in diminished NK cell recognition of these cells, due to the inhibitory 
effects of MHC-I. 
Next, to examine the ability of the NK cells to target drug resistant CD40L-
stimulated NHL cells, NK cells were co-cultured with unstimulated and CD40L-
stimulated NHL cells. Figure 6-7 shows a small increase in NK cell 
degranulation against CD40L-stimulated Ramos (a), SU-DHL-4 (b) or U2932 (c) 
cells, regardless of OV treatment. NK cell degranulation was enhanced when 
the PBMCs were treated with either OV, however, this preliminary experiment 
was only carried out in n=2 donors, therefore, statistical significance could not 
be determined. This pilot experiment suggests that CD40L stimulation, 
associated with changes in MHC-I (in Ramos and SU-DHL-4 cells, Figure 6-6) 
and ICAM-1 expression (in Ramos, SU-DHL-4, OCI-LY19 and U2932 cells, 
Figure 4-11), of NHL cell lines does not confer protection from NK cell-
mediated death, despite inducing resistance to chemotherapy (Chapter 4, 
section 4.2.5). These findings suggest that MHC-I expression may not be 
relevant for this degranulation and that other activatory or inhibitory ligands may 
be having an effect. These findings are being validated by ongoing laboratory 
studies. 
Lastly, to investigate the effects of CD40L stimulation on CD20 expression and 
examine the potential impact of CD40L:CD40 interactions on αCD20 therapy, 
CD20 expression was also analysed on unstimulated and CD40L-stimulated 
NHL cells, as shown in Figure 6-8. These data show a decrease in CD20 
expression on Ramos (a), Raji (b), SU-DHL-4 (c) and U2932 (e) cells, but not 
on OCI-LY19 (d) or OCI-LY3 (f) cells; however, these decreases were not 
statistically significant. Loss of CD20 expression on NHL cells by CD40L 
stimulation could result in diminished efficacy of αCD20 mAb therapy. This 
warrants further investigations which are beyond the scope of this work.  
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Figure 6-5 Effect of CD40L stimulation on Nectin-2 expression. 
NHL cell lines were cultured alone (blue) with CD40L+ (red) or parental (orange) 
L929 feeder layers for 24hrs. NHL cells were then stained for Nectin-2 
expression and analysed by flow cytometry. Expression is displayed as the fold 
increase in MFI of αNectin-2 antibody-labelled cells over isotype control 
antibody-labelled cells. Data shows mean fold increase from n=4 independent 
experiments + SEM. Statistical significance was determined using a One-way 
ANOVA, no significant differences were observed. 
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Figure 6-6  Effect of CD40L stimulation on MHC-I expression. 
NHL cell lines were cultured alone (blue) or on the CD40L+ (red) or parental 
(orange) L929 feeder layers for 24hrs. NHL cells were stained for MHC-I 
expression and analysed by flow cytometry. Relative expression is displayed as 
the fold increase in MFI of αMHC-I antibody-labelled cells over isotype control 
antibody-labelled cells. Data shows mean fold increase from n=4 independent 
experiments +SEM. Statistical significance was determined using a One-way 
ANOVA.  
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Figure 6-7 NK cells degranulate against CD40L-stimulated NHLs. 
Healthy donor PBMCs were cultured with reovirus or CVA21 for 48hrs.  NHL 
cell lines were cultured alone (white) or on CD40L+ (grey) L929 feeder layers for 
24hrs. Virally-activated PBMCs were then co-cultured with the targets (10:1 
ratio) for 1hr before supplementation with αCD3 and αCD56, to identify NK 
cells, αCD107a and b antibodies, to identify degranulating cells, and Brefeldin A 
to prevent re-internalisation of the CD107a and b and cultured for a further 4hrs. 
Degranulation was determined as %CD107+ NK cells. Data shows the mean of 
n=2 independent experiments +SEM.  
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Figure 6-8  Effect of CD40L stimulation on CD20 expression. 
NHL cell lines were cultured alone (Blue) with CD40L+ (red) or parental (orange) 
L929 feeder layers for 24hrs.  NHL cells were stained for CD20 expression and 
analysed by flow cytometry. Expression was measured as fold increase above 
isotype staining. Data shows mean fold increase for n=4 independent 
experiments + SEM. Analysed by One-way ANOVA, no significant differences 
were detected.  
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6.3 Discussion 
The work in this chapter examined the role of OVs, CVA21 and reovirus, in 
activating healthy donor NK cells and stimulating them to attack NHL cell line 
targets. This anti-NHL effect was also examined in combination with a 
candidate αCD20 mAb, BHH-2, a glycoengineered mAb that has undergone 
post-translational modification to remove a fucose molecule from its Fc region, 
giving it a higher affinity for FcγRIII (CD16) on NK cells (Kern et al., 2013). 
Reovirus and CVA21 both activated NK cells, as measured by CD69 
expression, by 48hrs (Figure 6-1). This result suggested a promising role for 
both OVs in stimulating NK cells to attack NHL targets. Previous research by 
Hall, et al., demonstrated similar upregulation of CD69 on healthy donor NK 
cells after reovirus treatment (Hall et al., 2012). To date, there is no published 
data showing CVA21-induced upregulation of CD69 on human healthy donor 
NK cells, however, research by Godeny, et al. (Godeny and Gauntt, 1987), and 
Yuan, et al. (Yuan et al., 2009), has shown enhanced NK cell activity, as 
measured by IFN-γ secretion, in CVB3-treated murine myocarditis models. This 
would suggest that CVA21 may be able to activate NK cells in vivo.  
CD107 degranulation assays showed that both OVs induced significant NK cell 
degranulation against most NHL cell line targets (the only exception being for 
CVA21-activated NK cells against Ramos targets), proving the potential for 
these OV in stimulating an anti-NHL immune response. IFN secretion can be 
partially or wholly responsible for CD69 upregulation on cells such as NK cells 
(Benlahrech et al., 2009), neutrophils (Atzeni et al., 2002), eosinophils (Ochiai, 
K. et al., 2000), and T cells (Sun et al., 1998). Data in Chapter 5 (section 5.2.1) 
demonstrated enhanced IFN secretion in CVA21-treated PBMC samples and 
previous research has shown that reovirus can induce IFN secretion in healthy 
donor PBMCs and activation of NK cells (Parrish et al., 2015). Research by Ho, 
et al., however, has shown that NHL PBMCs have a diminished ability to 
produce IFN in response to antigenic stimulation in vitro (Ho et al., 1988), 
potentially hampering OV-induced NK cell activation in NHL patients, compared 
with those observed in the healthy donor samples used in this study.  
Interestingly, given its ability to activate NK cells and induce higher levels of 
degranulation than CVA21, reovirus has proven itself a worthy candidate for 
further research as an immunotherapy for NHL. This data, coupled with the low 
cytotoxicity described in Chapter 4, outlines a role for reovirus as an 
immunotherapeutic, rather than a lytic, agent. Heat-inactivated replication-
incompetent reovirus has previously demonstrated CD8+ T cell-mediated killing 
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in a murine B16ova melanoma model (Prestwich, Robin J. et al., 2009), 
highlighting the role of the immune response when considering candidate OV, 
even in the absence of oncolysis. 
In order to expand upon the full potential of reovirus and CVA21 to target NHL, 
the role of T cells in an OV-mediated anti-NHL response could be investigated, 
as T cells, unlike NK cells, have the capacity to develop long-lasting memory 
responses (Aurelian, 2016), resulting in a lifelong immunity that could target 
relapsed NHL many years later, assuming the relapsed tumour maintains the 
expression of specific TAAs.  
BHH2 was chosen as a candidate αCD20 mAb due to its promising 
performance in other research and the superiority of GA101 (its parent form) 
over rituximab, in driving an NK cell-mediated response (Kern et al., 2013). 
CD20 was highly expressed on SU-DHL-4, U2932 and Ramos cells, with CD20 
expression on SU-DHL-4s being significantly higher than all other cell lines 
tested. The relatively low expression on Ramos cells may explain why OV-
activated NK cells degranulated significantly more against BHH-2-coated 
Ramos cells than uncoated, but not for the other two cell lines. Degranulation of 
NK cells following BHH2 is due to FCR engagement, consequently, more BHH2 
binding is likely to stimulate more NK cell degranulation in the absence of virus. 
Therefore, if Ramos cells had been coated with sub-optimal BHH2 levels, the 
added effect of OV-activation of NK cells may have been more apparent, i.e. the 
degranulation of the NK cells may be maximised by the αCD20 antibody 
preventing further activation by the OV. To test this, lower doses of BHH2 could 
be used, or the experiments could be repeated on cell lines with lower CD20 
expression such as the Raji, OCI-LY19 and OCI-Y3 cells. The BHH2 dose of 
5µg/mL was selected from a pilot experiment that used 5 and 10µg/mL, as this 
was comparable with rituximab doses reported in previously published work 
(Parrish et al., 2015). Cetuximab, an anti-epidermal growth factor receptor 
(αEGFr) mAb, was also used as a negative control for BHH2’s effects in n=2 
PBMC donors, as EGF was not expressed on the B cell lines and the mAb is 
humanised (Galizia et al., 2007), making it a better control than the isotype-
matched IgG1 isotype. NK cell degranulation against cetuximab-coated cells 
was similar to non-humanised isotype-matched controls (data not shown). 
Unfortunately, due to time constraints, it was not possible to investigate the 
ability of the virus-stimulated NK cells to kill NHL targets using Chromium 
release assays. This information would serve to validate the observed increases 
in NK cell degranulation against NHL targets and provided detailed information 
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on whether NHL cell lines are susceptible to NK cell degranulation-mediated 
killing. 
One potential issue with using αCD20 mAbs in patients is the elimination of 
CD20+ malignant cells, driving the propagation of a CD20- clone, (Alvaro-
Naranjo et al., 2003). The possibility of such clonal selection remains a good 
reason to use combination regimens to target the emergence of resistant cells. 
It would be interesting to examine the ability of both OV to induce an NK cell-
mediated response against resistant cells, such as OCI-LY19, which are 
resistant to both CVA21 and reovirus infection/oncolysis. This would prove a 
role for OV in eradicating drug/virus-resistant cell populations via activation of 
immune effector cells, such as NK cells.  
Given the ability of reovirus to also activate monocytes, as determined by IFN-α 
secretion in reovirus-treated isolated monocytes (Parrish et al., 2015), it would 
be interesting to explore the ability of OV to enhance ADCP, in the presence or 
absence of αCD20 antibodies. This was investigated briefly by stimulating 
healthy donor monocytes with either virus and measuring their ability to 
phagocytose FITC-labelled dextran molecules, however, no phagocytosis was 
detected (data not shown). Previous research has demonstrated ADCP of 
rituximab-coated CLL cell line targets (Borge et al., 2015) highlighting a 
potential role for combining OV with αCD20 mAbs to promote ADCP.  
Previous research has demonstrated the ability of NK cells to target drug-
resistant cancer cells, such as doxorubicin-resistant breast cancer cells 
(Hwang, M.H. et al., 2015). CD40L stimulation of NHL cell lines did not diminish 
NK degranulation against the targets. Moreover, it is possible that degranulation 
was enhanced slightly, suggesting a more pronounced role for NK cells in 
eradicating drug-resistant cells which warrants further validation. Of note, 
elevated MHC-I on CD40L-stimulated NHL cell lines would be expected to 
inhibit NK cell activity, however, it is possible that increased ICAM-1 expression 
(or changes in NK ligands not investigated), and sustained NHL: NK cell 
interactions, may overcome the inhibitory effects of enhanced MHC-1 
expression.  
The use of mAbs to promote NK cell killing of NK-“escaping” CLL cells has been 
validated in other studies (Veuillen et al., 2012). However, the downregulation of 
CD20 upon CD40L stimulation, although not significant in these assays, has 
previously been described (Jennifer et al., 2003), and may limit the 
effectiveness of aCD20 Abs in this setting. This may result in less binding of 
αCD20 mAbs that potentiated immune-mediated killing of these cells, thus 
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validating a role for combinations with OV therapy, as OV may enhance the 
efficacy of NK cell killing in cells with lower CD20 expression. The examination 
of NK ligand expression on NHL cell lines, with or without CD40L-stimulation, 
was needed to demonstrate whether these drug-resistant cells would remain as 
targets for an NK cell-mediated response. The relatively low levels of Nectin-2, 
and high levels of MHC-I, observed did not prevent them from stimulating NK 
cell degranulation.  
Future work should also investigate the role of OV infection in manipulating NHL 
susceptibility to NK-mediated killing. For example, NHL cells could be treated 
with OV for a short time to allow infection and assayed for susceptibility to NK 
cells to determine whether OV infection enhances NK cell recognition and 
killing. On infection, viruses such as CVA21, can downregulate MHC-I, the lack 
of which has been associated with higher NK-mediated killing (Ljunggren and 
Karre, 1990). It would also be interesting to explore the generation of an 
immune response against primary patient NHL targets, and whether OV-
resistant cell lines such as OCI-LY19 could be targeted by NK-mediated killing 
although this was beyond the scope of this work. 
The results highlighted in this chapter demonstrate a strong rationale for the 
application of OVs, reovirus and CVA21, and αCD20 mAb, BHH2, as potent 
inducers of an anti-NHL NK cell response, both as single agent therapies and in 
combination. Both strategies contributed to NK cell targeting of NHL cell lines by 
opsonising NHL cells for NK cell killing, in the case of BHH2, and activating the 
NK cells, in the case of the OVs.   
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Chapter 7: 
Assessing the efficacy of Oncolytic 
Viruses against Primary NHL B 
cells 
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Chapter 7  
7.1 Introduction 
Cell lines are a vital tool for in vitro research, but the availability of primary 
patient samples provides a better model of the cancer due to the presence of 
primary cancer cells, tumour fibroblasts and tumour-associated immune cells, 
and the fact that primary cells lack many of the mutations that cell lines can 
accumulate after years in culture. Despite advances in attempts to mimic this 
complex cell mixture in vitro, primary samples offer a superior representation of 
how the tumour may respond to treatment, not just in terms of tumour cell 
death, but also the activity of tumour-residing immune cells. The findings 
described in previous chapters were thus applied to samples derived from 
potential NHL patients where LNs were excised from patients and analysed to 
detect malignant cells.  
Cell line data showed efficacy for CVA21, but not for reovirus, in targeting NHL 
cell lines by direct oncolysis (Chapter 4, sections 4.2.2 and 4.2.3). Primary LN 
samples were treated with CVA21 and reovirus to measure the efficacy of both 
viruses in targeting malignant B cells. Further experimentation examined the 
ability of CVA21 to replicate in NHL samples to determine the possibility of 
producing progeny virions to perpetuate oncolysis. IFN-α production in 
response to CVA21 was also examined to elucidate the ability of primary LN 
samples to mount an antiviral IFN response against CVA21, given the 
diminished IFN production by NHL cell lines (Chapter 5, section 5.2.1) and 
lymphocytes derived from NHL patients (Ho et al., 1992).  
Lastly, considering the immune cell populations that reside in the LN, NHL 
patient samples were analysed for the presence of NK cells, and the ability of 
reovirus to activate those NK cells and promote an NK-mediated anti-NHL 
immune response. Data previously described demonstrates a role for both 
CVA21 and reovirus in the induction of an NK cell-mediated anti-NHL immune 
response (Chapter 6, section 6.2.1). This data was highly promising and 
showed that both viruses can enhance targeting of NHL cell lines by healthy 
donor peripheral blood NK cells.   
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7.2 Results 
7.2.1 Assessing the ability of reovirus to eradicate primary 
patient NHL cells 
Reovirus demonstrated poor cytotoxicity against NHL cell lines in isolation 
(Chapter 4, Section 4.2.2), however, data shown in this section set out to 
confirm these observations in primary samples. It is important to note that, while 
NHL cell lines were cultured at 3x105/mL in 0.5mL per well, primary mixed 
LNMC samples were cultured at 2x106/mL in 0.5mL per well, highlighting an 
important difference between isolated cell lines and primary malignant B cells in 
the context of mixed LNMCs. To assess the suitability of reovirus in targeting 
LN B cells, the expression of JAM-A on the surface of primary patient LN B cells 
was determined. Figure 7-1 shows the expression of JAM-A on primary patient 
LN B cells from 8 samples; 2 Follicular Lymphoma (FL), 1 Anaplastic Large T 
Cell Lymphoma (ALTCL), 1 reactive (potentially caused by an immune reaction 
to an infection in the LN, resulting in B cell expansion, LN swelling and a 
subsequent biopsy to investigate whether malignant cells were present), 1 
Marginal Zone Lymphoma (MZL) and 3 classical Hodgkin’s Lymphoma (cHL). It 
is important to note that, while this project was aimed at NHL, the diagnosis of 
the samples was unknown when samples were received and, as such, were not 
always from patients with NHL. JAM-A expression on patient LN B cells was 
above isotype controls in all samples; 6 samples expressed JAM-A between 4- 
and 10-fold increase over the isotype, while the ALTCL sample and one cHL 
sample expressed JAM-A at 23- and 15-fold increase over the isotype, 
respectively. As previously discussed (Chapter 2, section 2.4.2), reovirus relies 
on JAM-A to infect cells. This data illustrates a range of JAM-A expression on 
primary LN B cells and confirms that that JAM-A is present to facilitate viral 
entry. While reactive LN can present an interesting non-malignant control for 
NHL LN samples, reactive nodes are not normal LN and data derived from them 
in direct comparison with malignant cells should be interpreted with this in mind. 
In order to test the efficacy of reovirus on primary LN cells, in the context of the 
multi-cellular microenvironment of the LN, LN samples were cultured with 
increasing doses of reovirus for up to 120hrs. 120hrs was chosen as this was 
the earliest time point by which significant cell death was observed in virus-
treated cells in pilot studies. After 120hrs, the B cells were analysed by 
LIVE/DEAD™ exclusion. Figure 7-2 demonstrates that reovirus was highly 
effective at inducing significant cell death in some LN samples, especially the 
FL and DLBCL+FL. By contrast, reovirus induced little cell death in either cHL 
162 
 
samples and was ineffective against the MZL sample and the reactive LN 
sample. These results were comparable with those discussed previously in 
demonstrating the selective efficacy of reovirus against primary NHL samples 
(Alain et al., 2002). However, the lack of direct or immune-mediated cytotoxicity 
in other samples should not prohibit reovirus’ efficacy in patients, due to its 
demonstrated ability to promote anti-cancer immune responses in CLL (Parrish 
et al., 2015), AML (Hall et al., 2012) and melanoma (Errington et al., 2008). 
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Figure 7-1 JAM-A expression on B cells from primary patient LNs:  
LNMCs were isolated from LN biopsies from patients at diagnosis. The LNMCs 
were cultured overnight and then co-stained with either αCD19 or αCD20 
antibodies to identify the B lymphocyte population, and αJAM-A or an isotype 
antibody as a negative control. LN samples were analysed by flow cytometry 
and the MFI of JAM-A expression was measured on the CD19+ or CD20+ B 
cells. JAM-A levels are expressed as the fold increase in JAM-A MFI over the 
isotype control MFI.   
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Figure 7-2 The cytotoxic effects of reovirus on B cell populations. 
LNMCs were isolated from LN samples at diagnosis and cultured overnight. The 
cells were then treated with escalating doses of reovirus (1 and 10 pfu/cell) for 
120hrs. The CD19+ or CD20+ B cells were then analysed for viability by 
LIVE/DEAD™ exclusion. The percentage of dead cells in untreated samples 
has been subtracted from reovirus-treated results. Significance was determined 
by paired student’s t test.  
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7.2.2 Assessing the ability of CVA21 to eradicate primary 
patient NHL cells 
Previous data showed that CVA21 induced cell death in NHL B cell lines that 
express ICAM-1 (Chapter 4, sections 4.2.1 and 4.2.2). Therefore, CVA21 was 
also investigated for its ability to target malignant B cells within primary LN 
samples. Firstly, ICAM-1 expression on the B cell population within LN samples 
was determined. Figure 7-3 shows ICAM-1 expression on B cells from several 
primary patient LN samples; all samples expressed ICAM-1 with two samples, 
the FL (14111), and the reactive LN (141127), expressing levels with MFIs 20-
fold greater than that of the isotype control. All other samples expressed ICAM-
1 ranging from 5 to 17 times greater than the isotype control, demonstrating 
varied, but abundant, expression of ICAM-1 to facilitate CVA21 entry. 
LNMCs were isolated from LN samples and treated with CVA21 for up to 
120hrs; CD19+ or CD20+ B cells were subsequently analysed for viability by 
LIVE/DEAD™ staining. Figure 7-4 shows significant CVA21-induced B cell 
death in most samples. This is particularly high in one FL sample (160311) 
while all other samples, with the exception of reactive (151209) and cHL 
(170504A) show a lower but consistent increase in cell death following CVA21 
treatment. The cytotoxic effect of CVA21 was dose-dependent with a dose of 
1pfu/cell inducing significantly more cell death than 0.1pfu/cell. While 
investigating a correlation between ICAM-1 expression and susceptibility to 
CVA21 in LN B cells might provide some insight into the relevance of ICAM-1 
on susceptibility of these cells to CVA21, this analysis could not be performed 
due to low sample numbers. 
Replication is an expected outcome in lytic cell death (Bauzon and Hermiston, 
2014), therefore, to examine whether CVA21-induced cell death of primary LN 
B cells was indeed replication-dependent, TCID50 assays were performed on 
cell-free supernatants from CVA21-treated LNMCs. In addition, viral replication 
within healthy donor PBMCs, which were resistant to CVA21-induced cell death 
(Chapter 4, section 4.2.8), was examined for comparison. In Figure 7-5, TCID50 
assays showed that the high viral titres at the start of the experiment (input) had 
diminished significantly after 120hrs in culture in the LN samples (a). However, 
the titre at the same time point in the healthy donor samples remains much 
lower (b). (c) and (d) show data when 120hr TCID50s are expressed as a 
percentage of the input, to compare the sample types. This demonstrates a 
drastic reduction in virus copies in primary samples and may suggest that 
replication is either happening at a very low rate or not at all. Higher TCID50s 
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were observed when a higher dose of CVA21 was used, as expected. 
Complementary experiments investigated the ability of UV-inactivated CVA21 to 
target NHL primary B cells (n=2, data not shown). Although background cell 
death was high in these samples, CVA21-induced cell death appeared slightly 
increased in normal CVA21-treated cells, but there appeared to be no 
detectable increase in cell death in UV-inactivated CVA21-treated cells. 
As previously discussed (Chapter 2, section 2.4.1.2.1), the IFN response is one 
of the first lines of viral defence and may coordinate anti-tumour immune 
responses. In order to investigate the ability of primary LNMC samples to 
produce IFN-α in response to CVA21 infection, LNMCs and healthy PBMCs 
were treated with CVA21 for 48hrs, at which point the cell-free supernatant was 
analysed for IFN-α production by ELISA. Figure 7-6 (a) shows no IFN-α was 
detected in 5 out of 7 primary LN samples (all of which were NHL or cHL) but 
was secreted in response to CVA21 in the reactive (non-malignant) LN sample. 
This highlights a potential interesting difference between this single reactive LN 
and malignant LNs that is congruent with previous data on the diminished ability 
of NHL PBMCs to produce IFN-α (Ho et al., 1992) and the lack of IFN-α 
production by the cell lines (Chapter 5, section 5.2.1). The lack of IFN-α 
production by NHL LN samples was markedly different from healthy PBMCs 
which showed significant IFN-α production in response to CVA21 from all 4 
healthy PBMC donors in a dose-dependent manner, outlining an important 
difference between the response of NHL samples and PBMCs to CVA21. The 
IFN production observed from healthy PBMCs, which was absent from NHL 
primary samples, may reflect the different cellular composition of NHL/PBMC 
samples, or changes in cellular functions at different anatomical sites.  
However, it may also suggest compromised immune function in NHL patients, 
which would require further testing using PBMC from patients and/or healthy LN 
biopsy samples. The lack of IFN suggests an environment favourable for viral 
replication, although, because of the known role of type I IFN in coordinating OV 
anti-tumour immunity (Adair et al., 2013), may suggest that the virus may be 
unable to mount an anti-tumour immune response within the LN. This will be 
investigated further in 7.2.3. 
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Figure 7-3 ICAM-1 expression on B cells from primary patient LNs. 
PBMCs were isolated from LN biopsies from patients at diagnosis and stained 
with either αCD19 or αCD20 antibodies to identify the B lymphocyte population, 
and αICAM-1 or an isotype antibody as a negative control. The samples were 
analysed by flow cytometry to quantify the MFI of ICAM-1 on the CD19+ or 
CD20+ B cells. ICAM-1 levels were expressed as a fold increase of the ICAM-1 
MFI over the MFI of the isotype.  
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Figure 7-4 Cytotoxic effects of CVA21 on LN B cell populations. 
LNMCs were isolated from patient LN samples at diagnosis and cultured 
overnight. The cells were treated with escalating doses of CVA21 (0.1 and 1 
pfu/cell) for 120hrs and the viability of B cells assessed by LIVE/DEAD™ 
exclusion as previously described. The percentage of dead cells in untreated 
samples was subtracted from CVA21-treated results. Significance was 
determined by paired student’s T test.  
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Figure 7-5 Assessment of CVA21 Replication in LN samples vs healthy 
PBMCs. 
LN samples and healthy donor PBMCs were treated with CVA21 for 120hrs. 
Cell-free supernatants were taken at 0hrs as input (white bars) and again at 
120hrs when cell death was observed. Supernatants were then analysed for 
virus titre by TCID50 assay ((a) and (b)). To analyse this further, the titre values 
for both doses at 120hr are expressed as a percentage of the input (100%) viral 
titre ((c) and (d)). Lower titre values observed at later time points suggested 
diminishing viral load in sample supernatant, suggesting that little or no 
replication of CVA21 took place. Data shows n=3 for LNMC samples and n=4 
for healthy donor samples +SEM, significance was determined by One-way 
ANOVA. 
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Figure 7-6 IFN-α secretion by primary LN samples and healthy PBMCs in 
response to CVA21 treatment. 
LNMCs were isolated from patient LN biopsies (a) and healthy donors (b) and 
treated with CVA21 for 48hrs. Media was then collected and analysed for IFN-α 
secretion by ELISA. Graph shows data from n=6 independent experiments for 
the LN samples and n=4 independent healthy PBMC samples. Significance was 
determined by paired, two-tailed students T test by comparison with untreated 
samples.  
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7.2.3 Investigating the potential for an OV-induced anti-NHL 
immune response 
Research in Chapter 6 (section 6.2.1) outlined a promising role for CVA21 and 
reovirus as activators of healthy peripheral blood NK cells, as determined by 
increased CD69 expression and NK cell degranulation upon recognition of NHL 
cell line targets. Using primary patient LN samples, reovirus was analysed for its 
ability to promote an NK cell-mediated anti-NHL immune response, in terms of 
NK cell phenotype activation. Unfortunately, due to a limited number of 
samples, it was not possible to test CVA21 for its effects on NK cell activation. 
To test the effects of reovirus on primary LN NK cell activation, samples were 
treated with reovirus for 24hrs and analysed for CD69 expression on the NK 
cells (CD3-CD56+). Figure 7-7, shows a small increase in CD69 expression in 7 
out of 9 samples, although collectively this increase was not statistically 
significant, these results do suggest the potential for reovirus to induce NK cell 
activation in some LN samples. 
The NK cell population within healthy human LN typically represents 0.2-0.4% 
of cells in the LN (Bajenoff et al., 2006), casting doubt over whether an NK cell-
mediated response would be effective with such limited numbers. In the primary 
LN samples analysed in this study, NK cells constituted between 0.1-2% (mean 
0.81% ± 0.584%) of the lymphocyte population, as shown in Figure 7-8, in 
contrast to T cells that represented 45-75% (mean 47.56% ± 22.88%) in all but 
3 samples. Low NK cell numbers may present a challenge for inducing an 
effective NK-mediated anti-NHL response, warranting research into methods to 
overcome these low numbers.  
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Figure 7-7 Reovirus-induced activation of LN-residing NK cells. 
Primary LN samples were treated with reovirus for 24hrs before being co-
stained with αCD3 and αCD56 antibodies to identify the NK cell (CD3-CD56+) 
population. Samples were also stained with either an αCD69 antibody, to 
measure activation, or an isotype antibody as a negative control. CD69 MFI 
levels were expressed as a fold change above isotype control MFI values. 
Treated values were expressed as a ratio of the untreated. Statistical analysis 
was performed by One-way ANOVA, but no statistical significance was 
observed.  
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Figure 7-8 Immune effector cell populations in NHL Lymph Nodes. 
Primary NHL LN samples were co-stained with αCD3 and αCD56 antibodies to 
identify T cell (CD3+CD56-) and NK cell (CD3-CD56+) populations. Panel (a) 
representative FSC/SSC dot plot from an NHL sample gated on the lymphocyte 
population, (b) CD3/CD56 dot plot of the lymphocyte population, depicting NK 
cells (green) and T cells (pink). Panels (c) and (d) show representative panels 
for healthy donor PBMCs for comparison. (e) NK and T cell populations from 12 
patient samples as a percentage of lymphocytes. Error bars represent the mean 
± SEM from n=12 independent samples.  
(a) 
(d) 
(c) 
(b) 
(e) 
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7.2.4 Examining the potential to overcome low NK cell numbers 
in NHL LN. 
During a systemic viral infection, enhanced lymphocyte trafficking is evident 
throughout the lymphatic system, including the secondary lymphoid organs 
(Springer, 1995). Systemic delivery of an OV could induce a similar effect in a 
patient, resulting in enhanced migration of lymphocytes into LNs, including NK 
cells (Beuneu et al., 2009). Enhanced NK cell trafficking to LN in response to a 
virus could be exploited by OV therapy in HMs, specifically if the systemic 
delivery of a virus induced such enhanced migration. To test whether reovirus 
could induce NK cell trafficking to lymphoid organs, a non-tumour-bearing 
mouse model was infected with reovirus for 24hrs and their LNs were analysed 
for NK cell numbers. Figure 7-9 shows the schematic of the in vivo experiment; 
on day 0, 6-8-week-old non-tumour-bearing C57/Black 6 mice were inoculated 
with reovirus or PBS (control group) via tail vain injection. 24hrs later, the mice 
were sacrificed, and the inguinal, brachial and axillary LN were harvested, 
dissociated, and analysed by flow cytometry for NK cell numbers. 
Figure 7-10, shows the percentage of NK cells in the LN of PBS-treated mice 
was consistently low, within a range of 0.1-0.3% of the lymphocyte population, 
however, the percentage of NK cells was significantly enhanced in reovirus-
treated mice across all LN demonstrating systemic enhancement of NK cell 
trafficking to the LNs. 
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Figure 7-9 Schematic of the in vivo NK cell trafficking to LN experiment. 
On day 0, 6-8-week-old non-tumour-bearing C57/Black 6 mice were inoculated 
with 1x107 pfu reovirus in 100µL or 100µL PBS (control group) via tail vain 
injection. 24hrs later, mice were sacrificed, and the inguinal, brachial and 
axillary LN were harvested, dissociated, and analysed by flow cytometry for NK 
cell numbers. Due to projected low numbers in lymph nodes, brachial and 
axillary LN were combined. Image adapted from (Anatomyorgan, 2017)  
176 
 
R
ig
h
t 
B
ra
c h
ia
l/A
x i
lla
ry
L
e
ft
 B
ra
c h
ia
l/A
x i
lla
ry
R
ig
h
t 
In
g
u
in
a
l
L
e
ft
 I
n
g
u
in
a
l
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
L y m p h  N o d e  N K  c e ll p o p u la tio n s
L y m p h  N o d e s
%
 N
K
 C
e
ll
s
P B S
R EO
* * * *
 
Figure 7-10 Reovirus-induced NK migration into mouse LNs 
Non-tumour-bearing C57/BL6 mice were inoculated with either PBS (control) or 
reovirus (1x107 pfu/100µL in PBS) via tail vein injection. 24hrs later, mice were 
sacrificed, left and right inguinal, brachial and axillary LN were harvested, 
dissociated and analysed for NK cell numbers by flow cytometry. Data shows 
n=3 mice per condition from one experiment. Significance was determined by 
paired, two-tailed student’s T test. 
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7.3 Discussion 
Cell lines are a vital tool for in vitro research due to their immortality, infinite 
replicative capacity and availability. When multiple lines are used, as has been 
done in this project, they provide excellent insight into how cancer cells respond 
to treatment, when used in carefully designed and controlled experiments. 
Primary patient cells, on the other hand, provide a better representation of 
cancer, because they contain a mix of malignant and non-malignant cells, 
including tumour-associated immune cells and fibroblasts, and have not 
developed additional genetic abnormalities through long-term culture. These 
extra populations can provide growth support, or can mediate other effects, that 
will determine the outcome of treatment. Previous work by Ilkow, et al., outlined 
a role for Cancer-Associated Fibroblasts in promoting viral replication in 
malignant cells, enhancing the efficacy of OV treatment (Ilkow et al., 2015), and 
research by Breitbach, et al., showed VSV-induced tumour vasculature 
destruction, resulting in tumour cell death, in a 3D in vitro model of colon cancer 
(Breitbach et al., 2011). These findings emphasise the importance of 
considering the role of TME components when investigating the efficacy of 
novel OV treatments. 
Contrary to the cell line data (Chapter 4, section 4.2.2), reovirus induced cell 
death in primary LN samples, with the exception of the MZL and reactive (non-
malignant) samples (Figure 7-2). In support of this finding, reovirus has also 
demonstrated promising results as an anti-cancer agent for other models of 
HMs, such as myeloma (Thirukkumaran, C. M. et al., 2012), and lymphoma 
(Alain et al., 2002), including death of primary patient samples. It is possible that 
cell lines, which accrue multiple pro-survival mutations and are immortal, may 
be more resistant to reovirus than primary samples. However, it is also possible 
that malignant cells within the primary samples are being killed by bystander 
cytokine killing, as demonstrated by Errington, et al. (Errington et al., 2008); 
complementary research has also confirmed the ability of CVA21-induced 
cytokines to generate bystander killing using an AML cancer model (Louise 
Müller – manuscript submitted).  
It would be pertinent to examine OV-induced cytotoxicity on a greater number of 
samples to see if it would be possible to identify  “responders” and “non-
responders” of OV therapy, and enable identification of determinants of OV 
sensitivity, including the production of cytokines (Errington et al., 2008), the 
presence of immune effector cells that are activated by OV, or molecular 
changes associated with OV oncolysis such as  p53, Retinoblastoma protein 
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(Rb) and Ataxia telangiectasia mutated (ATM), which have all been implicated 
in the sensitivity of lymphoma cell lines to reovirus infection and oncolysis (Kim 
et al., 2010). To test whether reovirus-induced cell death is due to cytokine 
release or viral replication, plaque assays or TCID50 assays could be used to 
measure replication in primary NHL samples. Moreover, media from treated 
cells could be analysed for cytokine production and cytopathic effects, as 
performed on a single FL sample that was treated with reovirus and CVA21 and 
analysed for the secretion of cytokines using a Luminex assay (preliminary data 
not shown). This data confirmed the secretion of cytokines following reovirus 
and CVA21 treatment, for example, TNF-α was secreted suggesting a potential 
role for cytokine-induced cell death in NHL LN samples.  
ICAM-1 expression was significantly higher on LN B cells than healthy donor 
peripheral B cells (Chapter 4, section 4.2.8). This data is in keeping with 
previous data that demonstrated increased ICAM-1 expression on lymphomas, 
particularly DLBCL (The Human Protein Atlas, 2017). As expected, CVA21 
induced significant cell death in primary LN samples, but not the reactive LN 
sample, as expected.  
The low level or lack of CVA21 replication in susceptible NHL LN samples was 
unexpected, due to the significant viral replication and oncolysis observed on 
NHL cell lines (Chapter 4 Figure 4-5). This may mean that CVA21-induced cell 
death was not dependent on viral replication and was perhaps immune 
mediated. However, in two patient samples, the ability of UV-inactivated CVA21 
to induce cell death was evaluated; no cell death was observed in UV-
inactivated CVA21-treated cells (n=2 observation, data not shown), suggesting 
a role for viral replication in CVA21-induced cell death. Of interest, supernatants 
from CVA21-treated NHL LN samples did not contain detectable levels of IFN-α 
or IFN-γ (Figure 7-6 and IFN-γ data not shown), which would suggest limited 
immune cell activation by CVA21 and that CVA21-induced cell death may be 
dependent on viral replication and oncolysis.  
Reovirus has previously been described as a highly immunogenic virus 
((Prestwich, R. J. et al., 2008), (Hall et al., 2012), (White et al., 2008), (Errington 
et al., 2008)), and its ability to activate peripheral blood NK cells (Chapter 6, 
section 6.2.1) was comparable with the enhanced CD69 expression observed 
on NK cells from several primary malignant LN samples (Figure 7-7). Although 
the enhanced CD69 on primary NHL LN NK cells was not statistically 
significant, 4 NHL samples showed responses ranging from 1.5 to 4-fold 
increase over background levels, 3 samples showed weaker responses 
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between 1.1 and 1.5-fold increases, and 2 samples did not respond to reovirus 
treatment. These data are comparable with increased CD69 expression on 
healthy donor NK cell which was increased 4-5-fold above the untreated control 
by both OV (chapter 6, section 6.2.1). Figure 7-6 suggests that CVA21 is 
unable to induce IFN-α production in diseased LN, furthermore, the multiplex 
Luminex assay that was used to assess cytokine production from one OV-
treated FL sample showed detectable IFN-α following reovirus, but not CVA21 
treatment (data not shown. This suggests that reovirus may be more 
immunogenic than CVA21 in NHL LN samples. Complimentary research being 
carried out in the laboratory has shown that CVA21-induced IFN-α production is 
derived from pDCs (Louise Müller – Manuscript submitted), while reovirus 
induces IFN-α production in monocytes (Parrish et al., 2015). The fact that 
pDCs are only present in small numbers in the LN (~ 0.45% of LNMC 
population (Lehmann et al., 2010)), may account for the inability of CVA21-
treated LN samples to produce IFN-α. Fiore, et al., have also shown that pDC 
populations in NHL LN are significantly lower than in reactive LN controls, 
potentially accounting for the lack of IFN-α production in NHL LN samples (Fiore 
et al., 2006). 
In humans, NK cells comprise ~10% of the peripheral blood lymphocyte 
population (Li, Z.S. et al., 2011), however, the proportion of LN lymphocytes 
that are NK cells is much lower (0.2-0.4%, (Bajenoff et al., 2006)). Data 
presented in Figure 7-10 demonstrated reovirus’ ability to promote significant 
NK cell trafficking to the LN within 24hrs of systemic virus delivery. The 
C57/BL6 immunocompetent mouse strain used for this study was chosen as it 
has been used for OV therapy in a variety of cancer models (Robinson et al., 
2009), (Cheema et al., 2013), (Kober et al., 2015). While elucidating the 
mechanisms by which reovirus induces NK cell trafficking to the LN was beyond 
the scope of this work, future research could investigate this by examining the 
production of chemoattractant cytokines, such as CXCL10, which has been 
implicated in recruiting NK cells to tumour sites (Wendel et al., 2008). These 
experiments could measure CXCL10 production by reovirus-exposed LN and 
investigate the effects of CXCL10 blockade (by antibody or siRNA knockdown) 
on NK cell recruitment to murine LN. 
OVs have previously been investigated for their ability to manipulate NK cell 
trafficking in murine models, such as enhanced NK cell trafficking to reovirus-
treated prostate cancer tumours (Gujar, S.A. et al., 2011), an IL-12-expressing 
Maraba virus that elevated NK cell trafficking to colorectal cancer tumours 
(Alkayyal et al., 2017), and increased NK cell trafficking to glioma tumours in 
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measles virus-treated mice (Bhat and Rommelaere, 2015). This demonstrates a 
role for OV therapy in enhancing the anti-cancer immune repertoire, both in 
terms of immune cell activation and infiltration.  
Homing of NK cells to draining LN is a common feature of many viruses, such 
as influenza (Duan et al., 2017), and ECTV (ectromelia virus), in C57/BL6 mice 
48hrs post-infection (Parker et al., 2007). This could suggest that CVA21, as 
well as reovirus, may also promote NK cell trafficking to LN in an NHL context. 
To elaborate on the findings in this chapter, and to investigate whether the NK 
cells that traffic to the LN are activated by OV, future work could examine 
activation markers on NK cells, such as CD69 which has been used to measure 
murine NK cell activation in response to viruses (Wang, J. et al., 2012). LN 
could also be analysed for the presence of OV, to examine whether they can be 
delivered to the LN. Reovirus has been detected in the LN of mice in a 
melanoma model using C57/Bl6 mice (Ilett et al., 2009), and a role for dendritic 
cells and T cells as carriers of reovirus to LN metastases was reported.  
The research presented in this chapter outlines a potential for both CVA21 and 
reovirus to target primary LN B cells as both reovirus and CVA21 induced cell 
death in some malignant LN samples, but not the reactive sample, 
demonstrating specificity of OVs for malignant B cells. Reovirus demonstrated 
promise as an immunomodulatory agent by enhancing CD69 expression on 
NHL LN NK cells and by enhancing NK cell trafficking to LN in a non-tumour-
bearing C57/BL6 mouse model. The application of some of the findings from the 
previous chapters to primary patient material validates a potential role for 
reovirus and CVA21 in eradicating malignant cells in patients and represents 
the next step to the application of these OV for the treatment of NHL. However, 
future research is required to ascertain the mechanisms of efficacy of both 
reovirus and CVA21 against NHL within LN biopsies. 
 
  
181 
 
 
 
 
 
 
 
 
Chapter 8: 
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Chapter 8  
8.1 Conclusions 
The results presented within this study demonstrate that CVA21, unlike 
reovirus, is a potent cytolytic agent against NHL cell lines. CVA21 induced cell 
death in all but one cell line; OCI-LY19 cells were impervious to CVA21-induced 
cell death, probably due to the lack of the viral entry receptor, ICAM-1. CVA21-
induced cell death required replication-competent virus as UV-inactivation 
completely abrogated cell death. Reovirus, on the other hand, induced only 
minimal cell death in 3 out of six cell lines, even at doses 10 times higher than 
CVA21. CD40L stimulation of NHL B cells resulted in a vincristine-resistant 
phenotype, suggesting reduced efficacy of vincristine in LN-residing NHL B 
cells. CD40L stimulation also up-regulated ICAM-1 expression on most NHL cell 
lines, which correlated with enhanced susceptibility to CVA21 in Ramos and 
U2932 cell lines. This finding potentially outlines a role for CVA21 in targeting 
drug-resistant NHL cells. 
Further investigation into the determinants of susceptibility to CVA21, focused 
on the role of the antiviral IFN response to the virus. This investigation 
demonstrated that, although the susceptible NHL cell lines retain a functional 
IFN-α response (responsive to the addition of exogenous IFN), pre-treatment 
does not protect NHL cell lines from CVA21-induced cell death. This effect 
could be attributed to disruption of the IFN response pathway by CVA21 in 
homogenous NHL cell lines, but not primary healthy B cells in the context of 
PBMC. 
Further study also demonstrated a role for mTOR in CVA21 cytotoxicity as 
treating NHL cell lines with rapamycin resulted in diminished CVA21-induced 
cell death in most cell lines with the exception of Raji cells, which remained 
susceptible to CVA21-induced cell death; rapamycin blocked S6 
phosphorylation in these cells. This finding illustrates a role for S6 kinase in 
CVA21-induced cell death. Proliferation analysis of rapamycin-treated NHL cell 
lines showed minimal inhibition of cellular proliferation at 72hrs, suggesting that 
the anti-proliferative effects of rapamycin are not responsible for diminished 
CVA21-induced cell death. 
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The ability of an OV to induce an immune response to malignant, or virus-
infected, target cells provides an alternate mechanism by which an otherwise 
poor lytic agent, such as reovirus, can promote the destruction of cancer cells. 
Both OV, CVA21 and reovirus, induced NK cell activation after 48hrs of 
treatment, as measured by enhanced CD69 expression. This activation 
translated to virus-induced NK cell degranulation against NHL cell line targets, 
outlining a role for both OV in promoting immune-mediated destruction of NHL 
cells. Investigating the effects of reovirus and CVA21 in combination with BHH2, 
an αCD20 mAb, also showed that, while CVA21, reovirus and BHH2 promoted 
NHL cell targeting as single agents, this effect was enhanced when either OV 
was combined with BHH2 against Ramos cells. This illustrates a possible role 
for a combined OV-mAb therapy for the treatment of NHL. Moreover, despite 
inducing vincristine-resistance and enhancing MHC-I expression, CD40L 
stimulation of NHL cell lines did not protect them from recognition by OV-
activated NK cells, suggesting a role for OV therapy in targeting drug-resistant 
cells either as lytic, or immunotherapeutic, agents. 
Importantly, primary NHL cells, which offer a better representation of clinical 
disease than immortalised NHL cell lines, were susceptible to reovirus- and 
CVA21-induced cell death. This validates CVA21 as a potent cytotoxic agent 
against NHL cells, and establishes a role for reovirus in inducing cell death in 
primary cells, as opposed to isolated cell lines. 
Low NK cell numbers in human LN, as demonstrated by immunophenotypic 
studies of NHL LN samples, suggested a problem for OV in stimulating an NK 
cell-mediated immune response. Fortunately, systemic treatment of C57/BL6 
mice with reovirus induced NK cell trafficking to the LN, overcoming the poor 
NK cell population numbers and highlighting an additional role for OV in 
promoting an anti-NHL immune response, a finding that warrants further in vivo 
validation. 
NHL is a highly heterogeneous class of diseases with varied treatment 
response rates and poor survival in aggressive and relapsed cases, warranting 
research into alternative avenues of therapeutic intervention. The data 
presented in this thesis demonstrates the efficacy of two candidate OV, reovirus 
and CVA21, as potent inducers of NHL cell death through direct lytic killing for 
CVA21 and immune-mediated killing for both CVA21 and reovirus. These 
viruses also demonstrated efficacy against drug-resistant cells, emphasising 
their validity as promising anti-NHL therapies.  
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8.2 Future studies 
In order to develop the application of either reovirus or CVA21 for the treatment 
of NHL in the clinic, further validation will be required to enhance our knowledge 
of the efficacy of the OVs. These studies should examine the efficacy of both 
viruses in a wider array of patient NHL samples in terms of cytotoxicity and 
immune-mediated killing of malignant cells. This work could also be compared 
with more reactive nodes, to fully delineate a role for either virus in targeting 
cells in malignant nodes, specifically. Further immunophenotypic studies could 
investigate the effects of both viruses on the activation status of immune 
effector and immunosuppressive cells, to elaborate on their ability to manipulate 
the LN immune microenvironment. This research could be supplemented by 
access to peripheral blood from NHL patients, providing insights into the effects 
of CVA21 and reovirus on peripheral immune cells in terms of immune 
activation and NHL cell targeting. These studies could include, but would not be 
restricted to, examination of immune checkpoint markers, such as PD-1 on LN-
residing or peripheral blood immune effector cells, and PD-L1 on malignant 
cells, to allow the selection of appropriate immune checkpoint antibodies to 
enhance the efficacy of the OV. αPD-1 antibodies, such as nivolumab, have 
demonstrated successful outcomes in clinical trials for NHL, with 40% and 36% 
response rates in FL and DLBCL patients, respectively (Lesokhin et al., 2016).  
Further research could confirm the ability of both OV to target drug-resistant 
cells through direct cytotoxicity or immune-mediated killing. This work could 
include the utilisation for alternative pro-survival signals (other than CD40L) that 
play a role in drug resistance and relapse within the LN, such as BCR 
engagement and addition of exogenous cytokines.  
Importantly, in vivo models could develop these findings further to 1) investigate 
the effect of tumour burden in LN of treated mice, 2) test OV delivery, and 
replication within the NHL TME, 3) examine NK cell trafficking to LN and 4) 
characterise immune cell populations, activation by OV and the role for 
immune-mediated killing. Taken together, these studies would further validate 
the findings of this thesis and prove the applicability of CVA21 and reovirus as 
potential treatments for NHL. 
The work outlined in this thesis demonstrates a potential application for CVA21 
and reovirus in the treatment of NHL. This could be investigated further by 
combining either virus with drugs that are already being used to treat NHL, such 
as components of the R-CHOP regimen. While the ability of CVA21 to reduce 
melanoma tumour burden in immunodeficient mouse models has already been 
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investigated (Au 2005, shafren 2004), future combination strategies could be 
investigated in immunocompetent in vivo models, such as an immunocompetent 
NHL model using Female BALB/c mice (Touitou et al., 2007). The reported 
inability of CVA21 to infect cells expressing murine ICAM-1 could be overcome 
by transfecting murine NHL cells with human ICAM-1 and growing these cells in 
an immunocompetent mouse model, as has been demonstrated with human 
ICAM-1 on murine lungs in an immunocompetent BALB/c model (Traub et al., 
2013). This research could provide greater insight into the ability of CVA21 to 
target NHL cells in vivo and the role of the host immune system in targeting the 
disease.  
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Chapter 9  
9.1 STR Profiling results 
 
Figure 9-1: STR Profile results for Ramos cells  
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Figure 9-2: STR Profile results for Raji cells   
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Figure 9-3: STR Profile results for SU-DHL-4 cells   
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Figure 9-4: STR Profile results for OCI-LY19 cells   
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Figure 9-5: STR Profile results for U2932 cells   
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Figure 9-6: STR Profile results for OCI-LY3 cells 
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9.2 List of Suppliers 
Applied Biosystems Supplied by Fisher Scientific UK Ltd. 
ATCC American Type Culture Collection 
(ATCC), 10801 University Boulevard, 
Manassas, VA 20110 USA 
Axis Shields Axis Shield Diagnostics Ltd, Luna 
Place, The Technology Park, Dundee 
DD2 1XA, SCOTLAND 
BD Biosciences 1030 Eskdale Road, Winnersh 
Triangle, Wokingham, Berkshire 
RG41 5TS 
Beckman Coulter Beckman Coulter (UK) Ltd, Oakley 
Court, Kingsmead Business Park, 
London Road, High Wycombe United 
Kingdom HP11 1JU 
Biolegend 4B Highgate Business Centre, 33 
Greenwood Place, London NW5 
1LB, United Kingdom 
Corning Costar Distributed by Sigma Aldrich Ltd. 
DSMZ Inhoffenstraße 7B, 38124 
Braunschweig, GERMANY 
DuPont UK Ltd. Du Pont (U.K.) Limited, Crop 
Protection Products, 4th Floor, Kings 
Court, London Road, Stevenage, 
Hertfordshire, SG1 2NG 
eBioscience Ltd 2nd Floor, Titan Court, 3 Bishop 
Square, Hatfield, AL10 9NA,UK 
Eppendorf Supplied by Fisher Scientific UK Ltd. 
Falcon See BD Biosciences 
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Fisher Scientific UK Ltd. Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 
5RG, UK 
Gemini BV Laboratory Prinses Beatrixlaan 301, 7312 DG 
Apeldoorn, Nederland 
Hawksley Hawksley, Marlborough Road, 
Lancing Business Park, Lancing, 
Sussex, BN15 8TN 
Life technologies Ltd. 3 Fountain Drive, Inchinnan Business 
Park, Paisley, PA4 9RF, UK 
 
Mabtech Box 1233, SE-131 28 Nacka Strand, 
Sweden 
Millipore (UK) Ltd. Suite 3 & 5. Building 6. Croxley 
Green Business Park, Watford, 
WD18 8YH, UK 
 
Miltenyi Biotec Ltd. Almac House, Church Lane, Bisley, 
Surrey, GU24 9DR, UK 
  
National Health Service Blood and 
Transplant 
Bridle Path, Leeds, LS15 7TW, UK 
NHS Supplies Valley Point Valley Drive, Rugby , 
Warwickshire CV21 1TN, UK 
NuAire Inc. 2100 Fernbrook Lane N Plymouth, 
MN 55447, USA 
Nunc® Distributed by Fisher Scientific 
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Olympus KeyMed House, Stock Road, 
Southend-on-Sea, Essex, SS2 5QH, 
UK 
Oncolytics Biotech Inc. 1167 Kensington Crescent NW 
Calgary, AB, Canada 
Oxoid Oxoid Ltd., Wade Road, 
Basingstoke, Hampshire, RG24 
8PW, UK 
Pharmingen See BD Biosciences 
Qiagen Ltd. Boundary Court, Gatwick Road, 
Crawley, West Sussex, RH10 2AX, 
UK 
R & D Systems Europe Ltd. 19 Barton Lane, Abingdon Science 
Park, Abingdon,OX14 3NB, UK 
 
Santa Cruz Biotechnology Inc. Supplied by Insight Biotechnology 
Sanyo Sanyo Gallenkamp Plc., Monarch 
Way, Belton Park, Loughborough, 
LE11 5XG, UK 
 
Scientific Laboratory Supplies Wilford Industrial Estate, Ruddington 
Lane, Wilford, Nottingham, NG11 
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Sigma-Aldrich Ltd. Sigma Chemical Company, Fancy 
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Swann-Morton Supplied by NHS Supplies 
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VWR International Ltd. Hunter Boulevard, Magna Park, 
Lutterworth, Leicestershire, LE17 
4XN, UK 
  
  
  
  
  
  
 
  
197 
 
 
 
 
 
 
 
 
Chapter 10: 
References 
 
198 
 
Chapter 10  
Adair, R.A., Roulstone, V., Scott, K.J., Morgan, R., Nuovo, G.J., Fuller, M., 
Beirne, D., West, E.J., Jennings, V.A., Rose, A., Kyula, J., Fraser, S., Dave, R., 
Anthoney, D.A., Merrick, A., Prestwich, R., Aldouri, A., Donnelly, O., Pandha, 
H., Coffey, M., Selby, P., Vile, R., Toogood, G., Harrington, K. and Melcher, 
A.A. 2012. Cell carriage, delivery, and selective replication of an oncolytic virus 
in tumor in patients. Sci Transl Med. 4(138), p138ra177. 
Adair, R.A., Scott, K.J., Fraser, S., Errington-Mais, F., Pandha, H., Coffey, M., 
Selby, P., Cook, G.P., Vile, R., Harrington, K.J., Toogood, G. and Melcher, A.A. 
2013. Cytotoxic and immune-mediated killing of human colorectal cancer by 
reovirus-loaded blood and liver mononuclear cells. Int J Cancer. 132(10), 
pp.2327-2338. 
Ahuja, H., Foti, A., Bar-Eli, M. and Cline, M. 1990. The pattern of mutational 
involvement of RAS genes in human hematologic malignancies determined by 
DNA amplification and direct sequencing. Blood. 75(8), pp.1684-1690. 
Alain, T., Hirasawa, K., Pon, K.J., Nishikawa, S.G., Urbanski, S.J., Auer, Y., 
Luider, J., Martin, A., Johnston, R.N., Janowska-Wieczorek, A., Lee, P.W. and 
Kossakowska, A.E. 2002. Reovirus therapy of lymphoid malignancies. Blood. 
100(12), pp.4146-4153. 
Alain, T., Kim, T.S., Lun, X., Liacini, A., Schiff, L.A., Senger, D.L. and Forsyth, 
P.A. 2007. Proteolytic disassembly is a critical determinant for reovirus 
oncolysis. Mol Ther. 15(8), pp.1512-1521. 
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., 
Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., 
Moore, T., Hudson, J., Jr., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., 
Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., 
Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. and 
Staudt, L.M. 2000. Distinct types of diffuse large B-cell lymphoma identified by 
gene expression profiling. Nature. 403(6769), pp.503-511. 
Alkayyal, A.A., Tai, L.-H., Kennedy, M.A., de Souza, C.T., Zhang, J., Lefebvre, 
C., Sahi, S., Ananth, A.A., Mahmoud, A.B., Makrigiannis, A.P., Cron, G.O., 
Macdonald, B., Marginean, E.C., Stojdl, D.F., Bell, J.C. and Auer, R.C. 2017. 
NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis 
with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunology 
Research. 5(3), pp.211-221. 
Alvaro-Naranjo, T., Jaen-Martinez, J., Guma-Padro, J., Bosch-Princep, R. and 
Salvado-Usach, M.T. 2003. CD20-negative DLBCL transformation after 
rituximab treatment in follicular lymphoma: a new case report and review of the 
literature. Ann Hematol. 82(9), pp.585-588. 
American Cancer Society. 2017. Types of Non-Hodgkin Lymphoma. 
Amini, R.M., Berglund, M., Rosenquist, R., Von Heideman, A., Lagercrantz, S., 
Thunberg, U., Bergh, J., Sundstrom, C., Glimelius, B. and Enblad, G. 2002. A 
novel B-cell line (U-2932) established from a patient with diffuse large B-cell 
lymphoma following Hodgkin lymphoma. Leuk Lymphoma. 43(11), pp.2179-
2189. 
Anatomyorgan. 2017. Mouse Anatomy Diagram. 
199 
 
Andrews, P.S.a.P., Fiona and Sampson, Adam T. and Scott, Lisa and Coles, 
Mark. 2008. Simulating biology: towards understanding what the simulation 
shows. Proceedings of the 2008 Workshop on Complex Systems Modelling and 
Simulation, York, UK, September 2008. 
Andtbacka, R.H., Curti, B.D., Hallmeyer, S., Feng, Z., Paustian, C., Bifulco, C., 
Fox, B., Grose, M. and Shafren, D. 2015. Phase II calm extension study: 
Coxsackievirus A21 delivered intratumorally to patients with advanced 
melanoma induces immune-cell infiltration in the tumor microenvironment. 
Journal for ImmunoTherapy of Cancer. 3(2), pP343. 
Angelova, A.L., Witzens-Harig, M., Galabov, A.S. and Rommelaere, J. 2017. 
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying 
H-1 Parvovirus to Treat Blood and Solid Cancers. Front Oncol. 7, p93. 
Ann W. Silk, H.L.K., Mark Faries, Steven O’Day, Nashat Gabrail, Janice 
Mehnert, Jennifer Bryan, Jacqueline Norrell, Azra Haider, Praveen K. 
Bommareddy, Darren Shafren, Mark Grose and Andrew Zloza. 2017. CAPRA: 
A Phase Ib study of intratumoral oncolytic Coxsackievirus A21 (CVA21) and 
systemic pembrolizumab in advanced melanoma patients. Society for 
Immunotherapy of Cancer – 32nd Annual Meeting. 
Annels, N.E., Arif, M., Simpson, G.R., Denyer, M., Moller-Levet, C., Mansfield, 
D., Butler, R., Shafren, D., Au, G., Knowles, M., Harrington, K., Vile, R., 
Melcher, A. and Pandha, H. 2018. Oncolytic Immunotherapy for Bladder Cancer 
Using Coxsackie A21 Virus. Molecular Therapy - Oncolytics. 9, pp.1-12. 
Ansell, S.M. 2015. Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo 
Clin Proc. 90(8), pp.1152-1163. 
Arase, H., Arase, N. and Saito, T. 1996. Interferon gamma production by natural 
killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J Exp Med. 
183(5), pp.2391-2396. 
Arellano-Garcia, M.E., Misuno, K., Tran, S.D. and Hu, S. 2014. Interferon-γ 
Induces Immunoproteasomes and the Presentation of MHC I-Associated 
Peptides on Human Salivary Gland Cells. PLOS ONE. 9(8), pe102878. 
Armitage, J.O. and Weisenburger, D.D. 1998. New approach to classifying non-
Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-
Hodgkin's Lymphoma Classification Project. J Clin Oncol. 16(8), pp.2780-2795. 
ATCC. 2017. Human Coxsackievirus A 21 (ATCC® VR-850™)  
Atzeni, F., Schena, M., Ongari, A.M., Carrabba, M., Bonara, P., Minonzio, F. 
and Capsoni, F. 2002. Induction of CD69 activation molecule on human 
neutrophils by GM-CSF, IFN-gamma, and IFN-alpha. Cell Immunol. 220(1), 
pp.20-29. 
Au, G.G., Lincz, L.F., Enno, A. and Shafren, D.R. 2007. Oncolytic 
Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 
137(2), pp.133-141. 
Au, G.G., Lindberg, A.M., Barry, R.D. and Shafren, D.R. 2005. Oncolysis of 
vascular malignant human melanoma tumors by Coxsackievirus A21. Int J 
Oncol. 26(6), pp.1471-1476. 
Aurelian, L. 2016. Oncolytic viruses as immunotherapy: progress and remaining 
challenges. Onco Targets Ther. 9, pp.2627-2637. 
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H.Z. and Kamarul, T. 
2016. Potential of apoptotic pathway-targeted cancer therapeutic research: 
Where do we stand? Cell Death & Disease. 7(1), pe2058. 
200 
 
Bajenoff, M., Breart, B., Huang, A.Y., Qi, H., Cazareth, J., Braud, V.M., 
Germain, R.N. and Glaichenhaus, N. 2006. Natural killer cell behavior in lymph 
nodes revealed by static and real-time imaging. J Exp Med. 203(3), pp.619-631. 
Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, 
J.S., Hochberg, E.P. and Abramson, J.S. 2011. Evaluation of the addition of 
rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. 
Ann Oncol. 22(8), pp.1859-1864. 
Bartee, E., Bartee, M.Y., Bogen, B. and Yu, X.Z. 2016. Systemic therapy with 
oncolytic myxoma virus cures established residual multiple myeloma in mice. 
Mol Ther Oncolytics. 3, p16032. 
Basso, K. and Dalla-Favera, R. 2012. Roles of BCL6 in normal and transformed 
germinal center B cells. Immunol Rev. 247(1), pp.172-183. 
Batenchuk, C., Le Boeuf, F., Stubbert, L., Falls, T., Atkins, H.L., Bell, J.C. and 
Conrad, D.P. 2013. Non-replicating rhabdovirus-derived particles (NRRPs) 
eradicate acute leukemia by direct cytolysis and induction of antitumor 
immunity. Blood Cancer Journal. 3, pe123. 
Bauzon, M. and Hermiston, T. 2014. Armed therapeutic viruses - a disruptive 
therapy on the horizon of cancer immunotherapy. Front Immunol. 5, p74. 
Beider, K., Ribakovsky, E., Abraham, M., Wald, H., Weiss, L., Rosenberg, E., 
Galun, E., Avigdor, A., Eizenberg, O., Peled, A. and Nagler, A. 2013. Targeting 
the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and 
high-affinity CXCR4 antagonist BKT140. Clin Cancer Res. 19(13), pp.3495-
3507. 
Bellesso, M., Xavier, F.D., Costa, R.O., Pereira, J., Siqueira, S.A. and 
Chamone, D.A. 2011. Disease progression after R-CHOP treatment associated 
with the loss of CD20 antigen expression. Rev Bras Hematol Hemoter. 33(2), 
pp.148-150. 
Benlahrech, A., Donaghy, H., Rozis, G., Goodier, M., Klavinskis, L., Gotch, F. 
and Patterson, S. 2009. Human NK Cell Up-regulation of CD69, HLA-DR, 
Interferon gamma Secretion and Cytotoxic Activity by Plasmacytoid Dendritic 
Cells is Regulated through Overlapping but Different Pathways. Sensors 
(Basel). 9(1), pp.386-403. 
Beretta, L., Svitkin, Y.V. and Sonenberg, N. 1996. Rapamycin stimulates viral 
protein synthesis and augments the shutoff of host protein synthesis upon 
picornavirus infection. J Virol. 70(12), pp.8993-8996. 
Berget, E., Helgeland, L., Liseth, K., Lokeland, T., Molven, A. and Vintermyr, 
O.K. 2014. Prognostic value of bone marrow involvement by clonal 
immunoglobulin gene rearrangements in follicular lymphoma. J Clin Pathol. 
67(12), pp.1072-1077. 
Bernard Mach, Viktor Steimle, Eduardo Martinez-Soria, a. and Reith, W. 1996. 
REGULATION OF MHC CLASS II GENES: Lessons from a Disease. Annual 
Review of Immunology. 14(1), pp.301-331. 
Berry, L.J., Au, G.G., Barry, R.D. and Shafren, D.R. 2008. Potent oncolytic 
activity of human enteroviruses against human prostate cancer. Prostate. 68(6), 
pp.577-587. 
Beuneu, H., Deguine, J., Breart, B., Mandelboim, O., Di Santo, J.P. and 
Bousso, P. 2009. Dynamic behavior of NK cells during activation in lymph 
nodes. Blood. 114(15), pp.3227-3234. 
201 
 
Bhat, R., Dempe, S., Dinsart, C. and Rommelaere, J. 2011. Enhancement of 
NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer. 128(4), 
pp.908-919. 
Bhat, R. and Rommelaere, J. 2015. Emerging role of Natural killer cells in 
oncolytic virotherapy. Immunotargets Ther. 4, pp.65-77. 
Bhatt, A.P., Bhende, P.M., Sin, S.H., Roy, D., Dittmer, D.P. and Damania, B. 
2010. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine 
proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 115(22), 
pp.4455-4463. 
Black, L.R. and Aiken, C. 2010. TRIM5alpha disrupts the structure of 
assembled HIV-1 capsid complexes in vitro. J Virol. 84(13), pp.6564-6569. 
Borge, M., Belen Almejun, M., Podaza, E., Colado, A., Fernandez Grecco, H., 
Cabrejo, M., Bezares, R.F., Giordano, M. and Gamberale, R. 2015. Ibrutinib 
impairs the phagocytosis of rituximab-coated leukemic cells from chronic 
lymphocytic leukemia patients by human macrophages. Haematologica. 100(4), 
pp.e140-142. 
Bos, J.L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49(17), 
pp.4682-4689. 
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., 
Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., Vitale, M., Moretta, L., 
Lopez, M. and Moretta, A. 2003. Identification of PVR (CD155) and Nectin-2 
(CD112) as cell surface ligands for the human DNAM-1 (CD226) activating 
molecule. J Exp Med. 198(4), pp.557-567. 
Bradley, S., Jakes, A.D., Harrington, K., Pandha, H., Melcher, A. and Errington-
Mais, F. 2014. Applications of coxsackievirus A21 in oncology. Oncolytic 
Virother. 3, pp.47-55. 
Brady, G., MacArthur, G.J. and Farrell, P.J. 2007. Epstein-Barr virus and Burkitt 
lymphoma. J Clin Pathol. 60(12), pp.1397-1402. 
Brandstadter, J.D. and Yang, Y. 2011. Natural killer cell responses to viral 
infection. J Innate Immun. 3(3), pp.274-279. 
Breitbach, C.J., De Silva, N.S., Falls, T.J., Aladl, U., Evgin, L., Paterson, J., 
Sun, Y.Y., Roy, D.G., Rintoul, J.L., Daneshmand, M., Parato, K., Stanford, 
M.M., Lichty, B.D., Fenster, A., Kirn, D., Atkins, H. and Bell, J.C. 2011. 
Targeting tumor vasculature with an oncolytic virus. Mol Ther. 19(5), pp.886-
894. 
Bruu, D.A.L. 2013. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses 
and Newer Enteroviruses. A Practical Guide to Clinical Virology. 
Buchmeier, N.A. and Schreiber, R.D. 1985. Requirement of endogenous 
interferon-gamma production for resolution of Listeria monocytogenes infection. 
Proceedings of the National Academy of Sciences. 82(21), pp.7404-7408. 
Bundscherer, A., Hafner, C., Maisch, T., Becker, B., Landthaler, M. and Vogt, T. 
2008. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in 
malignant melanoma cell lines. Oncol Rep. 19(2), pp.547-553. 
Cai, J., Lin, Y., Zhang, H., Liang, J., Tan, Y. and Cavenee, W.K. 2017. Selective 
replication of oncolytic virus M1 results in a bystander killing effect that is 
potentiated by Smac mimetics. 114(26), pp.6812-6817. 
Campbell, J.A., Schelling, P., Wetzel, J.D., Johnson, E.M., Forrest, J.C., Wilson, 
G.A., Aurrand-Lions, M., Imhof, B.A., Stehle, T. and Dermody, T.S. 2005. 
Junctional adhesion molecule a serves as a receptor for prototype and field-
isolate strains of mammalian reovirus. J Virol. 79(13), pp.7967-7978. 
202 
 
Castleton, A., Dey, A., Beaton, B., Patel, B., Aucher, A., Davis, D.M. and 
Fielding, A.K. 2014. Human mesenchymal stromal cells deliver systemic 
oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of 
humoral immunity. Blood. 123(9), pp.1327-1335. 
Chao, M.P. 2013. Treatment challenges in the management of relapsed or 
refractory non-Hodgkin's lymphoma - novel and emerging therapies. Cancer 
Manag Res. 5, pp.251-269. 
Chawla-Sarkar, M., Lindner, D.J., Liu, Y.F., Williams, B.R., Sen, G.C., 
Silverman, R.H. and Borden, E.C. 2003. Apoptosis and interferons: role of 
interferon-stimulated genes as mediators of apoptosis. Apoptosis. 8(3), pp.237-
249. 
Cheema, T.A., Wakimoto, H., Fecci, P.E., Ning, J., Kuroda, T., Jeyaretna, D.S., 
Martuza, R.L. and Rabkin, S.D. 2013. Multifaceted oncolytic virus therapy for 
glioblastoma in an immunocompetent cancer stem cell model. Proceedings of 
the National Academy of Sciences. 110(29), pp.12006-12011. 
Chen, Z., Yang, L., Liu, Y., Tang, A., Li, X., Zhang, J. and Yang, Z. 2014. 
LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect 
and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway. Mol Cell 
Biochem. 385(1-2), pp.169-177. 
Cheng, X., Wang, W., Xu, Q., Harper, J., Carroll, D., Galinski, M.S., Suzich, J. 
and Jin, H. 2016. Genetic Modification of Oncolytic Newcastle Disease Virus for 
Cancer Therapy. J Virol. 90(11), pp.5343-5352. 
Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P. and Blenis, J. 2008. Rapamycin 
differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression 
of mRNA translation. Proc Natl Acad Sci U S A. 105(45), pp.17414-17419. 
Ciobanu, A., Stanca, O., Triantafyllidis, I. and Lupu, A. 2013. Indolent 
lymphoma: diagnosis and prognosis in medical practice. Maedica (Buchar). 
8(4), pp.338-342. 
ClinicalTrials.gov. 2014. Intratumoral CAVATAK (CVA21) and Ipilimumab in 
Patients With Advanced Melanoma (VLA-013 MITCI) (MITCI). 
ClinicalTrials.gov. 2015a. Intratumoral CAVATAK (CVA21) and Pembrolizumab 
in Patients With Advanced Melanoma (VLA-011 CAPRA) (CAPRA). 
ClinicalTrials.gov. 2015b. Study of Pembrolizumab With REOLYSIN® and 
Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. 
ClinicalTrials.gov. 2015c. Wild-Type Reovirus, Bortezomib, and 
Dexamethasone in Treating Patients With Relapsed or Refractory Multiple 
Myeloma. 
ClinicalTrials.gov. 2016. Pembrolizumab + CVA21 in Advanced NSCLC. 
ClinicalTrials.gov. 2017a. A Phase I/II Study of Pexa-Vec Oncolytic Virus in 
Combination With Immune Checkpoint Inhibition in Refractory Colorectal 
Cancer. 
ClinicalTrials.gov. 2017b. A Study of Recombinant Vaccinia Virus in 
Combination With REGN2810 for Renal Cell Carcinoma. 
ClinicalTrials.gov. 2017c. Viral Immunotherapy in Relapsed/Refractory Multiple 
Myeloma (MUKeleven). 
Clodi, K., Asgary, Z., Zhao, S., Kliche, K.O., Cabanillas, F., Andreeff, M. and 
Younes, A. 1998a. Coexpression of CD40 and CD40 ligand in B-cell lymphoma 
cells. Br J Haematol. 103(1), pp.270-275. 
203 
 
Clodi, K., Snell, V., Zhao, S., Cabanillas, F., Andreeff, M. and Younes, A. 
1998b. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J 
Haematol. 103(1), pp.217-219. 
Colamonici, O.R., Domanski, P., Sweitzer, S.M., Larner, A. and Buller, R.M. 
1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that 
blocks interferon alpha transmembrane signaling. J Biol Chem. 270(27), 
pp.15974-15978. 
Comins, C., Simpson, G.R., Rogers, W., Relph, K., Harrington, K., Melcher, A., 
Roulstone, V., Kyula, J. and Pandha, H. 2018. Synergistic antitumour effects of 
rapamycin and oncolytic reovirus. Cancer Gene Therapy. 25(5), pp.148-160. 
Comins, C., Spicer, J., Protheroe, A., Roulstone, V., Twigger, K., White, C.M., 
Vile, R., Melcher, A., Coffey, M.C., Mettinger, K.L., Nuovo, G., Cohn, D.E., 
Phelps, M., Harrington, K.J. and Pandha, H.S. 2010. REO-10: a phase I study 
of intravenous reovirus and docetaxel in patients with advanced cancer. Clin 
Cancer Res. 16(22), pp.5564-5572. 
Compagno, M., Lim, W.K., Grunn, A., Nandula, S.V., Brahmachary, M., Shen, 
Q., Bertoni, F., Ponzoni, M., Scandurra, M., Califano, A., Bhagat, G., Chadburn, 
A., Dalla-Favera, R. and Pasqualucci, L. 2009. Mutations of multiple genes 
cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 
459(7247), pp.717-721. 
Correia, C., Schneider, P.A., Dai, H., Dogan, A., Maurer, M.J., Church, A.K., 
Novak, A.J., Feldman, A.L., Wu, X., Ding, H., Meng, X.W., Cerhan, J.R., Slager, 
S.L., Macon, W.R., Habermann, T.M., Karp, J.E., Gore, S.D., Kay, N.E., Jelinek, 
D.F., Witzig, T.E., Nowakowski, G.S. and Kaufmann, S.H. 2015. BCL2 
mutations are associated with increased risk of transformation and shortened 
survival in follicular lymphoma. Blood. 125(4), pp.658-667. 
Critchley-Thorne, R.J., Simons, D.L., Yan, N., Miyahira, A.K., Dirbas, F.M., 
Johnson, D.L., Swetter, S.M., Carlson, R.W., Fisher, G.A., Koong, A., Holmes, 
S. and Lee, P.P. 2009. Impaired interferon signaling is a common immune 
defect in human cancer. Proc Natl Acad Sci U S A. 106(22), pp.9010-9015. 
CRUK. 2018. Non-Hodgkin lymphoma incidence statistics. 
Davis, R.E., Brown, K.D., Siebenlist, U. and Staudt, L.M. 2001. Constitutive 
nuclear factor kappaB activity is required for survival of activated B cell-like 
diffuse large B cell lymphoma cells. J Exp Med. 194(12), pp.1861-1874. 
De Paepe, P. and De Wolf-Peeters, C. 2007. Diffuse large B-cell lymphoma: a 
heterogeneous group of non-Hodgkin lymphomas comprising several distinct 
clinicopathological entities. Leukemia. 21(1), pp.37-43. 
de Souza, A.P., de Freitas, D.N., Antuntes Fernandes, K.E., D'Avila da Cunha, 
M., Antunes Fernandes, J.L., Benetti Gassen, R., Fazolo, T., Pinto, L.A., Scotta, 
M., Mattiello, R., Pitrez, P.M., Bonorino, C. and Stein, R.T. 2016. Respiratory 
syncytial virus induces phosphorylation of mTOR at ser2448 in CD8 T cells from 
nasal washes of infected infants. Clin Exp Immunol. 183(2), pp.248-257. 
Deng, H., Tang, N., Stief, A.E., Mehta, N., Baig, E., Head, R., Sleep, G., Yang, 
X.Z., McKerlie, C., Trudel, S., Stewart, A.K. and McCart, J.A. 2008. Oncolytic 
virotherapy for multiple myeloma using a tumour-specific double-deleted 
vaccinia virus. Leukemia. 22(12), pp.2261-2264. 
Deonarain, R., Cerullo, D., Fuse, K., Liu, P.P. and Fish, E.N. 2004. Protective 
Role for Interferon-β in Coxsackievirus B3 Infection. Circulation. 110(23), 
pp.3540-3543. 
204 
 
Devasthanam, A.S. 2014. Mechanisms underlying the inhibition of interferon 
signaling by viruses. Virulence. 5(2), pp.270-277. 
Diacovo, T.G., Blasius, A.L., Mak, T.W., Cella, M. and Colonna, M. 2005. 
Adhesive mechanisms governing interferon-producing cell recruitment into 
lymph nodes. J Exp Med. 202(5), pp.687-696. 
Diaz-San Segundo, F., Moraes, M.P., de Los Santos, T., Dias, C.C. and 
Grubman, M.J. 2010. Interferon-induced protection against foot-and-mouth 
disease virus infection correlates with enhanced tissue-specific innate immune 
cell infiltration and interferon-stimulated gene expression. J Virol. 84(4), 
pp.2063-2077. 
Ding, Y., Shan, L., Nai, W., Lin, X., Zhou, L., Dong, X., Wu, H., Xiao, M., Zhou, 
X., Wang, L., Li, T., Fu, Y., Lin, Y., Jia, C., Dai, M. and Bai, X. 2018. DEPTOR 
Deficiency-Mediated mTORc1 Hyperactivation in Vascular Endothelial Cells 
Promotes Angiogenesis. Cell Physiol Biochem. 46(2), pp.520-531. 
Dock, G., Brothers, L. and Company. 1904. The Influence of Complicating 
Diseases Upon Leukaemia.  Lea Brothers & Company. 
Donnelly, O.G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V., Scott, 
K., Peach, H., Phillips, R.M., Bond, J., Pandha, H., Harrington, K., Vile, R., 
Russell, S., Selby, P. and Melcher, A.A. 2013. Measles virus causes 
immunogenic cell death in human melanoma. Gene therapy. 20(1), pp.7-15. 
Dorff, T.B. and Crawford, E.D. 2013. Management and challenges of 
corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. 
Ann Oncol. 24(1), pp.31-38. 
Dormond, O., Contreras, A.G., Meijer, E., Datta, D., Flynn, E., Pal, S. and 
Briscoe, D.M. 2008. CD40-induced signaling in human endothelial cells results 
in mTORC2- and Akt-dependent expression of vascular endothelial growth 
factor in vitro and in vivo. J Immunol. 181(11), pp.8088-8095. 
Dotzauer, A. and Kraemer, L. 2012. Innate and adaptive immune responses 
against picornaviruses and their counteractions: An overview. World J Virol. 
1(3), pp.91-107. 
Douville, R.N., Su, R.C., Coombs, K.M., Simons, F.E. and Hayglass, K.T. 2008. 
Reovirus serotypes elicit distinctive patterns of recall immunity in humans. J 
Virol. 82(15), pp.7515-7523. 
Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat 
Rev Cancer. 3(1), pp.11-22. 
Drakos, E., Singh, R.R., Rassidakis, G.Z., Schlette, E., Li, J., Claret, F.X., Ford, 
R.J., Jr., Vega, F. and Medeiros, L.J. 2011. Activation of the p53 pathway by the 
MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical 
model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). 
Leukemia. 25(5), pp.856-867. 
Duan, X., Lu, J., Wang, H., Liu, X., Wang, J., Zhou, K., Jiang, W., Wang, Y. and 
Fang, M. 2017. Bidirectional factors impact the migration of NK cells to draining 
lymph node in aged mice during influenza virus infection. Exp Gerontol. 96, 
pp.127-137. 
Duncan, M.R., Stanish, S.M. and Cox, D.C. 1978. Differential sensitivity of 
normal and transformed human cells to reovirus infection. Journal of Virology. 
28(2), pp.444-449. 
Eigl, B.J., Winquist, E., Tu, D., Hotte, S.J., Canil, C.M., Gregg, R.W., Zulfiqar, 
M., North, S.A., Ellard, S., Ruether, J.D., Le, L.H., Kakumanu, A.S., Theis, A., 
Booth, C.M., Potvin, K.R., Chi, K.N. and Seymour, L. 2017. A randomized 
205 
 
phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in 
patients with metastatic castration resistant prostate cancer (mCRPC): 
Canadian Cancer Trials Group study IND 209. Journal of Clinical Oncology. 
35(15_suppl), pp.5021-5021. 
El-Serafi, I., Abedi-Valugerdi, M., Potacova, Z., Afsharian, P., Mattsson, J., 
Moshfegh, A. and Hassan, M. 2014. Cyclophosphamide alters the gene 
expression profile in patients treated with high doses prior to stem cell 
transplantation. PLoS One. 9(1), pe86619. 
Elankumaran, S., Chavan, V., Qiao, D., Shobana, R., Moorkanat, G., Biswas, 
M. and Samal, S.K. 2010. Type I interferon-sensitive recombinant newcastle 
disease virus for oncolytic virotherapy. J Virol. 84(8), pp.3835-3844. 
Elgueta, R., Benson, M.J., de Vries, V.C., Wasiuk, A., Guo, Y. and Noelle, R.J. 
2009. Molecular mechanism and function of CD40/CD40L engagement in the 
immune system. Immunol Rev. 229(1), pp.152-172. 
Elmore, S. 2007. Apoptosis: A Review of Programmed Cell Death. Toxicologic 
pathology. 35(4), pp.495-516. 
Errington, F., White, C.L., Twigger, K.R., Rose, A., Scott, K., Steele, L., Ilett, 
L.J., Prestwich, R., Pandha, H.S., Coffey, M., Selby, P., Vile, R., Harrington, 
K.J. and Melcher, A.A. 2008. Inflammatory tumour cell killing by oncolytic 
reovirus for the treatment of melanoma. Gene Ther. 15(18), pp.1257-1270. 
Erum Naqvi, I.-O.N. 2013. Reolysin. 
Esfandyari, T., Tefferi, A., Szmidt, A., Alain, T., Zwolak, P., Lasho, T., Lee, P.W. 
and Farassati, F. 2009. Transcription factors down-stream of Ras as molecular 
indicators for targeting malignancies with oncolytic herpes virus. Mol Oncol. 3(5-
6), pp.464-468. 
Faller, W.J., Jackson, T.J., Knight, J.R., Ridgway, R.A., Jamieson, T., Karim, 
S.A., Jones, C., Radulescu, S., Huels, D.J., Myant, K.B., Dudek, K.M., Casey, 
H.A., Scopelliti, A., Cordero, J.B., Vidal, M., Pende, M., Ryazanov, A.G., 
Sonenberg, N., Meyuhas, O., Hall, M.N., Bushell, M., Willis, A.E. and Sansom, 
O.J. 2015. mTORC1-mediated translational elongation limits intestinal tumour 
initiation and growth. Nature. 517(7535), pp.497-500. 
Federica, Z., Paolo, M., Roberta, B., Daniele, S., Roberto, M. and Francesco, T. 
2005. Controlling complement resistance in cancer by using human monoclonal 
antibodies that neutralize complement‐regulatory proteins CD55 and CD59. 
European Journal of Immunology. 35(7), pp.2175-2183. 
Ferguson, M.S., Lemoine, N.R. and Wang, Y. 2012. Systemic delivery of 
oncolytic viruses: hopes and hurdles. Adv Virol. 2012, p805629. 
Fields, P.A. and Wrench, D.J. 2015. Assessing risk and improving survival in 
lymphoma. Br J Gen Pract. 65(634), pp.220-221. 
Filley, A.C. and Dey, M. 2017. Immune System, Friend or Foe of Oncolytic 
Virotherapy? Front Oncol. 7, p106. 
Fiola, C., Peeters, B., Fournier, P., Arnold, A., Bucur, M. and Schirrmacher, V. 
2006. Tumor selective replication of Newcastle disease virus: association with 
defects of tumor cells in antiviral defence. Int J Cancer. 119(2), pp.328-338. 
Fiore, F., Von Bergwelt-Baildon, M.S., Drebber, U., Beyer, M., Popov, A., 
Manzke, O., Wickenhauser, C., Baldus, S.E. and Schultze, J.L. 2006. Dendritic 
cells are significantly reduced in non-Hodgkin's lymphoma and express less 
CCR7 and CD62L. Leukemia & Lymphoma. 47(4), pp.613-622. 
Fitzgerald-Bocarsly, P. 2002. Natural interferon-alpha producing cells: the 
plasmacytoid dendritic cells. Biotechniques. Suppl, pp.16-20, 22, 24-19. 
206 
 
Fitzsimmons, L., Boyce, A.J., Wei, W., Chang, C., Croom-Carter, D., Tierney, 
R.J., Herold, M.J., Bell, A.I., Strasser, A., Kelly, G.L. and Rowe, M. 2017. 
Coordinated repression of BIM and PUMA by Epstein–Barr virus latent genes 
maintains the survival of Burkitt lymphoma cells. Cell Death And Differentiation. 
25, p241. 
Fogel, L.A., Sun, M.M., Geurs, T.L., Carayannopoulos, L.N. and French, A.R. 
2013. Markers of Nonselective and Specific NK Cell Activation. The Journal of 
Immunology. 190(12), pp.6269-6276. 
Forsyth, P., Roldan, G., George, D., Wallace, C., Palmer, C.A., Morris, D., 
Cairncross, G., Matthews, M.V., Markert, J., Gillespie, Y., Coffey, M., 
Thompson, B. and Hamilton, M. 2008. A phase I trial of intratumoral 
administration of reovirus in patients with histologically confirmed recurrent 
malignant gliomas. Mol Ther. 16(3), pp.627-632. 
Gagez, A.L. and Cartron, G. 2014. Obinutuzumab: a new class of anti-CD20 
monoclonal antibody. Curr Opin Oncol. 26(5), pp.484-491. 
Galanis, E., Markovic, S.N., Suman, V.J., Nuovo, G.J., Vile, R.G., Kottke, T.J., 
Nevala, W.K., Thompson, M.A., Lewis, J.E., Rumilla, K.M., Roulstone, V., 
Harrington, K., Linette, G.P., Maples, W.J., Coffey, M., Zwiebel, J. and Kendra, 
K. 2012. Phase II trial of intravenous administration of Reolysin((R)) (Reovirus 
Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther. 
20(10), pp.1998-2003. 
Galizia, G., Lieto, E., De Vita, F., Orditura, M., Castellano, P., Troiani, T., 
Imperatore, V. and Ciardiello, F. 2007. Cetuximab, a chimeric human mouse 
anti-epidermal growth factor receptor monoclonal antibody, in the treatment of 
human colorectal cancer. Oncogene. 26(25), pp.3654-3660. 
Godeny, E.K. and Gauntt, C.J. 1987. Interferon and natural killer cell activity in 
coxsackie virus B3-induced murine myocarditis. European Heart Journal. 
8(suppl_J), pp.433-435. 
Gollamudi, R., Ghalib, M.H., Desai, K.K., Chaudhary, I., Wong, B., Einstein, M., 
Coffey, M., Gill, G.M., Mettinger, K., Mariadason, J.M., Mani, S. and Goel, S. 
2010. Intravenous administration of Reolysin, a live replication competent RNA 
virus is safe in patients with advanced solid tumors. Invest New Drugs. 28(5), 
pp.641-649. 
Good, D.J. and Gascoyne, R.D. 2008. Classification of non-Hodgkin's 
lymphoma. Hematol Oncol Clin North Am. 22(5), pp.781-805, vii. 
Groninger, E., Meeuwsen-De Boer, G.J., De Graaf, S.S., Kamps, W.A. and De 
Bont, E.S. 2002. Vincristine induced apoptosis in acute lymphoblastic 
leukaemia cells: a mitochondrial controlled pathway regulated by reactive 
oxygen species? Int J Oncol. 21(6), pp.1339-1345. 
Grote, D., Russell, S.J., Cornu, T.I., Cattaneo, R., Vile, R., Poland, G.A. and 
Fielding, A.K. 2001. Live attenuated measles virus induces regression of human 
lymphoma xenografts in immunodeficient mice. Blood. 97(12), pp.3746-3754. 
Gu, L., Xie, L., Zuo, C., Ma, Z., Zhang, Y., Zhu, Y. and Gao, J. 2015. Targeting 
mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity 
to 4E-BP1 null Burkitt Lymphoma. BMC Cancer. 15, p529. 
Gu, Y., Albuquerque, C.P., Braas, D., Zhang, W., Villa, G.R., Bi, J., Ikegami, S., 
Masui, K., Gini, B., Yang, H., Gahman, T.C., Shiau, A.K., Cloughesy, T.F., 
Christofk, H.R., Zhou, H., Guan, K.L. and Mischel, P.S. 2017. mTORC2 
Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-
Glutamate Antiporter xCT. Mol Cell. 67(1), pp.128-138.e127. 
207 
 
Guertin, D.A. and Sabatini, D.M. 2009. The pharmacology of mTOR inhibition. 
Sci Signal. 2(67), ppe24. 
Guglielmelli, T., Giugliano, E., Brunetto, V., Rapa, I., Cappia, S., Giorcelli, J., 
Rrodhe, S., Papotti, M. and Saglio, G. 2015. mTOR pathway activation in 
multiple myeloma cell lines and primary tumour cells: pomalidomide enhances 
cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience. 2(4), pp.382-394. 
Gujar, S., Dielschneider, R., Clements, D., Helson, E., Shmulevitz, M., Marcato, 
P., Pan, D., Pan, L.Z., Ahn, D.G., Alawadhi, A. and Lee, P.W. 2013. 
Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through 
virus-induced immunomodulation. Mol Ther. 21(2), pp.338-347. 
Gujar, S.A., Pan, D.A., Marcato, P., Garant, K.A. and Lee, P.W. 2011. Oncolytic 
virus-initiated protective immunity against prostate cancer. Mol Ther. 19(4), 
pp.797-804. 
Guri, Y., Colombi, M., Dazert, E., Hindupur, S.K., Roszik, J., Moes, S., Jenoe, 
P., Heim, M.H., Riezman, I., Riezman, H. and Hall, M.N. 2017. mTORC2 
Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell. 32(6), pp.807-
823.e812. 
Hadac, E.M. and Russell, S.J. 2006. 436. Coxsackievirus A21 Has Potent 
Oncolytic Activity in Multiple Myeloma. Molecular Therapy. 13, pS168. 
Hall, K., Scott, K.J., Rose, A., Desborough, M., Harrington, K., Pandha, H., 
Parrish, C., Vile, R., Coffey, M., Bowen, D., Errington-Mais, F. and Melcher, 
A.A. 2012. Reovirus-mediated cytotoxicity and enhancement of innate immune 
responses against acute myeloid leukemia. Biores Open Access. 1(1), pp.3-15. 
Hansmann, L., Groeger, S., von Wulffen, W., Bein, G. and Hackstein, H. 2008. 
Human monocytes represent a competitive source of interferon-alpha in 
peripheral blood. Clin Immunol. 127(2), pp.252-264. 
Hardy, R.R. and Hayakawa, K. 2001. B Cell Development Pathways. Annual 
Review of Immunology. 19(1), pp.595-621. 
Hashiro, G., Loh, P.C. and Yau, J.T. 1977. The preferential cytotoxicity of 
reovirus for certain transformed cell lines. Arch Virol. 54(4), pp.307-315. 
Hastie, E. and Grdzelishvili, V.Z. 2012. Vesicular stomatitis virus as a flexible 
platform for oncolytic virotherapy against cancer. J Gen Virol. 93(Pt 12), 
pp.2529-2545. 
Hausch, F., Kozany, C., Theodoropoulou, M. and Fabian, A.-K. 2013. FKBPs 
and the Akt/mTOR pathway. Cell Cycle. 12(15), pp.2366-2370. 
Hernandez-Ilizaliturri, F.J., Jupudy, V., Ostberg, J., Oflazoglu, E., Huberman, A., 
Repasky, E. and Czuczman, M.S. 2003. Neutrophils contribute to the biological 
antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined 
immunodeficiency mouse model. Clin Cancer Res. 9(16 Pt 1), pp.5866-5873. 
Hiddemann, W. and Cheson, B.D. 2014. How we manage follicular lymphoma. 
Leukemia. 28(7), pp.1388-1395. 
Ho, A.D., Moritz, T., Rensch, K., Hunstein, W. and Kirchner, H. 1988. Deficiency 
in interferon production of peripheral blood leukocytes from patients with non-
Hodgkin lymphoma. J Interferon Res. 8(4), pp.405-413. 
Ho, A.D., Moritz, T., Rensch, K., Hunstein, W. and Kirchner, H. 1992. Deficiency 
in interferon production of peripheral blood leukocytes from patients with non-
Hodgkin lymphoma. J Interferon Res. Spec No, pp.61-69. 
Hoelzer, D., Walewski, J., Döhner, H., Schmid, M., Hiddemann, W., Baumann, 
A., Serve, H., Dührsen, U., HÃ¼ttmann, A., Thiel, E., Dengler, J., Kneba, M., 
Schuler, M., Schmidt-Wolf, I., Beck, J., Hertenstein, B., Reichle, A., Domanska-
208 
 
Czyz, K., Fietkau, R., Horst, H.-A., Rieder, H., Schwartz, S., Burmeister, T. and 
Goekbuget, N. 2012. Substantially Improved Outcome of Adult Burkitt Non-
Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-
Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial. 
Blood. 120(21), pp.667-667. 
Holland, J. and Owens, T. 1997. Signaling through Intercellular Adhesion 
Molecule 1 (ICAM-1) in a B Cell Lymphoma Line: THE ACTIVATION OF Lyn 
TYROSINE KINASE AND THE MITOGEN-ACTIVATED PROTEIN KINASE 
PATHWAY. Journal of Biological Chemistry. 272(14), pp.9108-9112. 
Hollender, A., Kvaloy, S., Nome, O., Skovlund, E., Lote, K. and Holte, H. 2002. 
Central nervous system involvement following diagnosis of non-Hodgkin's 
lymphoma: a risk model. Ann Oncol. 13(7), pp.1099-1107. 
Homicsko, K., Lukashev, A. and Iggo, R.D. 2005. RAD001 (everolimus) 
improves the efficacy of replicating adenoviruses that target colon cancer. 
Cancer Res. 65(15), pp.6882-6890. 
Horwitz, M.S., Krahl, T., Fine, C., Lee, J. and Sarvetnick, N. 1999. Protection 
from lethal coxsackievirus-induced pancreatitis by expression of gamma 
interferon. J Virol. 73(3), pp.1756-1766. 
Howells, A., Marelli, G., Lemoine, N.R. and Wang, Y. 2017. Oncolytic Viruses-
Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front 
Oncol. 7, p195. 
Hubbard, A.K. and Rothlein, R. 2000. Intercellular adhesion molecule-1 (ICAM-
1) expression and cell signaling cascades. Free Radic Biol Med. 28(9), 
pp.1379-1386. 
Hwang, H.Y., Kim, J.Y., Lim, J.Y., Chung, S.K., Nam, J.H. and Park, S.I. 2007. 
Coxsackievirus B3 modulates cell death by downregulating activating 
transcription factor 3 in HeLa cells. Virus Res. 130(1-2), pp.10-17. 
Hwang, M.H., Li, X.J., Kim, J.E., Jeong, S.Y., Lee, S.W., Lee, J. and Ahn, B.C. 
2015. Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-
Resistant Breast Cancer Cells In Vitro. PLoS One. 10(8), pe0136209. 
Ilett, E.J., Prestwich, R.J., Kottke, T., Errington, F., Thompson, J.M., Harrington, 
K.J., Pandha, H.S., Coffey, M., Selby, P.J., Vile, R.G. and Melcher, A.A. 2009. 
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite 
pre-existing anti-viral immunity. Gene Ther. 16(5), pp.689-699. 
Ilkow, C.S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., 
Cousineau, S., Falls, T., Jennings, V.A., Boileau, M., Bellamy, D., Bastin, D., de 
Souza, C.T., Alkayyal, A., Zhang, J., Le Boeuf, F., Arulanandam, R., Stubbert, 
L., Sampath, P., Thorne, S.H., Paramanthan, P., Chatterjee, A., Strieter, R.M., 
Burdick, M., Addison, C.L., Stojdl, D.F., Atkins, H.L., Auer, R.C., Diallo, J.S., 
Lichty, B.D. and Bell, J.C. 2015. Reciprocal cellular cross-talk within the tumor 
microenvironment promotes oncolytic virus activity. Nat Med. 21(5), pp.530-536. 
Iqbal, J., Sanger, W.G., Horsman, D.E., Rosenwald, A., Pickering, D.L., Dave, 
B., Dave, S., Xiao, L., Cao, K., Zhu, Q., Sherman, S., Hans, C.P., 
Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Ott, G., Muller-Hermelink, 
H.K., Delabie, J., Braziel, R.M., Jaffe, E.S., Campo, E., Lynch, J.C., Connors, 
J.M., Vose, J.M., Armitage, J.O., Grogan, T.M., Staudt, L.M. and Chan, W.C. 
2004. BCL2 translocation defines a unique tumor subset within the germinal 
center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 165(1), pp.159-
166. 
209 
 
Israelsson, S., Jonsson, N., Gullberg, M. and Lindberg, A.M. 2011. Cytolytic 
replication of echoviruses in colon cancer cell lines. Virol J. 8, p473. 
Izumi, T. and Ozawa, K. 2000. [Clinical staging classification of non-Hodgkin's 
lymphoma]. Nihon Rinsho. 58(3), pp.598-601. 
Janeway CA Jr, T.P., Walport M, et al. 2001. B-cell activation by armed helper T 
cells. Immunobiology: The Immune System in Health and Disease. 5th edition. 
Jazirehi, A.R., Vega, M.I., Chatterjee, D., Goodglick, L. and Bonavida, B. 2004. 
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-
regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by 
Rituximab. Cancer Res. 64(19), pp.7117-7126. 
Jennifer, A., John, L.R., Andrea, B., Iñaki, S. and Fay, Y. 2003. Down‐regulation 
of CD20 on B cells upon CD40 activation. European Journal of Immunology. 
33(9), pp.2398-2409. 
Jhawar, S.R., Thandoni, A., Bommareddy, P.K., Hassan, S., Kohlhapp, F.J., 
Goyal, S., Schenkel, J.M., Silk, A.W. and Zloza, A. 2017. Oncolytic Viruses-
Natural and Genetically Engineered Cancer Immunotherapies. Front Oncol. 7, 
p202. 
Jiang, Z.K., Johnson, M., Moughon, D.L., Kuo, J., Sato, M. and Wu, L. 2013. 
Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-
immunized murine hosts. PLoS One. 8(9), pe73650. 
Johansson, E.S., Xing, L., Cheng, R.H. and Shafren, D.R. 2004. Enhanced 
cellular receptor usage by a bioselected variant of coxsackievirus a21. J Virol. 
78(22), pp.12603-12612. 
Jordan, M.A. and Wilson, L. 2004. Microtubules as a target for anticancer drugs. 
Nature Reviews Cancer. 4, p253. 
Jurianz, K., Ziegler, S., Garcia-Schuler, H., Kraus, S., Bohana-Kashtan, O., 
Fishelson, Z. and Kirschfink, M. 1999. Complement resistance of tumor cells: 
basal and induced mechanisms. Mol Immunol. 36(13-14), pp.929-939. 
Kahn, S.T., Flowers, C.R., Lechowicz, M.J., Hollenbach, K. and Johnstone, P.A. 
2005. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: 
optimizing involved-field radiotherapy in transplant patients. Cancer J. 11(5), 
pp.425-431. 
Karapanagiotou, E.M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, 
C., Newbold, K., Gore, M.E., Larkin, J., Syrigos, K.N., Coffey, M., Thompson, 
B., Mettinger, K., Vile, R.G., Pandha, H.S., Hall, G.D., Melcher, A.A., Chester, J. 
and Harrington, K.J. 2012. Phase I/II trial of carboplatin and paclitaxel 
chemotherapy in combination with intravenous oncolytic reovirus in patients 
with advanced malignancies. Clin Cancer Res. 18(7), pp.2080-2089. 
Karnad, A.B., Haigentz, M., Miley, T., Coffey, M., Gill, G. and Mita, M. 2011. 
Abstract C22: A phase II study of intravenous wild-type reovirus (Reolysin®) in 
combination with paclitaxel plus carboplatin in patients with platinum refractory 
metastatic and/or recurrent squamous cell carcinoma of the head and neck. 
Molecular Cancer Therapeutics. 10(11 Supplement), pp.C22-C22. 
Kater, A.P., Evers, L.M., Remmerswaal, E.B., Jaspers, A., Oosterwijk, M.F., van 
Lier, R.A., van Oers, M.H. and Eldering, E. 2004. CD40 stimulation of B-cell 
chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but 
also Bid expression and cells remain susceptible to autologous cytotoxic T-
lymphocyte attack. Br J Haematol. 127(4), pp.404-415. 
Kaufman, H.L., Kim, D.W., DeRaffele, G., Mitcham, J., Coffin, R.S. and Kim-
Schulze, S. 2010. Local and distant immunity induced by intralesional 
210 
 
vaccination with an oncolytic herpes virus encoding GM-CSF in patients with 
stage IIIc and IV melanoma. Ann Surg Oncol. 17(3), pp.718-730. 
Kaufman, H.L., Kohlhapp, F.J. and Zloza, A. 2015. Oncolytic viruses: a new 
class of immunotherapy drugs. Nat Rev Drug Discov. 14(9), pp.642-662. 
Kawauchi, K., Ogasawara, T. and Yasuyama, M. 2002. Activation of 
extracellular signal-regulated kinase through B-cell antigen receptor in B-cell 
chronic lymphocytic leukemia. Int J Hematol. 75(5), pp.508-513. 
Kelly, E. and Russell, S.J. 2007. History of oncolytic viruses: genesis to genetic 
engineering. Mol Ther. 15(4), pp.651-659. 
Kennedy, N.D., Le, G.N., Kelly, M.E., Harding, T., Fadalla, K. and Winter, D.C. 
2018. Surgical management of splenic marginal zone lymphoma. Ir J Med Sci. 
187(2), pp.343-347. 
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., 
Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., Bracci, L., Breckpot, K., Brough, 
D., Buqué, A., Castro, M.G., Cirone, M., Colombo, M.I., Cremer, I., Demaria, S., 
Dini, L., Eliopoulos, A.G., Faggioni, A., Formenti, S.C., Fučíková, J., Gabriele, 
L., Gaipl, U.S., Galon, J., Garg, A., Ghiringhelli, F., Giese, N.A., Guo, Z.S., 
Hemminki, A., Herrmann, M., Hodge, J.W., Holdenrieder, S., Honeychurch, J., 
Hu, H.-M., Huang, X., Illidge, T.M., Kono, K., Korbelik, M., Krysko, D.V., Loi, S., 
Lowenstein, P.R., Lugli, E., Ma, Y., Madeo, F., Manfredi, A.A., Martins, I., 
Mavilio, D., Menger, L., Merendino, N., Michaud, M., Mignot, G., Mossman, 
K.L., Multhoff, G., Oehler, R., Palombo, F., Panaretakis, T., Pol, J., Proietti, E., 
Ricci, J.-E., Riganti, C., Rovere-Querini, P., Rubartelli, A., Sistigu, A., Smyth, 
M.J., Sonnemann, J., Spisek, R., Stagg, J., Sukkurwala, A.Q., Tartour, E., 
Thorburn, A., Thorne, S.H., Vandenabeele, P., Velotti, F., Workenhe, S.T., 
Yang, H., Zong, W.-X., Zitvogel, L., Kroemer, G. and Galluzzi, L. 2014. 
Consensus guidelines for the detection of immunogenic cell death. 
Oncoimmunology. 3(9), pe955691. 
Kern, D.J., James, B.R., Blackwell, S., Gassner, C., Klein, C. and Weiner, G.J. 
2013. GA101 induces NK-cell activation and antibody-dependent cellular 
cytotoxicity more effectively than rituximab when complement is present. Leuk 
Lymphoma. 54(11), pp.2500-2505. 
Kheirallah, S., Caron, P., Gross, E., Quillet-Mary, A., Bertrand-Michel, J., 
Fournie, J.J., Laurent, G. and Bezombes, C. 2010. Rituximab inhibits B-cell 
receptor signaling. Blood. 115(5), pp.985-994. 
Kim, M., Williamson, C.T., Prudhomme, J., Bebb, D.G., Riabowol, K., Lee, 
P.W., Lees-Miller, S.P., Mori, Y., Rahman, M.M., McFadden, G. and Johnston, 
R.N. 2010. The viral tropism of two distinct oncolytic viruses, reovirus and 
myxoma virus, is modulated by cellular tumor suppressor gene status. 
Oncogene. 29(27), pp.3990-3996. 
Kinoshita, T. 1998. Decay-Accelerating Factor (CD55) A2 - Delves, Peter J. 
Encyclopedia of Immunology (Second Edition).  Oxford: Elsevier, pp.735-736. 
Kitada, S., Zapata, J.M., Andreeff, M. and Reed, J.C. 1999. Bryostatin and 
CD40-ligand enhance apoptosis resistance and induce expression of cell 
survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 106(4), 
pp.995-1004. 
Klein, K.A. and Jackson, W.T. 2011. Picornavirus subversion of the autophagy 
pathway. Viruses. 3(9), pp.1549-1561. 
Klimpel, G.R., Infante, A.J., Patterson, J., Hess, C.B. and Asuncion, M. 1990. 
Virus-induced interferon alpha/beta (IFN-alpha/beta) production by T cells and 
211 
 
by Th1 and Th2 helper T cell clones: a study of the immunoregulatory actions of 
IFN-gamma versus IFN-alpha/beta on functions of different T cell populations. 
Cell Immunol. 128(2), pp.603-618. 
Kober, C., Weibel, S., Rohn, S., Kirscher, L. and Szalay, A.A. 2015. 
Intratumoral INF-gamma triggers an antiviral state in GL261 tumor cells: a major 
hurdle to overcome for oncolytic vaccinia virus therapy of cancer. Mol Ther 
Oncolytics. 2, p15009. 
Kohlhapp, F.J., Zloza, A. and Kaufman, H.L. 2015. Talimogene laherparepvec 
(T-VEC) as cancer immunotherapy. Drugs Today (Barc). 51(9), pp.549-558. 
Korniluk, A., Kemona, H. and Dymicka-Piekarska, V. 2014. Multifunctional 
CD40L: pro- and anti-neoplastic activity. Tumour Biol. 35(10), pp.9447-9457. 
Koues, O.I., Oltz, E.M. and Payton, J.E. 2015. Short-Circuiting Gene Regulatory 
Networks: Origins of B Cell Lymphoma. Trends in Genetics. 31(12), pp.720-
731. 
Kratky, W., Reis e Sousa, C., Oxenius, A. and Sporri, R. 2011. Direct activation 
of antigen-presenting cells is required for CD8+ T-cell priming and tumor 
vaccination. Proc Natl Acad Sci U S A. 108(42), pp.17414-17419. 
Kuo, S.-H., Hsu, C.-H., Chen, L.-T., Lu, Y.-S., Lin, C.-H., Yeh, P.-Y., Jeng, H.-J., 
Gao, M., Yeh, K.-H. and Cheng, A.-L. 2011. Lack of compensatory pAKT 
activation and eIF4E phosphorylation of lymphoma cells towards mTOR 
inhibitor, RAD001. European Journal of Cancer. 47(8), pp.1244-1257. 
Kurland, J.F., Voehringer, D.W. and Meyn, R.E. 2003. The MEK/ERK pathway 
acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in 
a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced 
apoptosis. J Biol Chem. 278(34), pp.32465-32470. 
Labiotech.eu. 2015. The First Ever Oncolytic Immunotherapy is Set to Reach 
the European Market. 
Le Sage, V., Cinti, A., Amorim, R. and Mouland, A.J. 2016. Adapting the Stress 
Response: Viral Subversion of the mTOR Signaling Pathway. Viruses. 8(6). 
Lee, J.W., Yoo, N.J., Soung, Y.H., Kim, H.S., Park, W.S., Kim, S.Y., Lee, J.H., 
Park, J.Y., Cho, Y.G., Kim, C.J., Ko, Y.H., Kim, S.H., Nam, S.W., Lee, J.Y. and 
Lee, S.H. 2003. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer. 
89(10), pp.1958-1960. 
Lee, S.W., Cho, H.Y., Na, G., Yoo, M.R., Seo, S.K., Hur, D.Y., Han, J., Lee, 
C.K. and Choi, I. 2012. CD40 stimulation induces vincristine resistance via AKT 
activation and MRP1 expression in a human multiple myeloma cell line. 
Immunol Lett. 144(1-2), pp.41-48. 
Lehmann, C., Lafferty, M., Garzino-Demo, A., Jung, N., Hartmann, P., 
Fatkenheuer, G., Wolf, J.S., van Lunzen, J. and Romerio, F. 2010. 
Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph 
nodes of HIV-1 patients. PLoS One. 5(6), pe11110. 
Lei, X., Sun, Z., Liu, X., Jin, Q., He, B. and Wang, J. 2011. Cleavage of the 
adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated 
by Toll-like receptor 3. J Virol. 85(17), pp.8811-8818. 
Lennette, E.H., Fox, V.L., Schmidt, N.J. and Culver, J.O. 1958. The Coe virus: 
an apparently new virus recovered from patients with mild respiratory disease. 
Am J Hyg. 68(3), pp.272-287. 
Leopoldo, S.A., Ikuri, A.M., Héctor, R.R. and Leopoldo, F.R. 2001. Enforced 
and prolonged CD40 ligand expression triggers autoantibody production in vivo. 
European Journal of Immunology. 31(12), pp.3484-3492. 
212 
 
Leroy, K., Haioun, C., Lepage, E., Le Métayer, N., Berger, F., Labouyrie, E., 
Meignin, V., Petit, B., Bastard, C., Salles, G., Gisselbrecht, C., Reyes, F. and 
Gaulard, P. 2002. p53 gene mutations are associated with poor survival in low 
and low-intermediate risk diffuse large B-cell lymphomas. Annals of Oncology. 
13(7), pp.1108-1115. 
Lesokhin, A.M., Ansell, S.M., Armand, P., Scott, E.C., Halwani, A., Gutierrez, 
M., Millenson, M.M., Cohen, A.D., Schuster, S.J., Lebovic, D., Dhodapkar, M., 
Avigan, D., Chapuy, B., Ligon, A.H., Freeman, G.J., Rodig, S.J., Cattry, D., Zhu, 
L., Grosso, J.F., Bradley Garelik, M.B., Shipp, M.A., Borrello, I. and 
Timmerman, J. 2016. Nivolumab in Patients With Relapsed or Refractory 
Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 
34(23), pp.2698-2704. 
Levine, B. 2005. Eating oneself and uninvited guests: autophagy-related 
pathways in cellular defense. Cell. 120(2), pp.159-162. 
Li, X., Wang, P., Li, H., Du, X., Liu, M., Huang, Q., Wang, Y. and Wang, S. 
2017. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses 
against Virus and Tumor in Syrian Hamster Model. Clin Cancer Res. 23(1), 
pp.239-249. 
Li, Z.S., Shao, Z.H., Fu, R., Wang, J., Li, L.J., Zhang, T., Wang, H.Q., Wu, Y.H., 
Ruan, E.B., Song, J., Qu, W., Liu, H., Xing, L.M., Wang, X.M., Liang, Y., Guan, 
J. and Wang, G.J. 2011. [Percentages and functions of natural killer cell 
subsets in peripheral blood of patients with severe aplastic anemia]. Zhonghua 
Yi Xue Za Zhi. 91(16), pp.1084-1087. 
Lichty, B.D., Breitbach, C.J., Stojdl, D.F. and Bell, J.C. 2014. Going viral with 
cancer immunotherapy. Nat Rev Cancer. 14(8), pp.559-567. 
Lichty, B.D., Stojdl, D.F., Taylor, R.A., Miller, L., Frenkel, I., Atkins, H. and Bell, 
J.C. 2004. Vesicular stomatitis virus: a potential therapeutic virus for the 
treatment of hematologic malignancy. Hum Gene Ther. 15(9), pp.821-831. 
Lim, S.H., Beers, S.A., French, R.R., Johnson, P.W., Glennie, M.J. and Cragg, 
M.S. 2010. Anti-CD20 monoclonal antibodies: historical and future perspectives. 
Haematologica. 95(1), pp.135-143. 
Lind, K., Svedin, E., Domsgen, E., Kapell, S., Laitinen, O., Moll, M. and 
Flodstrom-Tullberg, M. 2016. Coxsackievirus counters the host innate immune 
response by blocking type III interferon expression. J Gen Virol. 97(6), pp.1-12. 
Liu, Y.-P., Suksanpaisan, L., Steele, M.B., Russell, S.J. and Peng, K.-W. 2013. 
Induction of antiviral genes by the tumor microenvironment confers resistance 
to virotherapy. Scientific Reports. 3, p2375. 
Ljunggren, H.G. and Karre, K. 1990. In search of the 'missing self': MHC 
molecules and NK cell recognition. Immunol Today. 11(7), pp.237-244. 
Lolkema, M.P., Arkenau, H.T., Harrington, K., Roxburgh, P., Morrison, R., 
Roulstone, V., Twigger, K., Coffey, M., Mettinger, K., Gill, G., Evans, T.R. and 
de Bono, J.S. 2011. A phase I study of the combination of intravenous reovirus 
type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer 
Res. 17(3), pp.581-588. 
Lopez, M., Aoubala, M., Jordier, F., Isnardon, D., Gomez, S. and Dubreuil, P. 
1998. The human poliovirus receptor related 2 protein is a new 
hematopoietic/endothelial homophilic adhesion molecule. Blood. 92(12), 
pp.4602-4611. 
Lord, S.J., Rajotte, R.V., Korbutt, G.S. and Bleackley, R.C. 2003. Granzyme B: 
a natural born killer. Immunol Rev. 193, pp.31-38. 
213 
 
Lukes, R.J. and Collins, R.D. 1975. New approaches to the classification of the 
lymphomata. Br J Cancer Suppl. 2, pp.1-28. 
Lun, X., Alain, T., Zemp, F.J., Zhou, H., Rahman, M.M., Hamilton, M.G., 
McFadden, G., Bell, J., Senger, D.L. and Forsyth, P.A. 2010. Myxoma Virus 
Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing 
Administration Routes and Synergy with Rapamycin. Cancer Research. 70(2), 
pp.598-608. 
Magnuson, B., Ekim, B. and Fingar, D.C. 2012. Regulation and function of 
ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem 
J. 441(1), pp.1-21. 
Mahauad-Fernandez, W.D. and Okeoma, C.M. 2016. The role of BST-
2/Tetherin in host protection and disease manifestation. Immun Inflamm Dis. 
4(1), pp.4-23. 
Maitra, R., Augustine, T., Dayan, Y., Chandy, C., Coffey, M. and Goel, S. 2017. 
Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal 
cancer. Oncotarget. 8(21), pp.35138-35153. 
Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D. and Lee, P.W. 2007. Ras 
transformation mediates reovirus oncolysis by enhancing virus uncoating, 
particle infectivity, and apoptosis-dependent release. Mol Ther. 15(8), pp.1522-
1530. 
Marsh, M. and Helenius, A. 2006. Virus Entry: Open Sesame. Cell. 124(4), 
pp.729-740. 
Medina, D.J., Sheay, W., Osman, M., Goodell, L., Martin, J., Rabson, A.B. and 
Strair, R.K. 2005. Adenovirus infection and cytotoxicity of primary mantle cell 
lymphoma cells. Exp Hematol. 33(11), pp.1337-1347. 
Menon, M.P., Pittaluga, S. and Jaffe, E.S. 2012. The histological and biological 
spectrum of diffuse large B-cell lymphoma in the World Health Organization 
classification. Cancer J. 18(5), pp.411-420. 
Miller, C.G. and Fraser, N.W. 2003. Requirement of an integrated immune 
response for successful neuroattenuated HSV-1 therapy in an intracranial 
metastatic melanoma model. Mol Ther. 7(6), pp.741-747. 
Minuk, G.Y., Paul, R.W. and Lee, P.W. 1985. The prevalence of antibodies to 
reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol. 
16(1), pp.55-60. 
Mita, A.C., Argiris, A., Coffey, M., Gill, G. and Mita, M. 2013. Abstract C70: A 
phase 2 study of intravenous administration of REOLYSIN® (reovirus type 3 
dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with 
squamous cell carcinoma of the lung. Molecular Cancer Therapeutics. 12(11 
Supplement), pp.C70-C70. 
Miyamoto, S., Inoue, H., Nakamura, T., Yamada, M., Sakamoto, C., Urata, Y., 
Okazaki, T., Marumoto, T., Takahashi, A., Takayama, K., Nakanishi, Y., 
Shimizu, H. and Tani, K. 2012. Coxsackievirus B3 is an oncolytic virus with 
immunostimulatory properties that is active against lung adenocarcinoma. 
Cancer Res. 72(10), pp.2609-2621. 
Moody, C.A., Scott, R.S., Amirghahari, N., Nathan, C.O., Young, L.S., Dawson, 
C.W. and Sixbey, J.W. 2005. Modulation of the cell growth regulator mTOR by 
Epstein-Barr virus-encoded LMP2A. J Virol. 79(9), pp.5499-5506. 
Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., Corbett, 
R.D., Johnson, N.A., Severson, T.M., Chiu, R., Field, M., Jackman, S., 
Krzywinski, M., Scott, D.W., Trinh, D.L., Tamura-Wells, J., Li, S., Firme, M.R., 
214 
 
Rogic, S., Griffith, M., Chan, S., Yakovenko, O., Meyer, I.M., Zhao, E.Y., 
Smailus, D., Moksa, M., Chittaranjan, S., Rimsza, L., Brooks-Wilson, A., 
Spinelli, J.J., Ben-Neriah, S., Meissner, B., Woolcock, B., Boyle, M., McDonald, 
H., Tam, A., Zhao, Y., Delaney, A., Zeng, T., Tse, K., Butterfield, Y., Birol, I., 
Holt, R., Schein, J., Horsman, D.E., Moore, R., Jones, S.J., Connors, J.M., 
Hirst, M., Gascoyne, R.D. and Marra, M.A. 2011. Frequent mutation of histone-
modifying genes in non-Hodgkin lymphoma. Nature. 476(7360), pp.298-303. 
Morris, D., Tu, D., Tehfe, M.A., Nicholas, G.A., Goffin, J.R., Gregg, R.W., 
Shepherd, F.A., Murray, N., Wierzbicki, R., Lee, C.W., Kuruvilla, S., Keith, B., 
Ahmed, A., Blais, N., Goss, G.D., Korpanty, G., Sederias, J., Laurie, S.A., 
Seymour, L. and Bradbury, P.A. 2016. A Randomized Phase II study of 
Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small 
Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – 
Canadian Cancer Trials Group IND 211. Journal of Clinical Oncology. 
34(15_suppl), pp.e20512-e20512. 
Mortola, E., Endo, Y., Ohno, K., Watari, T., Tsujimoto, H. and Hasegawa, A. 
1998. The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, 
to inhibit virus replication and apoptosis in cells infected with feline 
immunodeficiency virus. Vet Res Commun. 22(8), pp.553-563. 
Mounier, N., Briere, J., Gisselbrecht, C., Emile, J.F., Lederlin, P., Sebban, C., 
Berger, F., Bosly, A., Morel, P., Tilly, H., Bouabdallah, R., Reyes, F., Gaulard, 
P. and Coiffier, B. 2003. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--
associated resistance to chemotherapy in elderly patients with diffuse large B-
cell lymphoma (DLBCL). Blood. 101(11), pp.4279-4284. 
Mukherjee, A., Morosky, S.A., Delorme-Axford, E., Dybdahl-Sissoko, N., 
Oberste, M.S., Wang, T. and Coyne, C.B. 2011. The coxsackievirus B 3C 
protease cleaves MAVS and TRIF to attenuate host type I interferon and 
apoptotic signaling. PLoS Pathog. 7(3), pe1001311. 
Muro, S., Wiewrodt, R., Thomas, A., Koniaris, L., Albelda, S.M., Muzykantov, 
V.R. and Koval, M. 2003. A novel endocytic pathway induced by clustering 
endothelial ICAM-1 or PECAM-1. J Cell Sci. 116(Pt 8), pp.1599-1609. 
Muster, T., Rajtarova, J., Sachet, M., Unger, H., Fleischhacker, R., Romirer, I., 
Grassauer, A., Url, A., Garcia-Sastre, A., Wolff, K., Pehamberger, H. and 
Bergmann, M. 2004. Interferon resistance promotes oncolysis by influenza virus 
NS1-deletion mutants. Int J Cancer. 110(1), pp.15-21. 
Newcombe, N.G., Johansson, E.S., Au, G., Lindberg, A.M., Barry, R.D. and 
Shafren, D.R. 2004. Enterovirus capsid interactions with decay-accelerating 
factor mediate lytic cell infection. J Virol. 78(3), pp.1431-1439. 
Nicola E Annels, G.S., Mehreen Arif, Mick Denyer, Attya Iqbal, David Mansfield, 
Sarbjinder Sandhu, Alan Melcher, Kevin Harrington, Gough Au, Mark Grose, 
Darren Shafren, Hugh Mostafid, and Hardev Pandha. 2015. Oncolytic 
immunotherapy for the treatment of non-muscle invasive bladder cancer using 
intravesical coxsackievirus A21. Journal for Immunotherapy of Cancer. 3. 
Noonan, A.M., Farren, M.R., Geyer, S.M., Huang, Y., Tahiri, S., Ahn, D., 
Mikhail, S., Ciombor, K.K., Pant, S., Aparo, S., Sexton, J., Marshall, J.L., Mace, 
T.A., Wu, C.S., El-Rayes, B., Timmers, C.D., Zwiebel, J., Lesinski, G.B., 
Villalona-Calero, M.A. and Bekaii-Saab, T.S. 2016. Randomized Phase 2 Trial 
of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic 
Pancreatic Adenocarcinoma. Mol Ther. 24(6), pp.1150-1158. 
215 
 
O'Shea, C., Klupsch, K., Choi, S., Bagus, B., Soria, C., Shen, J., McCormick, F. 
and Stokoe, D. 2005. Adenoviral proteins mimic nutrient/growth signals to 
activate the mTOR pathway for viral replication. Embo j. 24(6), pp.1211-1221. 
Ochiai, H., Campbell, S.A., Archer, G.E., Chewning, T.A., Dragunsky, E., 
Ivanov, A., Gromeier, M. and Sampson, J.H. 2006. Targeted therapy for 
glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an 
oncolytic recombinant poliovirus. Clin Cancer Res. 12(4), pp.1349-1354. 
Ochiai, K., Kagami, M., Nakazawa, T., Sugiyama, T., Sueishi, M., Ito, M. and 
Tomioka, H. 2000. Regulation of CD69 expression on eosinophil precursors by 
interferon-gamma. Int Arch Allergy Immunol. 122 Suppl 1, pp.28-32. 
Oflazoglu, E. and Audoly, L.P. 2010. Evolution of anti-CD20 monoclonal 
antibody therapeutics in oncology. MAbs. 2(1), pp.14-19. 
Omar, A.R., Ideris, A., Ali, A.M., Othman, F., Yusoff, K., Abdullah, J.M., Wali, 
H.S., Zawawi, M. and Meyyappan, N. 2003. An overview on the development of 
newcastle disease virus as an anti-cancer therapy. Malays J Med Sci. 10(1), 
pp.4-12. 
Oncozine. 2013. Reolysin Meets Primary Endpoint for First Stage of Phase II 
Metastatic Melanoma Trial. 
Ong, S.T. and Le Beau, M.M. 1998. Chromosomal abnormalities and molecular 
genetics of non-Hodgkin's lymphoma. Semin Oncol. 25(4), pp.447-460. 
Osinska, I., Popko, K. and Demkow, U. 2014. Perforin: an important player in 
immune response. Cent Eur J Immunol. 39(1), pp.109-115. 
Pandha, H., Harrington, K., Ralph, C., Melcher, A., Grose, M. and Shafren, D. 
2015a. Phase I/II storm study: Intravenous delivery of a novel oncolytic 
immunotherapy agent, Coxsackievirus A21, in advanced cancer patients. 
Journal for ImmunoTherapy of Cancer. 3(2), pP341. 
Pandha, H., Harrington, K., Ralph, C., Melcher, A. and Shafren, D.R. 2015b. 
Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy 
agent, CAVATAK, in advanced cancer patients. Cancer Research. 75(15 
Supplement), pp.CT205-CT205. 
Parameswaran, R., Ramakrishnan, P., Moreton, S.A., Xia, Z., Hou, Y., Lee, 
D.A., Gupta, K., deLima, M., Beck, R.C. and Wald, D.N. 2016. Repression of 
GSK3 restores NK cell cytotoxicity in AML patients. Nature Communications. 7, 
p11154. 
Park, M.S., Garcia-Sastre, A., Cros, J.F., Basler, C.F. and Palese, P. 2003. 
Newcastle disease virus V protein is a determinant of host range restriction. J 
Virol. 77(17), pp.9522-9532. 
Parker, A.K., Parker, S., Yokoyama, W.M., Corbett, J.A. and Buller, R.M. 2007. 
Induction of natural killer cell responses by ectromelia virus controls infection. J 
Virol. 81(8), pp.4070-4079. 
Parrish, C., Scott, G.B., Migneco, G., Scott, K.J., Steele, L.P., Ilett, E., West, 
E.J., Hall, K., Selby, P.J., Buchanan, D., Varghese, A., Cragg, M.S., Coffey, M., 
Hillmen, P., Melcher, A.A. and Errington-Mais, F. 2015. Oncolytic reovirus 
enhances rituximab-mediated antibody-dependent cellular cytotoxicity against 
chronic lymphocytic leukaemia. Leukemia. 29(9), pp.1799-1810. 
Pasqualucci, L. and Dalla-Favera, R. 2014. SnapShot: diffuse large B cell 
lymphoma. Cancer Cell. 25(1), pp.132-132.e131. 
Pedersen, I.M., Buhl, A.M., Klausen, P., Geisler, C.H. and Jurlander, J. 2002. 
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic 
216 
 
lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-
dependent mechanism. Blood. 99(4), pp.1314-1319. 
Perry, A.M., Mitrovic, Z. and Chan, W.C. 2012. Biological prognostic markers in 
diffuse large B-cell lymphoma. Cancer Control. 19(3), pp.214-226. 
Phillips, D.C., Xiao, Y., Lam, L.T., Litvinovich, E., Roberts-Rapp, L., Souers, 
A.J. and Leverson, J.D. 2015. Loss in MCL-1 function sensitizes non-Hodgkin's 
lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). 
Blood Cancer J. 5, pe368. 
Pineda, A., Sancho, J.-M., Garcia, O., Esteve, J., Tormo, M., Martinez, P., Vall-
llovera, F., Martino, R., Montesinos, P., Gonzalez-Campos, J., Bergua, J., 
Calbacho, M., Gil, C., Vicent, A., Cladera, A., Hernandez, J., Moreno, M.-J., 
Serrano, A., Alonso, N., García, R., Barba, P., Fernandez, A., Miralles, P., 
Novo, A., Moraleda, J.M., Hernández, J.Á., Abella, E., Sanchez, M., Lopez, M.-
E., Bernal, T., Mateos, M.C., Lavilla, E. and Ribera, J.-M. 2015. Incidence, 
Treatment and Prognosis of Patients with Relapsed Burkitt 
Lymphoma/Leukemia Treated with Specific Chemotherapy or 
Immunochemotherapy in Spain. Blood. 126(23), pp.2723-2723. 
Press, O.W., Unger, J.M., Rimsza, L.M., Friedberg, J.W., LeBlanc, M., 
Czuczman, M.S., Kaminski, M., Braziel, R.M., Spier, C., Gopal, A.K., Maloney, 
D.G., Cheson, B.D., Dakhil, S.R., Miller, T.P. and Fisher, R.I. 2013. Phase III 
randomized intergroup trial of CHOP plus rituximab compared with CHOP 
chemotherapy plus (131)iodine-tositumomab for previously untreated follicular 
non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 31(3), pp.314-320. 
Prestwich, R.J., Errington, F., Ilett, E.J., Morgan, R.S., Scott, K.J., Kottke, T., 
Thompson, J., Morrison, E.E., Harrington, K.J., Pandha, H.S., Selby, P.J., Vile, 
R.G. and Melcher, A.A. 2008. Tumor infection by oncolytic reovirus primes 
adaptive antitumor immunity. Clin Cancer Res. 14(22), pp.7358-7366. 
Prestwich, R.J., Ilett, E.J., Errington, F., Diaz, R.M., Steele, L.P., Kottke, T., 
Thompson, J., Galivo, F., Harrington, K.J., Pandha, H.S., Selby, P.J., Vile, R.G. 
and Melcher, A.A. 2009. Immune-Mediated Antitumor Activity of Reovirus Is 
Required for Therapy and Is Independent of Direct Viral Oncolysis and 
Replication. Clinical Cancer Research. 15(13), pp.4374-4381. 
Qian, W., Liu, J., Tong, Y., Yan, S., Yang, C., Yang, M. and Liu, X. 2008. 
Enhanced antitumor activity by a selective conditionally replicating adenovirus 
combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction 
of apoptosis. Leukemia. 22(2), pp.361-369. 
Qiao, J., Dey, M., Chang, A.L., Kim, J.W., Miska, J., Ling, A., D, M.N., Han, Y., 
Zhang, L. and Lesniak, M.S. 2015. Intratumoral oncolytic adenoviral treatment 
modulates the glioma microenvironment and facilitates systemic tumor-antigen-
specific T cell therapy. Oncoimmunology. 4(8), pe1022302. 
Rahman, A. and Fazal, F. 2009. Hug tightly and say goodbye: role of 
endothelial ICAM-1 in leukocyte transmigration. Antioxid Redox Signal. 11(4), 
pp.823-839. 
Rahmani, M., Aust, M.M., Benson, E.C., Wallace, L., Friedberg, J. and Grant, S. 
2014. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in 
NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. 
Clin Cancer Res. 20(18), pp.4849-4860. 
Rai, S.S. and Wolff, J. 1996. Localization of the vinblastine-binding site on beta-
tubulin. J Biol Chem. 271(25), pp.14707-14711. 
217 
 
Randazzo, B.P., Tal-Singer, R., Zabolotny, J.M., Kesari, S. and Fraser, N.W. 
1997. Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate 
in CV-1 cells due to a translational block that can be overcome by coinfection 
with SV40. J Gen Virol. 78 ( Pt 12), pp.3333-3339. 
Reed, J.C. 2017. Bcl-2 on the brink of breakthroughs in cancer treatment. Cell 
Death And Differentiation. 25, p3. 
Reed, L.J. and Muench, H. 1938. A SIMPLE METHOD OF ESTIMATING FIFTY 
PER CENT ENDPOINTS12. American Journal of Epidemiology. 27(3), pp.493-
497. 
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., 
Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., Cranmer, L.D., Blank, C.U., 
O'Day, S.J., Ascierto, P.A., Salama, A.K., Margolin, K.A., Loquai, C., Eigentler, 
T.K., Gangadhar, T.C., Carlino, M.S., Agarwala, S.S., Moschos, S.J., Sosman, 
J.A., Goldinger, S.M., Shapira-Frommer, R., Gonzalez, R., Kirkwood, J.M., 
Wolchok, J.D., Eggermont, A., Li, X.N., Zhou, W., Zernhelt, A.M., Lis, J., 
Ebbinghaus, S., Kang, S.P. and Daud, A. 2015. Pembrolizumab versus 
investigator-choice chemotherapy for ipilimumab-refractory melanoma 
(KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16(8), 
pp.908-918. 
Robinson, M., Li, B., Ge, Y., Ko, D., Yendluri, S., Harding, T., VanRoey, M., 
Spindler, K.R. and Jooss, K. 2009. Novel immunocompetent murine tumor 
model for evaluation of conditionally replication-competent (oncolytic) murine 
adenoviral vectors. J Virol. 83(8), pp.3450-3462. 
Romano, M.F., Lamberti, A., Tassone, P., Alfinito, F., Costantini, S., Chiurazzi, 
F., Defrance, T., Bonelli, P., Tuccillo, F., Turco, M.C. and Venuta, S. 1998. 
Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic 
Lymphocytic Leukemia Cells. Blood. 92(3), pp.990-995. 
Rosen, L., Hovis, J.F., Mastrota, F.M., Bell, J.A. and Huebner, R.J. 1960. 
Observations on a newly recognized virus (Abney) of the reovirus family. Am J 
Hyg. 71, pp.258-265. 
Rudnicka, D., Oszmiana, A., Finch, D.K., Strickland, I., Schofield, D.J., Lowe, 
D.C., Sleeman, M.A. and Davis, D.M. 2013. Rituximab causes a polarization of 
B cells that augments its therapeutic function in NK-cell-mediated antibody-
dependent cellular cytotoxicity. Blood. 121(23), pp.4694-4702. 
Runkel, L., Pfeffer, L., Lewerenz, M., Monneron, D., Yang, C.H., Murti, A., 
Pellegrini, S., Goelz, S., Uze, G. and Mogensen, K. 1998. Differences in activity 
between alpha and beta type I interferons explored by mutational analysis. J 
Biol Chem. 273(14), pp.8003-8008. 
Sadler, A.J. and Williams, B.R. 2007. Structure and function of the protein 
kinase R. Curr Top Microbiol Immunol. 316, pp.253-292. 
Salles, G.A. 2007. Clinical features, prognosis and treatment of follicular 
lymphoma. Hematology Am Soc Hematol Educ Program. pp.216-225. 
Samson, A., Bentham, M.J., Scott, K., Nuovo, G., Bloy, A., Appleton, E., Adair, 
R.A., Dave, R., Peckham-Cooper, A., Toogood, G., Nagamori, S., Coffey, M., 
Vile, R., Harrington, K., Selby, P., Errington-Mais, F., Melcher, A. and Griffin, S. 
2018. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the 
treatment of liver cancer. 67(3), pp.562-573. 
Sangfelt, O., Erickson, S. and Grander, D. 2000. Mechanisms of interferon-
induced cell cycle arrest. Front Biosci. 5, pp.D479-487. 
218 
 
Sarkar, S., Sabhachandani, P., Ravi, D., Potdar, S., Purvey, S., Beheshti, A., 
Evens, A.M. and Konry, T. 2017. Dynamic Analysis of Human Natural Killer Cell 
Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. 
Frontiers in Immunology. 8, p1736. 
Sasaki, O., Karaki, T. and Imanishi, J. 1986. Protective effect of interferon on 
infections with hand, foot, and mouth disease virus in newborn mice. J Infect 
Dis. 153(3), pp.498-502. 
Saunders, R.N., Metcalfe, M.S. and Nicholson, M.L. 2001. Rapamycin in 
transplantation: a review of the evidence. Kidney Int. 59(1), pp.3-16. 
Sawicki, M.W., Dimasi, N., Natarajan, K., Wang, J., Margulies, D.H. and 
Mariuzza, R.A. 2001. Structural basis of MHC class I recognition by natural 
killer cell receptors. Immunol Rev. 181, pp.52-65. 
Saxton, R.A. and Sabatini, D.M. 2017. mTOR Signaling in Growth, Metabolism, 
and Disease. Cell. 169(2), pp.361-371. 
Sborov, D.W., Nuovo, G.J., Stiff, A., Mace, T., Lesinski, G.B., Benson, D.M., Jr., 
Efebera, Y.A., Rosko, A.E., Pichiorri, F., Grever, M.R. and Hofmeister, C.C. 
2014. A phase I trial of single-agent reolysin in patients with relapsed multiple 
myeloma. Clin Cancer Res. 20(23), pp.5946-5955. 
Schatz, J.H. 2011. Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's 
lymphoma: results, biology, and development strategies. Curr Oncol Rep. 13(5), 
pp.398-406. 
Schneider, W.M., Chevillotte, M.D. and Rice, C.M. 2014. Interferon-stimulated 
genes: a complex web of host defenses. Annu Rev Immunol. 32, pp.513-545. 
Schreiber, K.H., Ortiz, D., Academia, E.C., Anies, A.C., Liao, C.Y. and 
Kennedy, B.K. 2015. Rapamycin-mediated mTORC2 inhibition is determined by 
the relative expression of FK506-binding proteins. Aging Cell. 14(2), pp.265-
273. 
Scott, D.W. and Gascoyne, R.D. 2014. The tumour microenvironment in B cell 
lymphomas. Nature Reviews Cancer. 14, p517. 
Sehn, L.H. and Gascoyne, R.D. 2015. Diffuse large B-cell lymphoma: optimizing 
outcome in the context of clinical and biologic heterogeneity. Blood. 125(1), 
pp.22-32. 
Senac, J.S., Doronin, K., Russell, S.J., Jelinek, D.F., Greipp, P.R. and Barry, 
M.A. 2010. Infection and killing of multiple myeloma by adenoviruses. Hum 
Gene Ther. 21(2), pp.179-190. 
Shafren, D., Quah, M., Wong, Y., Andtbacka, R.H., Kaufman, H.L. and Au, G.G. 
2014. Combination of a novel oncolytic immunotherapeutic agent, CAVATAK 
(coxsackievirus A21) and immune-checkpoint blockade significantly reduces 
tumor growth and improves survival in an immune competent mouse melanoma 
model. Journal for ImmunoTherapy of Cancer. 2(3), pP125. 
Shafren, D.R., Au, G.G., Nguyen, T., Newcombe, N.G., Haley, E.S., Beagley, 
L., Johansson, E.S., Hersey, P. and Barry, R.D. 2004. Systemic therapy of 
malignant human melanoma tumors by a common cold-producing enterovirus, 
coxsackievirus a21. Clin Cancer Res. 10(1 Pt 1), pp.53-60. 
Shafren, D.R., Dorahy, D.J., Greive, S.J., Burns, G.F. and Barry, R.D. 1997a. 
Mouse cells expressing human intercellular adhesion molecule-1 are 
susceptible to infection by coxsackievirus A21. J Virol. 71(1), pp.785-789. 
Shafren, D.R., Dorahy, D.J., Ingham, R.A., Burns, G.F. and Barry, R.D. 1997b. 
Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular 
adhesion molecule 1 for cell entry. J Virol. 71(6), pp.4736-4743. 
219 
 
Shafren, D.R., Sylvester, D., Johansson, E.S., Campbell, I.G. and Barry, R.D. 
2005. Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer. 
115(2), pp.320-328. 
Sharp, D.W. and Lattime, E.C. 2016. Recombinant Poxvirus and the Tumor 
Microenvironment: Oncolysis, Immune Regulation and Immunization. 
Biomedicines. 4(3). 
Shatkin, A.J., Sipe, J.D. and Loh, P. 1968. Separation of ten reovirus genome 
segments by polyacrylamide gel electrophoresis. J Virol. 2(10), pp.986-991. 
Shi, Y., He, X., Zhu, G., Tu, H., Liu, Z., Li, W., Han, S., Yin, J., Peng, B. and Liu, 
W. 2015. Coxsackievirus A16 elicits incomplete autophagy involving the mTOR 
and ERK pathways. PLoS One. 10(4), pe0122109. 
Shinde, S., Wu, Y., Guo, Y., Niu, Q., Xu, J., Grewal, I.S., Flavell, R. and Liu, Y. 
1996. CD40L is important for induction of, but not response to, costimulatory 
activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by 
CD40L. The Journal of Immunology. 157(7), pp.2764-2768. 
Showkat, M., Beigh, M.A. and Andrabi, K.I. 2014. mTOR Signaling in Protein 
Translation Regulation: Implications in Cancer Genesis and Therapeutic 
Interventions. Mol Biol Int. 2014, p686984. 
Singh, P.K., Doley, J., Kumar, G.R., Sahoo, A.P. and Tiwari, A.K. 2012. 
Oncolytic viruses & their specific targeting to tumour cells. Indian J Med Res. 
136(4), pp.571-584. 
Skelding, K.A., Barry, R.D. and Shafren, D.R. 2009. Systemic targeting of 
metastatic human breast tumor xenografts by Coxsackievirus A21. Breast 
Cancer Res Treat. 113(1), pp.21-30. 
Sokolowski, N.A., Rizos, H. and Diefenbach, R.J. 2015. Oncolytic virotherapy 
using herpes simplex virus: how far have we come? Oncolytic Virother. 4, 
pp.207-219. 
Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, 
R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., 
Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., 
Hagenbeek, A., Haioun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., 
McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., 
Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. and 
Montserrat, E. 2004. Follicular lymphoma international prognostic index. Blood. 
104(5), pp.1258-1265. 
Solimando, A.G., Brandl, A., Mattenheimer, K., Graf, C., Ritz, M., Ruckdeschel, 
A., Stuhmer, T., Mokhtari, Z., Rudelius, M., Dotterweich, J., Bittrich, M., 
Desantis, V., Ebert, R., Trerotoli, P., Frassanito, M.A., Rosenwald, A., Vacca, 
A., Einsele, H., Jakob, F. and Beilhack, A. 2018. JAM-A as a prognostic factor 
and new therapeutic target in multiple myeloma. Leukemia. 32(3), pp.736-743. 
Springer, T.A. 1995. Traffic signals on endothelium for lymphocyte recirculation 
and leukocyte emigration. Annu Rev Physiol. 57, pp.827-872. 
Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N. and 
Bell, J.C. 2000. Exploiting tumor-specific defects in the interferon pathway with 
a previously unknown oncolytic virus. Nature Medicine. 6, p821. 
Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P. and Lee, P.W. 1998. The 
molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by 
reovirus. Embo j. 17(12), pp.3351-3362. 
Sugano, Y., Takeuchi, M., Hirata, A., Matsushita, H., Kitamura, T., Tanaka, M. 
and Miyajima, A. 2008. Junctional adhesion molecule-A, JAM-A, is a novel cell-
220 
 
surface marker for long-term repopulating hematopoietic stem cells. Blood. 
111(3), pp.1167-1172. 
Sun, S., Zhang, X., Tough, D.F. and Sprent, J. 1998. Type I interferon-mediated 
stimulation of T cells by CpG DNA. J Exp Med. 188(12), pp.2335-2342. 
Tacar, O., Sriamornsak, P. and Dass, C.R. 2013. Doxorubicin: an update on 
anticancer molecular action, toxicity and novel drug delivery systems. J Pharm 
Pharmacol. 65(2), pp.157-170. 
Takeuchi, O. and Akira, S. 2010. Pattern recognition receptors and 
inflammation. Cell. 140(6), pp.805-820. 
Tan, V.P. and Miyamoto, S. 2016. Nutrient-sensing mTORC1: Integration of 
metabolic and autophagic signals. J Mol Cell Cardiol. 95, pp.31-41. 
Terstappen, L.W., Nguyen, M., Lazarus, H.M. and Medof, M.E. 1992. 
Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic 
cell differentiation. J Leukoc Biol. 52(6), pp.652-660. 
Terui, Y., Sakurai, T., Mishima, Y., Mishima, Y., Sugimura, N., Sasaoka, C., 
Kojima, K., Yokoyama, M., Mizunuma, N., Takahashi, S., Ito, Y. and Hatake, K. 
2006. Blockade of bulky lymphoma-associated CD55 expression by RNA 
interference overcomes resistance to complement-dependent cytotoxicity with 
rituximab. Cancer Sci. 97(1), pp.72-79. 
The Human Protein Atlas. 2017. ICAM1. 
Thirukkumaran, C.M., Luider, J.M., Stewart, D.A., Cheng, T., Lupichuk, S.M., 
Nodwell, M.J., Russell, J.A., Auer, I.A. and Morris, D.G. 2003. Reovirus 
oncolysis as a novel purging strategy for autologous stem cell transplantation. 
Blood. 102(1), pp.377-387. 
Thirukkumaran, C.M., Nodwell, M.J., Hirasawa, K., Shi, Z.Q., Diaz, R., Luider, 
J., Johnston, R.N., Forsyth, P.A., Magliocco, A.M., Lee, P., Nishikawa, S., 
Donnelly, B., Coffey, M., Trpkov, K., Fonseca, K., Spurrell, J. and Morris, D.G. 
2010. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a 
biological therapeutic. Cancer Res. 70(6), pp.2435-2444. 
Thirukkumaran, C.M., Shi, Z.Q., Luider, J., Kopciuk, K., Gao, H., Bahlis, N., 
Neri, P., Pho, M., Stewart, D., Mansoor, A. and Morris, D.G. 2012. Reovirus as 
a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer 
Res. 18(18), pp.4962-4972. 
Thirukkumaran, C.M., Shi, Z.Q., Luider, J., Kopciuk, K., Gao, H., Bahlis, N., 
Neri, P., Pho, M., Stewart, D., Mansoor, A. and Morris, D.G. 2013. Reovirus 
modulates autophagy during oncolysis of multiple myeloma. Autophagy. 9(3), 
pp.413-414. 
Thorley-Lawson, D., Deitsch, K.W., Duca, K.A. and Torgbor, C. 2016. The Link 
between Plasmodium falciparum Malaria and Endemic Burkitt's Lymphoma-
New Insight into a 50-Year-Old Enigma. PLoS Pathog. 12(1), pe1005331. 
Touitou, V.r., Daussy, C.c., Bodaghi, B., Camelo, S., de Kozak, Y., Lehoang, P., 
Naud, M.-C., Varin, A., Thillaye-Goldenberg, B., Merle-Béral, H.l.n., Fridman, 
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